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CHAPTER I 
 
A GENERAL, STEREOSELECTIVE APPROACH TO THE CONSTRUCTION 
OF AZABICYCLIC RING SYSTEMS 
 
1.1. Introduction 
Azabicyclic ring skeletons are common structural subunits found in numerous 
alkaloid natural products. These motifs frequently comprise the core of biologically 
active and pharmaceutically significant compounds (Figure 1.1).
1
 Although 1-
azabicyclo[m.n.0]alkane ring systems are found in a number of natural products, 
asymmetric approaches to access them are limited.   
The first synthesis of azabicyclic ring systems dates back to the middle 19
th
 century, 
when δ-coniceine was obtained from the cyclization of N-bromoconiine with sulfuric 
acid.
2
 In general, the existing strategies for the construction of azabicyclic ring systems 
rely on Staudinger-aza-Wittig approaches, intramolecular cyclizations, cycloadditions 
([5+2], [4+2], and [2+2+2]), ring closing metathesis (RCM) strategies, and 
rearrangements (nitrone and intramolecular Schmidt rearrangements).
3
 Enantioselective 
approaches to larger azabicyclic ring systems are not well explored, and most that are 
reported lack stereocontrol.
4
  The purpose of our research is to develop general and 
highly enantioselective approaches to the construction of 1-azabicyclo[m.n.0]alkane ring 
2 
 
systems and apply this methodology towards the total synthesis of alkaloid natural 
products.  This warrants a brief introduction of indolizidine and pyrrolizidine alkaloids. 
 
 
Figure 1.1. Representative 1-azabicyclo[m.n.0]alkane ring systems, including  their 
alternative IUPAC nomenclature, of interest in both natural product synthesis and drug 
discovery.   
 
1.2. Indolizidine Ring Systems 
1.2.1. Indolizidine Alkaloid Natural Products 
Indolizidine alkaloids are isolated from a multitude of natural sources, including ants, 
amphibians, fungi, plants, and marine species.  These alkaloids possess interesting 
biological activities including insecticidal, antibacterial, antifungal, antiviral, and 
antimalarial activities.  Several alkaloids of this class function as potent and subtype 
selective noncompetitive blockers of the nicotinic acetylcholine receptor (nAChR), which 
3 
 
has been implicated in neurological disease states including Alzhiemers disease, 
Parkinson’s disease, schizophrenia, and epilepsy.5   
Indolizidine alkaloids are defined by a conserved 1-aza-bicyclo-[4.3.0]-octane core.  
This moiety has been observed in many alkaloid natural products, and a variety of 
approaches have been developed to enable the synthesis of these compounds.  Shown in 
Figure 1.2 are examples of indolizidine natural products that have been the focus of total 
synthesis efforts. 
 
Figure 1.2. Examples of indolizidine containing natural products. 
 
1.2.2. Synthetic Approaches to Indolizidine Ring Systems 
Due to the interest in the biological properties of alkaloid natural products, there 
has been a great deal of focus in the synthetic community towards the asymmetric 
synthesis of azaheterocycles and their implementation in the total synthesis of complex 
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natural products.  Over the past 10 years, many novel and attractive strategies for the 
synthesis of indolizidine natural products have been developed.  However, general 
approaches to access these ring systems are still lacking in the literature, as most methods 
are designed in the context of the synthesis of specific alkaloid natural products.
6
 
Recently, Mann and co-workers described a multicomponent reaction based on a 
cyclohydrocarbonylation (CHC) of phenylglycinol 1.16 to access 1.1 in 21% overall 
yield (Scheme 1.1).
7
  This is the most recent approach to the coniceine ring system prior 
to our work. 
 
 
Scheme 1.1. Synthesis of coniceine 
Renaud and co-workers built on previous work in the 1990s by Aube and Pearson to 
demonstrate the use of the intramolecular Schmidt rearrangement of primary azido 
alcohol 1.18 to access the indolizidine core of (-)-167B with excellent stereocontrol 
(Scheme 1.2).
8
   
 
Scheme 1.2.  Renaud synthesis of (-)-167B by intramolecual Schmidt rearrangement 
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A cycloaddition approach was utilized by Rovis and co-workers in 2006, who 
developed a rhodium(I)-catalyzed [2+2+2] cycloaddition between alkenyl isocyanates 
1.21 and alkynes 1.20 to access indolizinones and quinolizinones.
9
  The synthetic utility 
of this work was subsequently demonstrated by the Rovis group in 2009 in the 
enantioselective synthesis of alkaloid (-)-209D (Scheme 1.3).
10
 Reduction of the α,β 
unsaturated carbonyl is required to access the saturated 1.10, and the required reaction 
conditions limit the overall substrate scope of this approach. 
 
Scheme 1.3. Rovis’s synthesis of (-)-209D via rhodium-catalyzed [2+2+2] cycloaddition 
 
Yu and co-workers reported in 2010 the total synthesis of (+)-steviamine via a cyclic 
nitrone/reductive amination strategy, where Felkin-Anh control of the Grignard addition 
into the nitrone 1.1.24 is utilized to set the α-amine stereocenter, followed by reductive 
amination to construct the indolizidine ring system (Scheme 1.4).
11
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Scheme 1.4.  Yu Synthesis of Steviamine 
  
Several groups have employed ring closing metathesis in the construction of 
indolizidine rings of various alkaloid natural products.  In 2002, Valdes and co-workers 
demonstrated the use of an aza-Diels Alder/RCM strategy to access 5,8-disubstituted 
indolizidine ring cores (Scheme 1.5).
12
 The substitution pattern of the piperidone ring 
was found to exert a significant effect on the ring closing metathesis step. 
 
Scheme 1.5.  RCM strategy to access indolizidine ring system 1.32 
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In 2012, Shenvi and co-workers reported a stereoselective, intramolecular, formal 
hydroamination of dienamines by a nitrogen-directed hydroboration (Scheme 1.6). This 
is accomplished through an alkyl shift of the boronic amide formed by treatment of 
1.1.39 with borane-dimethyl sulfide and iodine, followed by Mitsunobu conditions to 
access the indolizidine core.  This methodology was shown to access several simple 
indolizidine alkaloids, including 207A.
13
 The substrate scope of this approach has yet to 
be fully explored, and substituent pattern of the substrates have a strong effect on 
stereoselectivity and yield. 
Scheme 1.6.  Shenvi Synthesis of 207A 
 
1.3. Pyrrolizidine Ring Systems 
1.3.1 Pyrrolizidine Alkaloid Natural Products 
Pyrrolizidine alkaloids (PAs) are heterocyclic compounds that are typically 
derived from the ester of basic alcohols known as necine bases. These alkaloids share a 
common 1-azabicyclo[3.3.0]octane core but differ based on oxygenation pattern and 
whether or not C1-C2 is saturated.
14
  Several natural products containing this azabicyclic 
core system are outlined in Figure 1.3. 
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Figure 1.3. Structure and numbering convention of pyrrolizidine alkaloids, and 
representative examples. 
 
While the amine bases themselves (Figure 1.4) are rarely isolated in nature, the 
corresponding mono- and diesters are more common, either as the tertiary amine or the 
N-oxide.    Plants containing pyrrolizidine alkaloids are toxic to mammals, but several 
insect species have evolved to employ them for their own chemical defense.  
Interestingly, their toxicity has been attributed to metabolism of the C1-C2 unsaturated 
congeners leading to the generation of highly reactive alkylating reagents.
15
 
 
Figure 1.4.  Common necine bases 
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1.3.2. Biosynthesis of Pyrrolizidine Alkaloids 
The pyrrolizidine alkaloid class of natural products are secondary metabolites 
produced by the homospermidine synthase (HSS) pathway in plants, and are believed 
serve as a chemical defense against herbivores.
16
  This pathway is also representative 
of the biosynthesis of homologously related azabicyclic cores of other alkaloid 
natural products including indolizidines. The basic building blocks of pyrrolizidine 
alkaloids are the polyamines spermidine and putrescine.  Both spermidine and 
putrescine are derived from arginine, and are used in the first pathway-specific step of 
PA biosynthesis in homospermidine formation catalyzed by HSS.
17
  The necine base 
moiety is then formed via an oxidative deamination/condensation sequence.  These 
simple azabicyclic moieties can then be transported from the root of the plant to other 
organs, where additional modification results in complex alkaloid natural products. 
 
Figure 1.5. Biosynthesis of the azabicyclic core moiety of pyrrolizidine alkaloids 
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1.3.3. Synthetic Approaches to Pyrrolizidine Ring Systems 
The PAs have historically proven to be synthetically challenging, which has 
encouraged the development of many conceptually distinct approaches towards their 
synthesis.  Several approaches have utilized cycloaddition reactions with pyrrolidines or 
intramolecular substitutions to access the azabicyclic core structure.  These methods are 
directed towards the synthesis of complex alkaloid natural products and general 
approaches to the pyrrolizidine ring skeleton are not well-reported in the literature.
6
 
An approach to  (-)-supinidine, a basic pyrrolizidine alkaloid building block, was last 
reported by Takahata and co-workers in 1991, where a Katsuki-Sharpless kinetic 
resolution of 1.55 was used to access 1.56.  The synthesis of (-)-supinidine (1.57) 
required 18 steps and was accomplished in 3.5% overall yield.
18
 
 
Scheme 1.7. Takahata synthesis of (-)-supinidine 
 
In 1980, Vedejs and co-workers reported the stereoselective total synthesis of 
retronecine (1.62).  This was accomplished through a 1,3 dipolar cycloaddition between 
azomethane ylide 1.59 and methyl acrylate for direct construction of the pyrrolizidine 
core 1.61 (Scheme 1.8).
19
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Scheme 1.8. Vedejs synthesis of retronecine 
 
Similarly, Tufariello and co-workers in 1980 disclosed a synthesis of retronecine 
utilizing a nitrone 1,3 dipolar cycloaddition to access the pyrrolizidine core (Scheme 
1.9).
20
  Oxidation of hydroxylamine 1.63 provided nitrone 1.64, which in the presence of 
γ-hydroxycrotonate (1.65) underwent cycloaddition with desired regio- and 
stereochemistry to provide advanced intermediate 1.66. 
 
Scheme 1.9. Tufariello synthesis of retronecine 
 
White and co-workers described in 2000 a conceptually unique approach to the 
synthesis of C3 alkylated hydroxylated pyrrolizidines through a ring closing metathesis / 
transannular cyclization method (Scheme 1.10). Stereoselective epoxidation of 
azacyclooctene 1.68 followed by transannular opening by nitrogen when treated with 
12 
 
lithium hydroxide produces  pyrrolizidine 1.70 where the hydroxyl configurations are set 
unambiguously.
21
 
 
Scheme 1.10.  Transannular cyclization approach to polyhydroxylated pyrrolizidines 
 
Pearson and co-wokers reported the reductive double cyclization of azidoepoxides as 
an effective method to generate pyrrolizidine and indolizidine alkaloids. This was applied 
to the total synthesis of (+)-australine, where the reductive double-cyclization of azido 
epoxy tosylate 1.71 provided the pyrrolizidine 1.72, a precursor to (+)-autraline (1.73), in 
good yield (Scheme 1.11).
22
  While effective, this method suffers from poor 
stereoselectivity during epoxidation to access precursor 1.71.   
 
 
Scheme 1.11.  Pearson synthesis of (+)-australine 
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A majority of these previously discussed approaches are directed towards the 
synthesis of alkaloid natural products with varying substitution patterns, and general 
approaches to the formation of these ring systems remains under-reported.  Recognizing 
an apparent need in the literature for rapid, enantioselective approaches to these 
azabicyclic ring systems, we decided to study novel methods for their construction and 
use in the total synthesis of diverse alkaloid natural products. 
 
1.4. Stereoselective Synthesis of Medium 1-azabicyclo[m.n.0]alkyl Ring Systems 
1.4.1. Previous Attempts to Access Azabicyclic Ring Systems 
Our efforts towards the enantioselective synthesis of azabicyclic ring systems were 
first born in attempts to synthesize the azepine natural product stemaphylline, a member 
of the stemona class of alkaloids (Figure 1.6).  Stemaphylline (1.74) and its 
corresponding N-oxide was isolated and characterized from the root extracts of Stemona 
aphylla by Pitchaya and co-workers in 2009.23 Plants containing these alkaloids have 
been historically employed in traditional medicine in their native regions, and therefore 
have biological properties that warrant further investigation. 
 
Figure 1.6. Stemaphylline and stemaphylline-N-oxide 
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Initial attempts in our lab towards the total synthesis stemaphylline utilized 
previous efforts for the organocatalytic enantioselective synthesis of N-alkyl aziridines.  
In this approach a Lewis acid-mediated aziridine opening/reductive elimination protocol 
was envisioned to install the azabicyclic skeleton of stemaphylline.  Unfortunately, 
attempts to open the aziridine rings 1.78 and 1.79 to the corresponding amines led to 
complex mixtures, and efforts to optimize the reaction conditions were unsuccessful 
(Scheme 1.12). As the problems associated with the aziridine approach appeared to be 
difficult to overcome, a new strategy to set the α-amine stereocenter of the indolizidine 
core was required. 
 
 
Scheme 1.12.  Proposed enantioselective synthesis of 1-azabicyclo[m.n.0]alkane ring 
systems 
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 1.4.2. Chiral tert-Butanesulfinylimines as Chiral Directing Groups  
An established method for installation of the α-nitrogen stereocenter of chiral 
amines involves the formation of an N-substituted imine (1.84), followed by nucleophilic 
addition into the imine, and finally deprotection to the desired amine (Figure 1.7).
1
  
Many practical examples of this strategy involve placement of a chiral protecting group 
on the nitrogen substituent.  Numerous chiral auxiliaries have been developed over the 
past thirty years that take advantage of nucleophilic addition into imines to set the chiral 
center of corresponding amines.  Early studies by Franklin Davis at Temple University 
led to the development of para-toluenesulfinimines (pTS-imines) in their 
enantiomerically pure form.
24
  Davis went on to further demonstrate that the 1,2-addition 
of organometallic reagents to the chiral imine could be used in asymmetric synthesis to 
create carbon-nitrogen stereocenters.
25
  Building on this work, Garcia Ruano at the 
University of Madrid described chiral tert-butanesfinimines (tBS-imines) in his seminal 
1996 paper.
26
  He demonstrated that enhanced diastereofacial selectivity could be 
achieved in the aziridination of chiral sulfinimines with sulfur ylides compared to the 
pTS-imine group.  Despite the foundation laid down by Ruano, tBS-imines did not find 
wide-spread use as a chiral amine building block until the extensive studies carried out by 
Jonathan Ellman, who pioneered the large-scale synthesis of enantiopure tert-
butanesulfinamide and demonstrated its versatility as a robust directing group, with an 
economical price, and facile installation/removal.
27
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Figure 1.7.  Method for the preparation of α chiral amines 
  
1.4.3.  Synthetic Approach for Azabicyclic Ring Systems 
Our proposed method for the asymmetric synthesis of azabicyclic ring systems was 
inspired by Jonathan Ellman’s enantioselective synthesis of 2-substituted pyrrolidines 
using tert-butanesulfinamine that proceeds with high yield and stereoselectivity (Scheme 
1.13)
28
.  Addition of Grignard reagent 1.88 with a latent aldehyde moiety to a chiral 
aldimine provided the sulfinamine 1.89 in high yield and diastereoselectivity.  A one-pot 
N-deprotection/acetal hydrolysis facilitated an intramolecular reductive amination to 
produce the optically active 2-substituted pyrrolidine 1.90 in high enantiomeric excess. 
 
Scheme 1.13.   Approach to the synthesis of chiral 2-substituted pyrrolidines. 
 
We envisioned a protocol involving a diastereoselective indium-mediated 
allylation, N-alkylation to afford 1.92, RCM to provide 1.93, and finally a one-pot 
17 
 
deprotection/hydrolysis/intramolecular reductive amination sequence to access 
azabicyclic ring skeletons 1.94 with high enantioselectivity (Scheme 1.14). 
 
Scheme 1.14. Approach to synthesis of azabicyclic ring systems 
 
1.4.4. Synthesis of Azabicyclic Ring Systems 
To explore the scope and potential applications of this strategy, we began 
preparing pyrrolizidine, indolizidine, and azepine ring systems utilizing chiral tert-
butanesulfinamide as a chiral directing group.    Indium-mediated allylation as described 
by Xu and coworkers would be utilized to set the α-nitrogen stereocenter (Scheme 
1.15).
29
  Chiral aldimine 1.96 underwent indium-mediated allylation to afford amine 1.97 
as a single diastereomer after chromatography with >15:1  diastereoselectivity. N-
allylation followed by RCM provided 1.99 in 67% yield over the two steps. 
Hydrogenation to reduce the alkene, followed by a one-pot deprotection/acetal 
hydrolysis/reductive amination sequence provided indolizidine 1.1 as a single enantiomer 
in 81% yield over the two steps.  This approach for (+)-coniceine, the simplest alkaloid 
possessing the indolizidine azabicyclic core, required only six steps and proceeded in 
43% overall yield.  This compared favorably to previous syntheses, with the latest having 
been accomplished in 21% overall yield.
18
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Scheme 1.15. Synthesis of indolizidine ring system 
 
Application of this approach towards the enantioselective synthesis of 
pyrrolo[1,2-a]azepine 1.2 proved more challenging. In this instance we were unable to 
alkylate 1.97 with a number of butenyl substrates (Cl, Br, I, OMs, OTs, and OTf) and 
bases in a reasonable yield.  Therefore, we utilized an alternative approach, where the 
alkene required for RCM to the 7-membered ring would be incorporated into the starting 
material, and the acetal would be added through Grignard addition into the imine.  This 
circumvented the need to alkylate the tert-butanesulfinylamine with the butenyl substrate.  
Condensation of 4-pentenal (1.100) with chiral tert-butanesulfinamine afforded 
the desired chiral aldimine 1.101 in 95% yield (Scheme 1.16).  Grignard addition of 
1.102 proceeded in 88% yield, which, after N-allylation, yielded 1.103 as a single 
diastereomer after chromatography, with “anti-Ellman” diastereoselectivity >9:1, as will 
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be later discussed.
30
  RCM with 2
nd
 generation Grubbs catalyst afforded 1.104 in 78% 
yield.  Hydrogenation to reduce the alkene, followed by a one-pot deprotection/acetal 
hydrolysis/reductive amination sequence provided 1.2 in 86% yield over the two steps 
and 45% overall yield for the six step sequence. 
 
Scheme 1.16. Synthesis of azepine ring system 
 
For the pyrrolo[1,2-a]azocine core 1.3, a similar protocol was employed to that of 
the indolizidine core 1.1. Alkylation of key sulfinamide 1.107 with 5-bromo-1-pentene 
proceeded smoothly to provide 1.105, which then underwent RCM with Grubbs II to 
deliver 1.106 in 70% yield for the two steps (Scheme 1.17).  Hydrogenation to reduce the 
alkene, followed by a one-pot deprotection/acetal hydrolysis/reductive amination 
sequence provided 1.3 in 87% yield over the two steps and 60% overall yield for the six-
step sequence. 
20 
 
 
Scheme 1.17. Synthesis of decahydropyrrolo[1,2-a]azocine ring system 
 
A parallel strategy was also applied to chiral aldimine 1.106 to access 
pyrrolizidine ring system 1.109 (Scheme 1.18). Grignard addition into aldimine 1.106, 
followed by N-allylation facilitated 1.107 to be reached in 77% yield over two steps as a 
single diastereomer after chromatography.  RCM then provided 1.108 in 98% yield.  
Alcohol deprotection, alkylation with benzyl chloride, followed by a one-pot 
deprotection/acetal hydrolysis/reductive amination sequence provided 1.109. 
Unfortunately, further efforts to deprotect the O-benzyl group to the necine base were 
unsuccessful and led to decomposition of the starting materials.  However, this strategy 
could potentially allow for broad derivitization at the C1 methoxy position, enabling the 
library synthesis of unnatural pyrrolizidine alkaloids for biological studies. 
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Scheme 1.18. Synthesis of pyrrolizidine ring system 
 
1.4.5.  Synthesis of Azabicyclic Lactam Ring Systems 
Because many natural products possess the azabicyclic lactam ring skeletons 
1.113-1.115, we next applied our methodology to this core motif (Scheme 1.19).
31
  
Indium-mediated allylation of chiral aldimine 1.110 proceeded in 88% yield and >10:1 
diastereoselectivity to access 1.111.  Acid-mediated ring closure facilitated access to 
pyrrolidinone the key linchpin intermediate 1.112 in 97% yield. Allylation of lactam 
1.112 and subsequent RCM with Grubbs II provided indolizidone 1.113 in 87% yield for 
the two step sequence.  Similarly, alkylation of 1.112 with either butenyl bromide or 
pentenyl bromide, followed by RCM with Grubbs II, afforded azepinone 1.114 or 
azeocinone 1.115, respectively.  The azabicyclic lactam ring systems were prepared in 
five steps through the common linchpin intermediate 1.112, with overall yields ranging 
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from 56-69%.  The alkene can either be reduced or serve as a handle for further 
functionalization. 
Scheme 1.19.  Synthesis of azabicyclic lactam ring systems 
 
1.5. StereoselectiveSynthesis of Small to Large 1-azabicyclo[m.n.0]alkyl Ring 
Systems 
1.5.1. Alternative Approach to Azabicyclic Ring Systems 
The previously described efforts towards the enantioselective synthesis of 1-
azabicyclo[m.n.0] alkyl ring systems were a notable advance, however we believed 
improvements remained to be realized in order to develop a streamlined route to access 
small to large azabicyclic ring systems.  Drawbacks of the initial methodology included 
the necessity for conceptually different transformations depending on the ring size 
required and lack of the ability for rapid access to diverse azabicyclic ring systems from a 
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single linchpin intermediate.
32
  There were also inconsistencies in alkylation to the tert-
butanesulfinyl nitrogen which necessitated the need for a route that provided a more 
predictable reactivity. Given the wide commercial availability and ease of preparation of 
chloroalkyl alcohols, we envisioned a more modular approach than our previous 
methodology, which would allow for the rapid generation of diverse azabicyclic cores for 
applications in medicinal chemistry and diversity-oriented synthesis, as well as the total 
synthesis of complex natural products.   De Kimpe and co-workers recently demonstrated 
the asymmetric synthesis of 2-arylpyrrolidines 1.118 from γ-chloro N-(tert-
butanesulfinyl)ketimines 1.117 (Scheme 1.20 A), and  Brown and co-workers employed 
a related strategy for the total synthesis of (-)-tashiromine 1.120 and (-)-epilupinine 1.121 
(Scheme 1.20 B).
33,34 
 
Scheme 1.20.  Application of γ-chloro N-(tert-butanesulfinyl)ketimines to access pyrroles 
and azabicyclic systems in high enantioselectivity. 
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Inspired by these results, we envisioned further expanding this methodology and 
ultimately applying it towards the synthesis of the stemona alkaloid natural product 
stemaphylline.  As shown in Scheme 1.21, the azabicyclic core would be installed 
through a deprotection / intramolecular cyclization / N-alkylation sequence, followed by 
ring closing metathesis. 
 
Scheme 1.21. Approach for the synthesis of stemaphylline 
 
We sought to develop a protocol that would subject various chloroalkyl N-(tert-
butanesulfinyl)aldimines 1.127 to an asymmetric allylation reaction to provide 1.128 in 
high diastereomeric ratio.
 
 Deprotection and alkylation of the pyrrolidine would afford 
azocines 1.129, substrates for a ring closing metathesis reaction to provide general, 
enantioselective access to 1-azabicyclo[m.n.0]alkane cores 1.130 with an embedded 
olefin as a handle for further functionalization (Scheme 1.22). 
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Scheme 1.22. Envisioned route to access diverse 1-azabicyclo[m.n.0]alkane cores 
 
1.5.2.  Synthesis of Small to Large 1-azabicyclo[m.n.0]alkane Ring Systems 
The chloroalkyl N-(tert-butanesulfinyl)aldimines 1.127 were easily prepared in 
92-94% yields by condensing the corresponding chloroaldehydes 1.131 with  the Ellman 
(S)- tert-butanesulfinamide.  A subsequent indium-mediated allylation reaction affords 
the anticipated (R)-anti-adducts 1.128 in >9:1 diastereoselectivity and up to 86% yield.  
After column chromatography, single diasteromers of analogs 1.128 were isolated, which 
were carried forward. Acid-mediated deprotection and base-induced, microwave-assisted 
cyclization and alkyation with the required allyl, butenyl and pentenyl bromides smoothly 
afforded the chiral N-alkyl azocines 1.129 in 63-83% yields for the three step, one-pot 
reaction sequence (Scheme 1.23).   To enable the one-pot sequence, a number of bases, 
solvents and temperatures were evaluated; however, K2CO3, NaI in DMF under 
microwave irradiation (120 
°
C, 15 min) proved to be general for our substrates, including 
the larger 7-azocine rings.   
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Scheme 1.23. Stereoselective synthesis of N-alkyl azocines 1.129 
 
With all of the chiral N-alkyl azocines 1.129 in hand, we focused on the RCM to 
provide the 1-azabicyclo[m.n.0]alkane systems 1.130.   Initial attempts following several 
known reaction conditions with Grubbs II failed to provide the desired unsaturated 1-
azabicyclo[5.4.0]tridecane core of 1.132 (Scheme 1.24).   
 
Scheme 1.24. RCM  approaches to access the 1-azabicyclo[m.n.0]alkane cores 
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A survey of the literature regarding RCM methods with tertiary amines suggested 
that protection of the amine by in situ generation of ammonium salts enabled facile ring-
closing.
35,36
   Thus, treatment of 1.129c1 with 1.1 equivalent of camphor sulfonic acid 
(CSA) in 0.05 M toluene, followed by the addition of 10 mol% of Grubbs II and 
microwave heating for 1 hour at 100 
o
C,  provided the unsaturated 1-
azabicyclo[5.4.0]tridecane core of 7 in 70% isolated yield.  An evaluation of additional 
acids led to the use of trifluoroacetic acid (TFA), which was equally effective (68% 
yield) and allowed for simpler purification (Scheme 1.25). 
 
Scheme 1.25.  Optimal RCM conditions for the enantioselective synthesis of the 
unsaturated 1-azabicyclo[m.n.0]alkane cores 1.4.15. 
 
With a robust protocol in hand for the RCM, all of the chiral N-alkyl azocines 
1.129 were converted, under these optimal conditions, into the desired unsaturated 1-
azabicyclo[5.4.0]alkane cores 1.130 (Figure 1.8).  Yields for the RCM reaction averaged 
70% for all the substrates 1.129, providing high yielding, stereoselective access to each of 
the key 1-azabicyclo[m.n.0]alkane systems 1.130.  Overall yields from the commercial 
aldehydes 1.131 ranged from 29-59%, demonstrating a general route to access these 
important azabicyclic ring systems. 
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Figure 1.8. Mono-unsaturated 1-azabicyclo[m.n.0]alkane ring systems 1.4.15 synthesized 
 
In summary, we have developed a novel approach for the general and 
enantioselective synthesis of a diverse array of small to large 1-azabicyclo[m.n.0]alkane 
ring systems with an embedded olefin handle for further functionalization. We were also 
able to extend this methodology to access the respective lactam congeners that are found 
in a host of natural products as well as pharmaceutical preparations.  The stereochemistry 
is established via a highly diastereoselective indium-mediated allylation of an Ellman 
sulfinimine in greater than 9:1 dr, which is readily separated by column chromatography 
to afford a single diastereomer.  This methodology allows for the rapid preparation of 1-
azabicyclo[m.n.0]alkane ring systems that are not readily accessible through any other 
chemistry in excellent overall yields and, for many systems including the pyrrolo[1,2-
a]azepine, and pyrrolo[1,2-a]azocine, are the only enantioselective preparations reported 
to date.  With a strategy to stereoselectively access azabicyclic ring systems now 
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optimized, we next focused on the applications of this methodology to the total synthesis 
of alkaloid natural products. 
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Experimental Methods 
Flame-dried (under vacuum) glassware was used for all reactions. All reagents 
and solvents were commercial grade and purified prior to use when necessary. Thin layer 
chromatography (TLC) was performed on glass-backed silica gel. Visualization was 
accomplished with UV light, and/or the use of anisaldehyde and ceric ammonium 
molybdate solutions followed by charring on a hot-plate. Chromatography on silica gel 
was performed using Silica Gel 60 (230-400 mesh) from Sorbent Technologies. IR 
spectra were recorded as thin films and are reported in wavenumbers (cm
-1
). 
1
H & 
13
C 
NMR spectra were recorded on Bruker DRX-400 (400 MHz) or Bruker AV-NMR (600 
MHz) instrument. Chemical shifts are reported in ppm relative to residual solvent peaks 
as an internal standard set to δ 7.26 and δ 77.0 (CDCl3). Mass spectra were obtained on a 
Micromass Q-Tof API-US mass spectrometer was used to acquire high-resolution mass 
spectrometry (HRMS) data.  The value Δ is the error in the measurement (in ppm) given 
by the equation Δ = [(ME – MT)/ MT] × 10
6
, where ME is the experimental mass and MT is 
the theoretical mass.  The HRMS results were obtained with ES as the ion source and 
leucine enkephalin as the reference.   
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(R)-2-methyl-N-(pent-4-en-1-ylidene)propane-2-sulfinamide (1.101).  
4-pentenal (11.89 mmol, 0.5 g) was dissolved in THF (40 mL) and Ti(OEt)4 (23.79 
mmol, 2 eq.) was added followed by (R)-(+)-2-methyl-2-propanesulfinamide (2.0 mmol, 
1.0 eq.). The mixture was stirred at rt for 5 h. The reaction is then quenched by addition 
of an equal volume of sat. NaHCO3. The resulting mixture is filtered through a pad of 
Celite
®
 and the filter cake rinsed washed with EtOAc. The filtrate was extracted with 
EtOAc (3 x 40 mL), the combined organic layer was washed with water, brine and dried 
over magnesium sulfate. Concentration in vacuo gave the crude aldimine which was 
purified by flash chromatography (4:1 to 1:1 Hex/EtOAc) to yield the desired product 
2.11 g (95%) as a colorless oil: [α]D
20
 = +276.3 (c = 1.00, CHCl3); 
1
H NMR (400.1 MHz, 
CDCl3) δ (ppm): 8.08 (t, J = 4.4 Hz, 1H), 5.83 (m, 1H), 5.05 (m, 2H), 2.62 (m, 2H), 2.40 
(q, J = 6.8, 2H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 168.7, 136.6, 115.7, 56.4, 35.2, 
29.2, 22.2; HRMS (TOF, ES+) C9H18NOS [M+H]
+
 calc'd 188.1131, found 188.1130. 
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(R)-N-((S)-1-(1,3-dioxan-2-yl)hept-6-en-3-yl)-2-methylpropane-2-sulfinamide (1.133) 
Magnesium turnings (4.99 g, 205.2 mmol) were flame dried with catalytic amount of 
Iodine in 500 mL reaction flask.  70 mL of THF was added, followed by dropwise 
addition of 2-(2-Bromoethyl)-1,3-dioxane (6.94 mL, 51.3 mmol). The reaction mixture 
was periodically cooled in a rt water bath to prevent refluxing. After addition of the 2-(2-
bromoethyl)-1,3-dioxane solution was complete, the reaction mixture was stirred for 1 h. 
The solution was then transferred to a different flask and was cooled to −78 °C. Upon 
cooling, precipitate was observed and to the solid N-tert-Butanesulfinyl imine 1.101 (1.63 
g, 10.26 mmol) in 20 mL THF was added dropwise to the Grignard solution, the solution 
was stirred for overnight at −48 °C and then warmed to rt. The reaction mixture was 
quenched with sat NH4Cl and extracted with EtOAc (3 x 40 mL).  The organic layer was 
dried over sodium sulfate.  Concentration in vacuo gave crude product as >9:1 dr, which 
was then purified by  flash column chromatography (4:1 to 1:1 Hex/EtOAc) to yield the 
product in 2.74 g (88%) as a pale yellow oil: [α]D
20
 = +55.1 (c = 1.00, CHCl3); 
1
H NMR 
(400.1 MHz, CDCl3) δ (ppm): 5.80 (m, 1H), 5.05 (dd, J = 8.7, 17.2 Hz, 1H), 4.97 (dd, J = 
8.4 Hz, 1H), 4.51 (t, J = 4.4 Hz, 1H), 4.07 (dd, J = 10.8, 5.2 Hz, 2H), 3.75 (dt, J = 12.4, 
2.0 Hz, 2H), 3.23 (m, 1H), 3.05 (d, J = 6.8 Hz, 1H), 2.15 (q, J = 7.6, 2H), 2.07 (m, 1H), 
1.56-1.75 (m, 6H), 1.54 (m, 1H), 1.33 (d, J = 13.6 Hz, 1H), 1.20 (s, 9H);  13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 137.9, 115.1, 101.9, 101.8, 66.8, 58.7, 56.2, 55.7, 36.9, 
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35.4, 31.2, 29.8, 29.7, 25.7, 25.6, 22.6; HRMS (TOF, ES+) C15H30NO3S [M+H]
+
 calc'd 
304.1946, found 304.1945. 
 
 
(R)-N-((S)-1-(1,3-dioxan-2-yl)hept-6-en-3-yl)-N-allyl-2-methylpropane-2-sulfinamide 
(1.103).   
To a solution of 1.133 (303 mg, 1 mmol) in DMF (2.8 mL) at -20 
o
C was added 1 M 
LiHMDS in THF (1.76 mL, 1.76 mmol) dropwise. The mixture was stirred for 20 mins 
and allyl bromide (0.43 mL, 5 mmol) was added. After stirring for 2 h, the reaction was 
quenched with sat. NH4Cl, extracted with EtOAc (3 x 10 mL).  The organic layer was 
washed with water, brine and dried over Na2SO4.  Concentration in vacuo gave the 
residue which was then purified by automated flash chromatography (4:1 Hex/EtOAc) to 
yield the product in 274.4 mg (80%) as a pale yellow oil: [α]D
20
 = -40.5 (c = 1.00, 
CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.71-5.89 (m, 2H), 5.15 (m, 2H), 4.98 
(m, 2H), 4.49 (t, J = 5.2 Hz, 1H), 4.08 (dd, J = 11.6, 4.4 Hz, 2H), 3.95 (dd, J = 16.4, 5.2 
Hz, 1H), 3.73 (t, J = 12.4 Hz, 2H), 3.11 (dd, J = 16.4, 7.2 Hz, 2H), 2.93 (m, 1H), 2.17 (m, 
1H), 2.05 (m, 2H), 1.87 (m, 1H),  1.70 (m, 1H), 1.62 (m, 4H), 1.32 (d, J = 13.6 Hz, 1H), 
1.19 (s, 9H);  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 137.9, 136.1, 117.4, 114.8, 101.9, 
66.8, 57.8, 45.1, 33.0, 32.8, 30.7, 27.6, 25.7, 23.6; HRMS (TOF, ES+) C18H34NO3S 
[M+H]
+
 calc'd 344.2259, found 344.2260. 
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(S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)-2,3,4,7-tetrahydro-1H-
azepine (1.104)  
To a solution of 1.103 (195.7 mg, 0.57 mmol) in CH2Cl2 (60 mL) was added 2
nd
 Gen. 
Grubbs (24.2 mg, 0.028 mmol). The mixture was refluxed for 1 h and concentrated. The 
resulting crude product was purified by automated flash chromatography (4:1 to 1:1 
Hex/EtOAc) to yield the desired product 140.2 mg (78%) as yellow oil: [α]D
20
 = +27.5 (c 
= 0.55, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.71 (m, 1H), 5.62 (m, 1H), 4.54 
(t, J = 4.8 Hz, 1H), 4.11 (dd, J = 7.4, 4.8 Hz, 2H), 3.64-3.88 (m, 4H), 3.52 (m, 1H), 2.28 
(m, 2H), 2.05 (m, 2H), 1.86 (m, 1H), 1.58-1.73 (m, 4H), 1.33 (q, J = 13.6 Hz, 1H), 1.2 (s, 
9H);  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 131.1, 128.8, 102.1, 66.8, 60.8, 58.4, 42.3, 
32.3, 32.2, 27.6, 25.7, 25.0, 23.5; HRMS (TOF, ES+) C16H30NO3S [M+H]
+
 calc'd 
316.1946, found 316.1946. 
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(R)-N-(3-(1,3-dioxan-2-yl)propylidene)-2-methylpropane-2-sulfinamide (1.96).  
To a solution of 3-(1,3-dioxan-2-yl)propanal (2.1 g, 14.6 mmol) in CH2Cl2 (100 mL) was 
added (R)-2-methylpropane-2-sulfinamide (2.12 g, 17.5 mmol) and CuSO4 (7.0 g, 43.8 
mmol). The reaction mixture was stirred at rt overnight. The mixture was filtered through 
a through celite pad and washed with CH2Cl2. Concentration in vacuo gave the crude 
product which was purified by automated flash chromatography (4:1 to 1:1 Hex/EtOAc) 
to yield the desired product 1.91 g (91%) as yellow oil: [α]D
20
 = -208.8 (c = 0.86, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 8.11 (t, J = 4.0 Hz, 1H), 4.62 (t, J = 4.8 Hz, 1H), 
4.10 (dd, J = 6.0, 4.8 Hz, 2H), 3.76 (m, 2H), 2.64 (sextet, J = 4.0 Hz, 2H), 2.07 (m, 1H), 
1.93 (m, 2H), 1.32 (dm, J = 13.8 Hz, 1H), 1.18 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 169.1, 101.0, 67.0, 56.7, 30.8, 30.7, 25.8, 22.5; HRMS (TOF, ES+) C11H22NO3S 
[M+H]
+
 calc'd 248.1320, found 248.1319. 
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(R)-N-((R)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-2-methylpropane-2-sulfinamide (1.97).   
In-Mediated allylation were done according to procedures published by Lin and co-
workers. To a reaction flask containing 1.96 (1.1 g, 4.45 mmol) and indium powder (2.05 
g, 17.8 mmol) was added saturated aqueous NaBr solution (90 mL) followed by the allyl 
bromide (1.54 mL, 17.8 mmol). The resulting suspension stirred at rt overnight. The 
reaction was quenched by the addition of saturated aqueous NaHCO3 and filtered through 
a pad of celite. The aqueous layer was extracted with EtOAc (3x), dried over Na2SO4, 
filtered, concentrated in vacuo to give the crude product as >19:1 dr, which was then 
purified by  flash chromatography (1:1 Hex/EtOAc) to yield the allylation product 1.12 g 
(87%) as a pale yellow oil: [α]D
20
 = -46.4 (c = 1.79, CHCl3); 
1
H NMR (400.1 MHz, 
CDCl3) δ (ppm): 5.77 (m, 1H), 5.16 (d, J = 4 Hz, 1H), 5.13 (s, 1H), 4.51 (t, J = 4.5 Hz, 
1H), 4.08 (dd, J = 5.0, 6.3 Hz, 2H), 3.74 (dt, J = 10, 2.2 Hz, 2H), 3.30 (m, 1H), 3.23 (d, J 
= 6.5 Hz, 1H), 2.37 (m, 2H), 2.05 (m, 1H), 1.63 (m, 3H), 1.33 (br, J = 14 Hz, 1H), 1.19 
(s, 9H);  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 133.9, 119.0, 101.9, 66.8, 55.8, 55.0, 
40.5, 31.3, 29.2, 25.7, 22.6; HRMS (TOF, ES+) C14H28NO3S [M+H]
+
 calc'd 290.1790, 
found 290.1790. 
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General Procedure for N-alkylation: 
To a solution of sulfinamide 1.97 (1 equiv), in DMF at -20 
o
C was added LiHMDS (1 M, 
1.0 equiv) and the mixture was stirred for 20 mins. Bromide (1.5 equiv.) was then added 
slowly to the mixture and the reaction was stirred for 3 hrs at rt.  The reaction was 
quenched with saturated NH4Cl solution and extracted with EtOAc (3x).  The combined 
organic extracts were washed with water and the dried over Na2SO4. Filtration and 
concentration afforded the crude product, which was purified by flash chromatography 
(4:1 Hex/EtOAc).  
 
 
(R)-N-((R)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-N-allyl-2-methylpropane-2-sulfinamide 
(1.98).  
The product was prepared according to the general procedure using allyl bromide. The 
reaction was run on a 1 mmol scale, to afford the product  as a off white gum (263.2 mg, 
80%): [α]D
20
 = +40.1 (c = 1.11, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.82 (m, 
2H), 5.03-5.21 (m, 4H), 4.49 (t, J = 4.8 Hz, 1H), 4.07 (dd, J = 6.8, 4.8  Hz, 2H), 3.94 (dd, 
J = 11.6, 5.2 Hz, 1H), 3.74 (t, J = 12.0 Hz, 2H), 3.20 (dd, J = 9.6, 6.8 Hz, 1H), 3.09 (q, J 
= 6.8 Hz, 1H), 2.24-2.41 (m, 2H), 2.34 (t, J = 6.2 Hz, 1H), 1.83 (m, 1H), 1.65-1.73 (m, 
2H), 1.62 (m, 1H), 1.33 (d, J = 13.6 Hz, 1H), 1.19 (s, 9H);  13C NMR (100.6 MHz, 
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CDCl3) δ (ppm): 136.5, 135.9, 117.4, 117.1, 102.2, 67.0, 58.2, 45.2, 39.1, 33.0, 27.6, 
25.9, 23.9; HRMS (TOF, ES+) C17H32NO3S [M+H]
+
 calc'd 330.2103, found 330.2104. 
 
  
(R)-N-((R)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-2-methyl-N-(pent-4-en-1-yl)propane-2-
sulfinamide (1.105).  
The product was prepared according to the general procedure using 5-bromopent-1-ene. 
The reaction was run on a 1 mmol scale, to afford the product as yellow oil (303.4 mg, 85 
α]D
20
 = +39.7 (c = 0.91, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.79 (m, 2H), 
5.03 (m, 4H), 4.51 (t, J = 4.8 Hz, 1H), 4.07 (dd, J = 6.8, 4.8  Hz, 2H), 3.94 (dt, J = 12.0, 
2.4 Hz, 2H), 3.23 (m, 1H), 3.06 (q, J = 6.4 Hz, 1H), 2.56 (m, 1H), 2.33 (m, 2H), 2.07 (m, 
3H), 1.59-1.86 (m, 6H), 1.32 (d, J = 13.6 Hz, 1H), 1.19 (s, 9H);  13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 137.8, 136.0, 117.1, 115.14, 102.3, 67.0, 66.9, 57.9, 42.8, 39.2, 33.1, 
31.6, 29.6, 28.0, 24.0; HRMS (TOF, ES+) C19H36NO3S [M+H]
+
 calc'd 358.2416, found 
358.2416. 
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(R)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)-1,2,3,6-tetrahydropyridine 
(1.99).  
To a solution of 1.98 (200 mg, 0.61 mmol) in CH2Cl2 (65 mL) was added 2
nd
 Gen. 
Grubbs (25.9 mg, 0.030 mmol). The mixture was refluxed for 1 h and concentrated. The 
resulting crude product was purified by automated flash chromatography (4:1 to 1:1 
Hex/EtOAc) to yield the desired product 154.2 mg (84%) as off white solid: [α]D
20
 = 
+20.7 (c = 1.05, CHCl3);  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.69 (m, 2H), 4.53 (t, J 
= 5.2 Hz, 1H), 4.10 (dd, J = 7.6, 4.0 Hz, 2H), 3.85 (m, 1H), 3.76 (tt, J = 12.0, 2.8 Hz, 
2H), 3.29-3.40 (m, 2H), 2.55 (m, 1H), 2.01-2.13 (m, 1H), 1.85-1.91 (m, 2H), 1.70-1.79 
(m, 1H), 1.57-1.66 (m, 2H), 1.34 (d, J = 13.6 Hz, 1H), 1.16 (s, 9H);  13C NMR (100.6 
MHz, CDCl3) δ (ppm): 125.26, 123.57, 102.17, 67.00, 58.62, 56.90, 36.46, 32.86, 28.16, 
26.88, 25.85, 23.49; HRMS (TOF, ES+) C15H28NO3S [M+H]
+
 calc'd 302.1790, found 
302.1788. 
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(R)-8-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)-1,2,3,4,7,8-
hexahydroazocine (1.106).  
To a solution of 1.105 (217.8 mg, 0.61 mmol) in CH2Cl2 (65 mL) was added 2
nd
 Gen. 
Grubbs (25.9 mg, 0.030 mmol). The mixture was refluxed for 1 h and concentrated. The 
resulting crude product was purified by automated flash chromatography (4:1 to 1:1 
Hex/EtOAc) to yield the desired product 178.6 mg (82%) as off white solid: [α]D
20
 = 
+24.6 (c = 1.16, CHCl3);  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.75 (m, 2H), 4.52 (t, J 
= 4.4 Hz, 1H), 4.09 (m, 2H), 3.75 (m, 3H), 3.19 (m, 2H), 2.3-2.4 (m, 2H), 2.15-2.2 (m, 
1H), 1.98-2.1 (m, 2H), 1.53-1.8 (m, 5H), 1.45 (m, 1H), 1.30 (d, J = 13.6 Hz, 1H), 1.18 (s, 
9H);  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 132.3, 127.6, 102.5, 67.0, 66.9, 58.2, 45.8, 
32.7, 31.2, 30.9, 27.4, 25.9, 24.0, 23.9; HRMS (TOF, ES+) C17H32NO3S [M+H]
+
 calc'd 
330.2103, found 330.2104.  
 
General Procedure for Alkene-Reduction: 
To a solution of sulfinamide (0.43 mmol) in EtOH (7 mL) was added Pd/C (45.6 mg, 
0.43 mmol). The reaction mixture was purged and back filled with H2 gas. The mixture 
was stirred at rt overnight. The mixture was filtered through celite pad and washed with 
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CH2Cl2. Concentration in vacuo gave the crude product which was used without 
purification.  
 
 
(R)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)piperidine (1.134):  
[α]D
20
 = -3.06 (c = 1.00, CHCl3);  
1
HNMR (400.1 MHz, CDCl3) δ (ppm): 4.52 (t, J = 5.2 
Hz, 1H), 4.09 (dd, J = 6.4, 4.4 Hz, 2H), 3.75 (t, J = 11.6 Hz, 2H), 3.19-3.26 (m, 2H), 3.04 
(m, 1H), 2.02-2.12 (m, 1H), 1.77-1.92 (m, 3H), 1.46-1.72 (m, 7H), 1.34 (d, J = 13.6 Hz, 
1H), 1.16 (s, 9H);  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 102.3, 67.1, 59.2, 58.5, 40.7, 
32.7, 29.0, 26.3, 25.9, 25.7, 23.7, 19.6; HRMS (TOF, ES+) C15H30NO3S [M+H]
+
 calc'd 
304.1946, found 304.1946. 
 
 
(S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)azepane (1.135): 
[α]D
20
 = -1.7 (c = 0.33, CHCl3);  
1
HNMR (400.1 MHz, CDCl3) δ (ppm): 4.52 (t, J = 5.2 
Hz, 1H), 4.10 (dd, J = 6.8, 4.8 Hz, 2H), 3.75 (t, J = 12.0 Hz, 2H), 3.48 (q, J = 6.0 Hz, 
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1H), 3.37 (m, 1H), 3.08 (m, 1H), 2.05 (m, 1H), 1.82-1.89 (m, 2H), 1.77 (m, 1H), 1.45-
1.65 (m, 9H), 1.33 (d, J = 13.6 Hz, 1H), 1.21 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 101.5, 66.3, 60.8, 57.7, 42.3, 33.3, 32.1, 29.7, 27.6, 27.1, 25.3, 23.9, 23.5; HRMS 
(TOF, ES+) C16H32NO3S [M+H]
+
 calc'd 318.2103, found 318.2101. 
 
 
(R)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)azocane (1.136):  
[α]D
20
 = -16.9 (c = 0.34, CHCl3); 
1
HNMR (400.1 MHz, CDCl3) δ (ppm): 4.51 (t, J = 5.2 
Hz, 1H), 4.08 (m, 2H), 3.75 (tt, J = 12.0, 2.4 Hz, 2H), 3.31-3.38 (m, 2H), 3.14-3.25 (m, 
2H), 2.01-2.12 (m, 1H), 1.81-1.89 (m, 2H), 1.57-1.74 (m, 8H), 1.52 (m, 1H), 1.30-1.44 
(m, 3H), 1.2 (s, 9H);  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 102.3, 67.0, 59.7, 58.6, 
43.5, 33.1, 32.8, 29.2, 28.9, 28.6, 25.9, 25.0, 24.1, 22.9; HRMS (TOF, ES+) C17H34NO3S 
[M+H]
+
 calc'd 332.2259, found 332.2257. 
 
General Procedure for Ring Closure. 
To the crude product cooled to 0 
o
C was added 5 ml of 95:5 TFA/H2O, after stirring at rt 
for 1 h the mixture was concentrated in vacuo to remove the TFA /H2O solvent. The 
residue was dissolved in DCE and PS-NaBH(OAc)3 (0.5 g, 1.08 mmol) was added and 
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placed on a shaker overnight. The beads were filterd off and the solvent was concentrated 
in vacuo to give the crude azabicyclic product. Purification by flash chromatography 
gave the desired azabicylic ring product. 
 
 
(S)-octahydroindolizine (1.1).  
Flash chromatography (9:1:0.5 CH2Cl2/MeOH/NH3) yield the product 10.1 mg (81% 
over 2-steps) as a yellow oil: [α]D
20
 = + 1.9 (c = 1.14, EtOH);  1H NMR (400.1 MHz, 
MeOD) δ (ppm):  4.44 (dt, J= 2, 4 Hz, 1H), 3.61, m, 1H), 3.37 (m, 1H), 3.12 (m, 1H), 
2.98 (t, J= 12.6 Hz, 1H), 2.04 (m, 1H), 1.89-1.39 (m, 9H); 13C NMR (100.6 MHz, 
MeOD) δ (ppm): 62.2, 58.2, 45.9, 31.8, 29.8, 28.9, 23.5, 23.1;  HRMS (TOF, ES+) 
C8H16N [M+H]
+
 calc'd 126.1277, found 126.1276. 
 
 
(S)-octahydro-1H-pyrrolo[1,2-a]azepine (1.2).  
Flash chromatography (9:1:0.5 CH2Cl2/MeOH/NH3) yield the product 11.9 mg (86% 
over 2-steps) as off white solid: [α]D
23
 = +0.6 (c = + 1.55, EtOH); 1H NMR (400.1 MHz, 
MeOD) δ (ppm):  4.57 (s, 1H), 3.60 (m, 2H), 3.23 (m, 1H), 3.17 (m, 1H), 2.05-1.59 (m, 
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12H);  
13
C NMR (100.6 MHz, MeOD) δ (ppm): 62.21, 60.41, 46.51, 32.29, 31.83, 29.46, 
27.57, 26.13, 25.74; HRMS (TOF, ES+) C14H18O4 [M+H]
+
 calc'd 140.1439, found 
140.1439. 
 
 
(S)-decahydropyrrolo[1,2-a]azocine (1.3).  
Flash chromatography (9:1:0.5 CH2Cl2/MeOH/NH3) yield the product 13.3 mg (87% 
over 2-steps) as off white solid: [α]D
20
 = + 1.1 (c = 1.85, EtOH);  1H NMR (400.1 MHz, 
MeOD) δ (ppm):  3.62 (m, 2H), 3.34 (m, 1H), 3.18 (m, 2H), 1.6-2.0 (m, 14H);  13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 60.7, 57.4, 44.2, 30.8, 28.1, 27.9, 24.6, 24.1, 24.0, 23.2;  
HRMS (TOF, ES+) C10H20N [M+H]
+
 calc'd 154.1596, found 154.1594. 
 
 
(S)-methyl 4-((tert-butylsulfinyl)imino)butanoate (1.110).  
To a solution of methyl 4-oxobutanoate  (10 g, 86.2 mmol) in CH2Cl2 (500 mL) was 
added (S)-2-methylpropane-2-sulfinamide (12.9 g, 106.2 mmol) and CuSO4 (54.7 g, 
344.0 mmol). The reaction mixture was stirred at rt overnight. The mixture was filtered 
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through a pad of celite and washed with CH2Cl2. Concentration in vacuo gave the crude 
product which was purified by automated flash chromatography (4:1 to 1:1 Hex/EtOAc) 
to yield the desired product 17.9 g (95%) as yellow oil: [α]D
20
 = +178.1 (c = 1.67, 
CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 8.13 (t, J = 2.8 Hz, 1H), 3.68 (s, 3H), 
2.82-2.94 (m, 2H), 2.70-2.82 (m, 1H), 2.59-2.67 (m, 1H), 1.17 (s, 9H);  
13
C NMR (100.6 
MHz, CDCl3) δ (ppm): 172.4, 167.3, 56.9, 51.9, 31.2, 29.2, 22.4; HRMS (TOF, ES+) 
C9H18NO3S [M+H]
+
 calc'd 220.1007, found 220.1007. 
 
 
(S)-methyl-4-((S)-1,1-dimethylethylsulfinamido)hept-6-enoate (1.111).  
In-Mediated allylation were done according to procedures previously shown above for 
1.97. The reaction was run on a 50 mmol scale, to afford the crude product as >19:1 dr, 
which was then purified by  flash chromatography (1:1 Hex/EtOAc) to yield the 
allylation product 11.5 g (88%) as yellow oil: [α]D
20
 = +45.7 (c = 0.95, CHCl3); 
1
H NMR 
(400.1 MHz, CDCl3) δ (ppm): 5.78 (m, 1H), 5.15 (m, 2H), 3.67 (s, 3H), 3.40 (m, 1H), 
3.22 (d, J= 7.2 Hz, 1H), 2.40 (m, 3H), 1.90 (m, 1H), 1.75 (m, 1H), 1.20 (s, 9H);  13C 
NMR (100.6 MHz, CDCl3) δ (ppm): 173.9, 133.6, 119.6, 56.1, 55.1, 51.9, 40.1, 30.5, 
30.1, 22.8; HRMS (TOF, ES+) C12H24NO3S [M+H]
+
 calc'd 262.1477, found 262.1476. 
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(S)-5-allylpyrrolidin-2-one (1.112).  
To a solution of compound 1.111 (2.61 g, 10 mmol) in methanol (100 mL) was added 10 
mL of 12 N HCl aqueous solution at room temperature. The resultant mixture was then 
stirred at rt for 2 h. After concentrated, the residue was dissolved in 150 mL CH2Cl2 and 
200 mL of saturated aqueous Na2CO3 was added. After stirring overnight, the mixture is 
extracted with CH2Cl2; combined organic extracts were washed with water and brine and 
dried over Na2SO4. Filtration and concentration afforded the crude product, which was 
purified by flash chromatography (1:1 Hex/EtOAc) to yield the desired product 1.21 g 
(97%) as brown oil: [α]D
20
 = +2.5 (c = 1.16, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ 
(ppm); 6.43 (br s, 1H), 5.74 (m, 1H), 5.11 (d, J = 12.7 Hz, 2H), 3.70 (q, J = 6.5 Hz, 1H), 
2.32 (m, 2H), 2.22 (m, 3H), 1.76 (m, 1H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 173.4, 
153.5, 146.9, 130.5, 125.5, 125.2, 116.6, 113.9, 111.9, 60.6, 55.7, 34.1, 28.6, 14.2; 
HRMS (TOF, ES+) C7H12NO [M+H]
+
 calc'd 126.0919, found 126.0921. 
 
General Procedure for lactam N-alkylation: 
To a solution of lactam 1.112 (1 equiv), in DMF at 0 
o
C was added NaH (1.02 equiv) and 
the mixture was stirred for 10 mins and additional 10 mins at rt. At 0 
o
C bromide (1.5 
equiv.) was then added slowly to the mixture and the reaction was warmed to rt and 
stirred for 2 hrs.  The reaction was quenched with water and extracted with EtOAc (3x).  
The combined organic extract was the dried over Na2SO4. Filtration and concentration 
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afforded the crude product, which was purified by flash chromatography (1:1 
Hex/EtOAc).  
 
 
(S)-1,5-diallylpyrrolidin-2-one (1.137): 
The product was prepared according to the general procedure using allyl bromide. The 
reaction was run on a 5 mmol scale, to afford the product as a light brown oil (800.3 mg, 
97%): [α]D
20
 = -21.4 (c = 0.44, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.70 (m, 
2H), 5.17 (m, 4H), 4.33 (dd, J = 10.4, 5.2 Hz, 1H), 3.67 (septet,  J = 4.0 Hz, 1H), 3.55 
(dd, J = 7.2 Hz, 1H), 2.8-2.47 (m, 3H), 2.05-2.23 (m, 2H), 1.77 (m, 1H);  13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 175.03, 132.93, 132.89, 56.79, 43.25, 37.48, 30.18, 23.43; 
HRMS (TOF, ES+) C10H15NO [M+H]
+
 calc'd 166.1228, found 166.1223. 
 
 
(S)-5-allyl-1-(but-3-en-1-yl)pyrrolidin-2-one (1.138):  
The product was prepared according to the general procedure using 4-bromobut-1-ene. 
The reaction was run on a 5 mmol scale, to afford the product as colorless oil (868.2 mg, 
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97%): [α]D
20
 = -26.3 (c = 0.73, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.66-
5.82 (m, 2H), 5.03-5.18 (m, 4H), 3.66-3.80 (m, 2H), 2.97 (m, 1H), 2.18-2.57 (m, 7H), 
1.69-1.78 (m, 1H);  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 175.3, 135.3, 132.9, 118.9, 
117.0, 57.0, 39.7, 37.6, 31.9, 30.3, 23.6; HRMS (TOF, ES+) C11H18NO [M+H]
+
 calc'd 
180.1388, found 180.1387. 
 
 
(S)-5-allyl-1-(pent-4-en-1-yl)pyrrolidin-2-one (1.139): 
 The product was prepared according to the general procedure using 5-bromopent-1-ene. 
The reaction was run on a 5 mmol scale, to afford the product as colorless oil (916.8 mg, 
95%): [α]D
20
 = -25.3 (c = 0.84, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.65-
5.86 (m, 2H), 4.97-5.17 (m, 4H), 3.61-3.69 (m, 2H), 2.93 (m, 1H), 2.22-2.44 (m, 3H), 
2.10-2.20 (m, 1H), 2.07 (m, 3H), 1.55-1.79 (m, 3H);  
13
C NMR (100.6 MHz, CDCl3) δ 
(ppm): 175.2, 137.8, 132.9, 118.9, 115.3, 57.0, 40.0, 37.7, 31.3, 30.3, 26.7, 23.6; HRMS 
(TOF, ES+) C12H19NO [M+H]
+
 calc'd 194.2931, found 194.2929. 
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General Procedure for ring closing metathesis of N-alkyl lactam: 
To a solution of N-alkyl-lactam (1 equiv), in CH2Cl2 was added 2
nd
 Gen. Grubbs (0.05 
equiv). The mixture was refluxed for 1 – 2 h and concentrated. The resulting crude 
product was purified by automated flash chromatography (1:1 Hex/EtOAc) to yield the 
desired product. 
 
 
(S)-1,2,8,8a-tetrahydroindolizin-3(5H)-one (1.113):  
The product was prepared according to the general procedure. The reaction was run on a 
3 mmol scale, to afford the product as a brown oil (316.5 mg, 77%): [α]D
20
 = -27.3 (c = 
0.62, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.78 (m, 1H), 5.69 (m, 1H), 4.24 
(dd, J = 16.0, 2.5 Hz, 1H), 3.55 (m, 2H), 2.25-2.42 (m, 4H), 1.99 (m, 2H), 1.68 (m, 1H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 174.4, 124.3, 123.6, 53.1, 40.5, 32.6, 30.1, 25.7; 
HRMS (TOF, ES+) C8H12NO [M+H]
+
 calc'd 138.0919, found 138.0916. 
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(S)-5,6,9,9a-tetrahydro-1H-pyrrolo[1,2-a]azepin-3(2H)-one (1.114).  
The product was prepared according to the general procedure. The reaction was run on a 
3 mmol scale, to afford the product as colorless oil (339.8 mg, 75%): [α]D
20
 = -22.3 (c = 
0.52, CHCl3); 
1H NMR (400.1 MHz, MeOD) δ (ppm):  5.89 (m,1H), 5.80 (m, 1H), 3.81 
(m, 2H), 3.08 (dt, J = 1.6, 8 Hz, 1H), 2.4-2.2 (m, 7H), 1.66 (m, 1H);  13C NMR (100.6 
MHz, CDCl3) δ (ppm):176.89, 132.37, 129.76, 60.49, 42.61, 36.90, 31.34, 28.61, 26.48; 
HRMS (TOF, ES+) C9H14NO [M+H]
+
 calc'd 152.1119, found 152.1116. 
 
 
(S)-1,2,6,7,10,10a-hexahydropyrrolo[1,2-a]azocin-3(5H)-one (1.115).  
The product was prepared according to the general procedure. The reaction was run on a 
3 mmol scale, to afford the product as colorless oil (252.5 mg, 51%): [α]D
20
 = -20.8 (c = 
0.42, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.81 (m, 1H), 5.71 (m, 1H), 3.81 
(dt, J = 13.6, 4.0 Hz, 1H), 3.58 (septet, J = 4.8  Hz, 1H), 2.74 (m, 1H), 2.34-2.45 (m, 2H), 
2.21-2.32 (m, 2H), 2.11-2.20 (m, 2H), 1.97-2.10 (m, 2H), 1.64-1.76 (m, 1H), 1.48-1.52 
(m, 1H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 175.9, 133.4, 125.8, 61.6, 42.9, 33.1, 
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30.5, 26.9, 24.6, 24.5; HRMS (TOF, ES+) C10H16NO [M+H]
+
 calc'd 166.1232, found 
166.1233. 
 
 
(S,E)-N-(6-chlorohexylidene)-2-methylpropane-2-sulfinamide (1.127c). 
To a solution of 6-chlorohexanal (7.37 g, 54.79 mmol) in DCM (219 ml) at ambient 
temperature was added CuSO4 (20.11 g, 126.02 mmol) and (S)-2-methylpropane-2-
sulfinamide (7.64 g, 63.01 mmol) in a single batch.  The reaction was stirred for 12 h, at 
which point the starting material was fully consumed by TLC analysis (4:1 Hex/EtOAc, 
rf = 0.35).  The heterogeneous mixture was filtered through a silica pad and concentrated 
in vacuo to yield a viscous oil, which was purified by flash chromatography (4:1 
Hex/EtOAc) to afford the desired product as a clear oil (12.34 g, 94%).  [α]D
20
 = +157.9° 
(c = 1.5, MeOH). 1H NMR (400.1 MHz, CDCl3) δ (ppm): 8.05 (t, J = 4.5 Hz, 1H); 3.52 
(t, J = 6.5 Hz, 2H); 2.53 (m, 2H); 1.79 (m, 2H); 1.66 (m, 2H); 1.51 (m, 2H); 1.18 (s, 9H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 169.26, 56.64, 44.82, 35.96, 32.37, 26.56, 24.78, 
22.42.  HRMS (TOF, ES+) C10H21NOSCl [M+H]
+
 calc'd 238.1032, found 238.1034. 
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(S)-N-((R)-9-chloronon-1-en-4-yl)-2-methylpropane-2-sulfinamide (1.128c). 
NaBr (380 g) was dissolved in 841 mL of deionized H2O.  To this fully dissolved 
saturated NaBr solution was added aldimine 1.127c (10.00g, 42.05 mmol) and indium 
powder (19.31 g, 168.2 mmol).  The mixture was stirred vigorously for 5 min., then allyl 
bromide (20.35 g, 168.2 mmol)  added in a single batch. Vigorous stirring was continued 
for 9 h, at which point the starting material was consumed by TLC analysis (1:1 
Hex/EtOAc, rf = 0.34).  The mixture was quenched with NaHCO3 and extracted x5 with 
EtOAc.  The organic fractions were combined, washed with brine, dried over Na2SO4, 
and concentrated in vacuo to yield crude oil.  Purification by flash chromatography (1:1 
Hex/ EtOAc) afforded the desired product as a clear oil (10.10 g, 86%).  [α]D
20
 = +25.7° 
(c = 1.5, MeOH). 1H NMR (400.1 MHz, CDCl3) δ (ppm):  5.77 (m, 1H);5.15 (m, 2H); 
3.52 (t, J = 6.5Hz, 2H); 3.30 (sextet, J = 6.1 Hz, 1H); 3.21 (br d, J = 6.1 Hz, 1H); 2.35 
(dp, J1 = 6.5 Hz, J2 = 10.4 Hz, 2H); 1.763 (quint., J = 6.5 Hz, 2H); 1.53- 1.32 (m, 5H).  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 134.23, 119.14, 55.92, 54.83, 45.08, 40.56, 
34.91, 32.60, 26.88, 24.92, 22.79.  HRMS (TOF, ES+) C13H27NOSCl [M+H]
+
 calc'd 
280.1502, found 280.1504. 
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(S)-1,2-diallylazepane (1.129c1). 
A 4N solution of HCl / dioxanes (14.92 ml) was cooled to 0°C and slowly added to a 
microwave vial containing sulfinamide 1.128c (2.0 g, 7.15 mmol).  Solution was then 
brought to ambient temperature and stirred for an additional 45 min, and concentrated in 
vacuo to afford the deprotected amine as the HCl salt in quantitative yield.   The amine 
was dissolved in DMF (35.9 mL), then K2CO3 (1.98 g, 14.34 mmol) and NaI (1.18 g, 
7.89 mmol) were added in a single batch.  The vial was sealed and submitted to 
microwave irradiation at 120°C for 15 min.  LC/MS analysis showed full consumption of 
starting material to the cyclized secondary amine.  Allyl bromide (0.954 g, 7.89 mmol) 
and an additional equivalent of K2CO3 (0.99 g, 7.15 mmol) was then added to the pale 
yellow solution at ambient temperature, and stirring was continued for 4 h.  Mixture was 
dissolved in 5% LiCl solution and extracted with Et2O (5 x 40 mL).  Organic fractions 
were combined, washed with brine, dried over Na2SO4, and concentrated in vacuo to 
yield a pale yellow crude oil.  Purification by flash chromatography (1:1 Hex/EtOAc) 
afforded the desired product as a clear oil (0.82g, 64%). [α]D
20
 = -5.0° (c = 0.9, MeOH). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.82 (m, 2H); 5.19-4.93 (m, 4H); 3.22 (m, 2H); 
2.85 (m, 1H); 2.70 (m, 2H); 2.26 (m, 1H); 2.06 (m, 1H); 1.75 (m, 1H); 1.66-1.38 (m, 7H).  
13
C NMR (100.6 MHz, CDCl3) δ (ppm):  137.98, 137.51, 115.99, 115.66, 62.45, 55.71, 
49.83, 39.34, 32.65, 28.88, 27.53, 25.78.  HRMS (TOF, ES+) C12H22N [M+H]
+
 calc'd 
180.1752, found 180.1751. 
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(S)-octahydropyrido[1,2-a]azepine (1.130c1).  
To a solution of diene 1.4.14c1 (106 mg, 0.59 mmol) in toluene (11.8 mL) was added 
trifluoroacetic acid (71 mg, 0.62 mmol), and Grubbs 2
nd
 generation catalyst (49 mg, 0.06 
mmol).  Solution was submitted to microwave irradiation for 1 h at 100°C.  The toluene 
was removed in vacuo, and the crude residue purified to afford the desired product as the 
TFA salt (105 mg, 68%). [α]D
20
 = +45.2° (c = 1.25, MeOH). 1H NMR (400.1 MHz, 
CDCl3) δ (ppm): 5.88 (m, 1H); 5.64 (m, 1H); 3.94 (m, 1H); 3.57 (m, 2H); 3.18-3.04 (m, 
2H); 2.73 (t, 1H); 2.25 (m, 1H); 2.24-1.92 (m, 3H); 1.89-1.72 (m, 3H); 1.58 (m, 2H).  
13
C 
NMR (100.6 MHz, CDCl3) δ (ppm): 126.83, 120.24, 63.64, 55.70, 54.32, 31.93, 30.59, 
27.21, 26.00, 21.96.  HRMS (TOF, ES+) C10H18N [M+H]
+
 calc'd 152.1439, found 
152.1440.  
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CHAPTER II 
 
TOTAL SYNTHESIS OF THE ALKALOID NATURAL PRODUCTS (+)-
AMABILINE AND GRANDISINE D 
 
2.1. Introduction 
Alkaloid natural products are a large, structurally diverse group of naturally-
occurring compounds originating from plants, animals, and microbes.  They have a 
reputation as both nature’s blessing and curse, responsible for the beneficial properties of 
natural medicines such as willow bark, and the detrimental effects of poisons such as 
deadly nightshade.
1
  The profound biological activity found in alkaloids have led to their 
use as drug leads to develop treatments in various therapeutic areas such as pain relief, 
gastrointestinal disorders, and cardiac disorders.
2-3
  However, alkaloids are relatively 
underrepresented in the context of newly introduced medicines, with supply constraints 
of these natural products cited as a barrier to  biological characterization and 
development of many of these compounds.
4
  Total synthesis attempts to overcome this by 
providing methods to access these biologically-relevant compounds in greater quantities  
has remained an area of interest in the organic synthesis community for decades.  Our 
efforts towards the total synthesis of two natural products belonging to the pyrrolizidine 
and indolizidine alkaloid classes will be described. 
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2.1.1. Pyrrolizidine Alkaloids 
Pyrrolizidine alkaloids (2.1), historically referred to as necine bases, share a 
common azabicyclo[3.3.0]octane core, but differ based on the oxygenation pattern and 
whether or not C1-C2 is saturated (Figure 2.1).
5
  While the amine bases themselves are 
rarely isolated in nature, the corresponding mono- and di-esters are more common, as 
either the tertiary amine or the N-oxide.    Members of this family of alkaloids possess a 
wide range of biological activities including antitumor, antibacterial, anti-inflammatory, 
carcinogenic and hepatotoxic activity, with several members entering human clinical 
trials.  A number of racemic routes to the pyrrolizidine alkaloid core (2.1) have been 
developed, but recent efforts have focused on asymmetric approaches.  Further 
commentary on these approaches can be found in Chapter 1. 
Plants containing pyrrolizidine alkaloids are toxic to humans and animals, 
however, several insect species have evolved to adapt them for their own chemical 
defense.
6
  Interestingly, the toxicity of these compounds has been attributed to liver 
metabolism of the C1-C2 unsaturated congeners leading to the generation of highly 
reactive alklyating agents.  Our interest in the synthesis of (+)-amabiline stemmed from 
our success in the development of our methodology for the enantioselective synthesis of 
azabicyclic ring systems. 
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Figure 2.1. Structures of pyrrolizidine alkaloids 
 
2.1.2. Indolizidine Alkaloids 
Indolizidine alkaloids (IAs) have been isolated from a myriad of sources 
including ants, frog, fungi and trees. IAs have exhibited interesting biological activities 
including insecticidal, antibacterial, fungicidal, analgesic, and anticancer activities.
7
  
Indolizidine alkaloids are defined by a 1-aza-bicyclo-[4.3.0]-octane core similar that of 
the pyrrolizidine alkaloids. Shown in Figure 2.2 are several examples of indolizidine-
containing natural products.  This core system serves as an important scaffold in 
biologically active and pharmaceutically significant compounds, and the literature is rich 
with the total synthesis and biological evaluation of compounds containing the 
indolizidine skeleton.
8
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Figure 2.2.  Examples of indolizidine-containing natural products. 
 
2.2. Total Synthesis of (+)-Amabiline 
2.2.1. Introduction 
(+)-Amabiline is a pyrrolizidine alkaloid isolated by Smith and co-workers from 
the leaves of the Chinese flowering plant Cynoglossum amabiline.9  This class of 
alkaloids has exhibited activity at a wide range of biological targets, including subtype-
specific neuronal nicotinic acetylcholine receptors and muscarinic acetylcholine 
receptors.
10
  These receptors are involved in normal central nervous system functions, 
such as memory and motor function, as well as pathological conditions such as 
Parkinson’s disease, schizophrenia, and Alzheimer’s disease.  
There are at least three fates for the metabolism of pyrrolizidine alkaloids such as 
(+)-amabiline (Figure 2.3).
11,12
  They can be metabolized by flavin-containing 
monooxygenases (FMO) to the water soluble N-oxide, which leads to excretion of the 
compounds.  Conversely, metabolism by cytochrome P450 enzymes, primarily CYP3A4, 
converts compounds to the dehydropyrrolizidine metabolite 2.11 that is believed to lead 
to toxicity in animals and humans.  In the case of some insects, the presence of the 
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enzyme senecionine N-oxidase (SNO) will convert the compounds to the N-oxide, where 
they can be sequestered and used as a deterrent to other insect and animal predators.  This 
process describes an interesting case of an animal species utilizing the defensive 
mechanism of a plant in the form of a compound not produced endogenously by the 
insect to protect itself from predators. 
 
Figure 2.3. Metabolic fate of pyrrolizidine alkaloids 
 
2.2.2. Retrosynthetic Analysis of (+)-Amabiline 
Our approach for the total synthesis of (+)-amabiline was based on a 
retrosynthetic analysis outlined in Figure 2.4. Our retrosynthesis began with cleavage of 
the ester bond to liberate the necine base (-)-supinidine and (-)-viridifloric acid.  (-)-
Supinidine has been previously synthesized, but the most expedient route required was 18 
steps.
13
  By employing a novel extension of our newly developed azacine methodology, 
the azabicyclic moiety could be accessed from 2.14, which would be derived from the 
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commercial diol 2.16 and (S)-tert-butylsulfinimine 2.17.  (-)-Viridifloric acid would be 
prepared as prescribed by Schulz, via 2.15, from commercial 2.18 and 2.19.
14
 
 
Figure 2.4. Retrosynthetic Analysis of (+)-Amabiline 
 
2.2.3 Synthesis of (+)-Amabiline 
Efforts initially focused on the synthesis of 2.15 (Scheme 2.1).
 
 As was described 
in the retrosynthesis, the (-)-viridifloric acid moiety needed to be constructed in a manner 
that would allow for esterification with alcohol 2.14.  Alkylation of phosphonate ester 
2.18 with 2.19 provided 2.20 in 93% yield.  A Horner-Wadsworth-Emmons reaction with 
acetaldehyde provided alkene 2.21, and although purification proved troublesome due to 
volatility of the low molecular weight α,β-unsaturated ester, the desired product was 
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obtained in 78% yield.  The alkene then underwent a Sharpless dihydroxylation to afford 
(S,S)-diol 2.21 in >8:1 dr. Ester hydrolysis provided the (-)-viridifloric acid (2.13), 
identical in all respects to the natural acid, which was then protected as the dioxolane 
congener 2.15 to avoid possible complication during the subsequent esterification.  Thus, 
the synthesis of 2.15 required five steps and proceeded in 48% overall yield. 
 
 
Scheme 2.1. Synthesis of protected (-)-viridifloric acid 
 
With 2.16 in hand, attention was now directed to the synthesis of key intermediate 
2.15 (Scheme 2.2).   Commercial diol 2.21 was mono-silyated, followed by MnO2 
oxidation of the allylic alcohol to deliver aldehyde 2.22 in 84% yield for the two steps.  
Condensation of 2.22 with (S)-tert-butyl sulfinimine gave 2.23 in 79% yield.   Addition of 
Grignard reagent 2.24 provides 2.25 in >9:1 dr., which was subsequently allylated to 
deliver 2.26 in 77% yield for the two steps. 
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Scheme 2.2. Synthesis of advanced intermediate 2.27 
 
The diastereoselectivity of this particular Grignard reaction is interesting as it 
does not follow the predicted outcome of the Ellman chelation model proposed during the 
seminal studies of nucleophilic additions into chiral aldimines.  As shown in Figure 2.5, 
nucleophilic addition of a Grignard reagent into a chiral sulfinimine would be expected to 
proceed through a six-membered chelate transition state, however this rationale leads us 
to the opposite diastereomer than that observed in our instance, as determined by X-ray 
crystallography.  In cases where the imine or Grignard reagent contains a heteroatom, it is 
possible for an intramolecular interaction to disrupt the six-member transition state.  This 
causes the Grignard reaction to proceed through an open transition state, which is referred 
to as “anti-Ellman” selectivity. 
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Figure 2.5.  Ellman’s proposed transition states for Grignard addition into chiral tert-
butanesulfinimines 
 
A RCM reaction of 2.26 employing Grubbs II smoothly led to pyrrolidine 2.27, 
and TBAF deprotection generated the key intermediate 2.15. Single X-ray 
crystallography (Figure 2.6) confirmed the absolute stereochemistry of 2.15 as (S,S). 
 
Figure 2.6.  ORTEP drawing of X-ray crystallographically determined structure of 2.15 
67 
 
There is speculation that the oxygen of the acetal group may disrupt the chelation 
of magnesium to the aldimine species, leading to an open transition state, but at this time 
a definitive mechanism to explain the rationale for our observed diastereoselectivity has 
not been proven.  A similar result using this Grignard reagent was reported by Ellman 
and coworkers, however there was no commentary offered regarding the observed “anti-
Ellman” diastereoselectivity.15  
 We anticipated that deprotection of the acetal and the sulfinamine of 2.15 would 
liberate the free aldehyde and amine, respectively, followed by an intramolecular 
condensation to form the imine that would then be reduced in situ to provide (-)-
supinidine (2.13).   However, classical Ellman conditions and a number of other variants 
failed to facilitate this transformation, affording complex mixtures of polar species.   
 
Scheme 2.3. Attempted deprotection to necine base 
 
Therefore, we elected to first couple 2.16 and 2.15, followed by global 
deprotection and intramolecular reductive amination.  This also proved challenging due 
to the sterically hindered acid 2.15.  We evaluated various coupling reagents 
(EDCI/DMAP, TBTU/DBU, DCC/DMAP, HATU/DIEA) and protocols, and none 
provided any trace of the ester product.   Therefore, we decided to convert the hydroxyl 
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of 2.15 into a leaving group, and attempt to install the ester linkage by employing the acid 
as a nucleophile.
16
  A mesyalte derivative afforded a 45% conversion to the desired ester, 
but 2.28, a tosylate variant, afforded the desired ester in 82% yield (Figure 2.7). 
 
Figure 2.7.  Coupling of 2.15 with (+)-viridifloric acid precursor 2.16 
 
 A final acid-mediated global deprotection of the acetal, the dioxolane, and the 
sulfinamine enabled the intramolecular condensation to form the imine, which was then 
reduced in situ by MP-BH(OAc)3 to deliver (+)-amabiline (2.4) in 37% yield in a one-pot 
reaction sequence (average of 84% yield/transformation).   Thus, the first total synthesis 
of (+)-amabiline (2.4) was completed in 15 synthetic steps (10 steps longest linear 
sequence) and in 6.2% overall yield.  The synthetic (+)-amabiline was identical to the 
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data reported for natural 2.4.
17
  Moreover, this represents a notable improvement in the 
synthesis of the pyrrolizidine core, as previous efforts have required up to 18 steps to 
deliver (-)-supinidine (2.12), the parent necine base, that could be used to rapidly and 
stereoselectively access other pyrrolizidine alkaloids and azabicyclic-ring containing 
compounds. 
 
Scheme 2.4.  Synthesis of (+)-amabiline 
 
 Based on the structural similarity of amabiline to other pyrrolizidine alkaloids 
with anticholinergic activity, we evaluated our synthetic amabiline against all five 
mAChR receptors (M1-M5).  Interestingly, amabiline possessed no activity at any of the 
mAChRs (IC50 >10 µM). 
Conversion of amabiline to the corresponding N-oxide (2.29) proceeded through 
treatment with mCPBA to facilitate N-oxidation.  There is precedence for these 
conditions to demonstrate chemoselectivity for the N-oxide over the possible epoxide by-
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product in closely related natural products.
18
  Preliminary results observed by liquid 
chromatography/ mass spectrometry corroborates with those reports, showing conversion 
to the unsaturated N-oxide, however a larger scale will be required for further studies.  
We plan to complete a metabolic study where treating 2.4 with human cytochrome P450 
liver enzymes should show conversion to the N-oxide and/or dehydropyrrolizidine 
products, demonstrating the in vivo relation between the two natural products. 
 
Scheme 2.5.  N-oxidation of amabiline to amabiline-N-oxide 
 
In summary, we have completed the first total synthesis of (+)-amabiline (2.4), 
requiring only 15 synthetic steps (10 steps longest linear sequence) in 6.2% overall yield.   
This highly convergent and concise synthesis will enable the preparation of unnatural, 
unsaturated pyrrolizidine alkaloids for additional biological evaluation.   
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2.3. Total Synthesis of Grandisine D 
2.3.1.  Introduction 
Grandisines A-G are indolizidine alkaloids isolated by Carroll and co-workers 
from the leaves of the Australian rain forest tree Elaeocarpus grandis (Figure 2.8).19 
These alkaloids display selective human δ-opioid receptor affinity. Selective activation of 
the δ-opioid receptor is an attractive strategy for the development of new analgesics with 
better side-effect profiles, making grandisines potential analgesic agents.  To further 
investigate the interesting biology and synthetic challenge of grandisine D, we decided to 
pursue its total synthesis. 
 
 
Figure 2.8. Structures of the indolizidine alkaloids grandisines A-G 
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2.3.2. Tamura Total Synthesis of Grandisine D 
Grandisine D was previously synthesized by Tamura and co-workers in 2009.
20
  
Their synthesis featured a Bronsted-acid mediated Morita-Bayless-Hillman (MBH) ring 
closure and stereoselective aldol condensation with (S)-5-methylcyclohexenone as key 
steps.  Deoxygenation at the C1 and C3 positions afforded grandisine D. 
 
Figure 2.9.  Tamura’s Retrosynthesis of Grandisine D 
 
Tamura’s synthesis of Grandisine D was initiated by the synthesis of aminal 2.39 
utilizing the method previously described by Lee and co-workers from (S)-malic acid in 6 
steps. Treatment of aminal 2.39 with TfOH and Me2S in CH3CN effected the desired 
MBH ring closure in good yield and stereoselectivity (96:4).  Removal of the acetoxy 
group of 2.42 through deacetylation followed by Barton-McCombie deoxygenation 
afforded lactam 2.43.   
73 
 
 
Scheme 2.6. Tamura’s total synthesis of Grandisine D 
 
  Deprotection of the acetal provided aldehyde 2.37, which then underwent the 
key boron mediated aldol reaction to afford 2.44 in quantitative yield as a single 
diastereomer.  Dess-Martin oxidation of the resulting alcohol followed by reduction of 
the lactam accomplished the first total synthesis of Grandisine D, requiring 26 steps. 
 
Scheme 2.7. Tamura total synthesis of grandisine D 
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2.3.3. Taylor Total Synthesis of Grandisine D 
During our efforts towards the total synthesis of grandisine D, a second total 
synthesis of the alkaloid was reported in 2011 by Taylor and co-workers.
21
  As outlined 
in Scheme 2.8, their synthesis featured an alkyne-acetal cyclization as their key step, and 
was accomplished in 13 steps with 10% overall yield from the commercially available L-
proline chiral starting material.  
  
 
Scheme 2.8. Taylor synthesis of (+)-grandisine D 
 
Taylor and co-workers went on to describe the synthesis of grandisine B from 
grandisine D in a one-pot tandem aminination-imination sequence with treatment of 35% 
aqueous ammonia, which is interesting as the isolation procedure of the grandisine 
natural products also includes an extraction with aqueous ammonia.  It is now believed 
that Grandisine B is an artifact of the isolation process and not a naturally occurring 
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compound.  This hypothesis is further corroborated by a lack of detection of Grandisine 
B by (+) ESI MS in crude methanol extracts.   
 
Scheme 2.9. Synthesis of Grandisine B 
 
2.3.4. Retrosynthesis of Grandisine D. 
Our interest in the total synthesis of grandisine D stemmed from our success in 
the application of our methodology for the enantioselective synthesis of azabicyclic ring 
systems and their applications towards various pyrrolizidine and stemona alkaloids.
22
   
Our retrosynthesis of Grandisine D led to the same key aldol chemistry as that 
employed by Tamura and Taylor, but a fundamentally new approach to the indolizidine 
core (Scheme 2.10).  2.32 would be accessed by an aldol reaction between 8-
formylindolizidine 1.3.22 and known (S)-5-methylcyclohexanone. 8-Formylindolizidine 
2.50 would be prepared from Grignard addition and RCM of (S)-sulfinyl aldimine 2.51. 
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Scheme 2.10. Retrosynthesis of grandisine D 
 
2.3.5. Synthesis of Grandisine D 
Starting from commercial diol 2.52, a mono-silyation and oxidation sequence, 
followed by conversion into the corresponding (S)-N-sulfinyl aldimine 2.51 under 
Ti(OEt)4-mediated conditions proceeded in 74% yield for the three steps.  Following the 
Ellman protocol, addition of Grignard reagent 2.55 to 2.51 afforded the desired 
sulfinamide 2.56 in 79% yield with >10:1 dr. Previous attempts towards alkylation of 
sulfinyl-protected amides had proven difficult; however alkylation of 2.56 with butenyl 
triflate and HMPA as an additive provided 2.57 as a single diastereomer after column 
chromatography in 87% yield (Scheme 2.11).  
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Scheme 2.11. Synthesis of advanced intermediate 2.57 
 
As shown in Scheme 2.12, a RCM reaction with Grubbs II delivered the 
piperidine ring in 96% yield, followed by removal of the TBS group and allylic oxidation 
with manganese dioxide to provide key aldehyde 2.50 in 93% yield for the two steps. 
Next, an aldol reaction employing boron-enolate methodology with 2.50 and enone 2.36 
followed by oxidation to the ketone provided 2.60 in 77% yield. Finally, application of 
the one-pot deprotection/acetal hydrolysis/ reductive amination sequence afforded 2.32 in 
47% yield. Our synthetic (+)-grandisine D was in agreement with the reported 
characterization data for the natural product, as well as the previous synthetic efforts. 
Thus, the total synthesis of grandisine D, employing our azabicyclic methodology, 
required only 11 steps from commercial starting materials in 16.4% overall yield and 
with excellent stereocontrol throughout.  Based on previous work by Tamura and Taylor, 
the total synthesis of (+)-grandisine D also constitutes a formal total synthesis of (-)-
grandisine B. 
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Scheme 2.12. Synthesis of Grandisine D from advanced intermediate 2.58 
 
2.3.6. Synthesis of Unnatural Analogue of Grandisine D 
To further highlight the use of this methodology for the streamlined synthesis of 
diverse unnatural analogues of natural products and pharmaceutically relevant scaffolds, 
we applied it towards the synthesis of an unnatural analogue of (+)-grandisine D, in 
which the nitrogen atom was moved from 4-position to the 9-position, resulting in a 
fundamentally new molecular architecture. Starting with (S)-N-sulfinyl aldimine 2.61, an 
indium-mediated allylation reaction afforded 2.62 in 87% yield with greater than 19:1 
diastereoselectivity, and, after column chromatography, a single diastereomer. 2-
methylenepropane-1,3-diol was mono-protected as a TBS ether and the remaining 
hydroxyl converted to the corresponding allylic bromide 2.63 in 85% yield for the two 
steps. Allylation of 2.62 with 2.63 provided 2.64 in 90% yield, followed by an RCM 
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reaction with Grubbs II afforded 2.65 in 81% yield for the two steps. Deprotection of the 
TBS ether and oxidation delivered key aldehyde 2.66, in 95% yield for the two steps. 
 
Scheme 2.13. Synthesis of advanced intermediate 2.66 
 
  Once again, an aldol reaction employing boron-enolate methodology with 2.66 
and enone 2.66, followed by oxidation provided 2.68 in 67% yield. Finally, application of 
the one-pot deprotection/ acetal hydrolysis/reductive amination sequence produced the 
unnatural analogue of (+)-grandisine D 2.69 in 49% yield. The synthesis of 2.69 
proceeded in 11 steps (the longest linear sequence was 9 steps) from commercial 
materials in 17.8% overall yield. 
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Scheme 2.14. Synthesis of unnatural analogue 2.69 
 
In summary, our approach towards the rapid and enantioselective synthesis of 
indolizidine azabicyclic systems enabled the total synthesis of (+)-grandisine D in 11 
synthetic steps and 16.4% overall yield, a notable advance over the two previous 
syntheses, and also represents a formal total synthesis of (-)-grandisine B.  This 
methodology allows for either enantiomer to be prepared based on the stereochemistry of 
the tert-butyl sulfinamide employed and the nature of the transition state in the initial 
allylation.   The versatility of this approach was highlighted in the rapid synthesis of 
unnatural analogs of grandisine D, demonstrating its applicability towards the synthesis 
of other natural products and pharmaceutically relevant scaffolds. 
 
 
 
81 
 
References 
1. Cushnie, T. P. T.; Cushnie, B.; Lamb, A. J. Int. J. Antimicrob. Agents 2014, 44, 
377–386. 
2. Qiu, S.; Sun, H.; Zhang, A.-H.; Xu, H.-Y.; Yan, G.-L.; Han, Y.; Wang, X.-J. Chin. 
J. Nat. Med. 2014, 12, 401–406. 
3. Heinrich, M.; Lee Teoh, H. J. Ethnopharmacol. 2004, 92, 147–162. 
4. Amirkia, V.; Heinrich, M. Phytochem. Lett. 2014. 
5. Robins, D. J. Nat. Prod. Rep. 1991, 8, 213–221. 
6. Hartmann, T.; Biller, A.; Witte, L.; Ernst, L.; Boppré, M. Biochem. Syst. Ecol. 
1990, 18, 549–554. 
7. Katavic, P. L.; Venables, D. A.; Forster, P. I.; Guymer, G.; Carroll, A. R. Society 
2006, 1295–1299. 
8. Michael, J. P. Nat. Prod. Rep. 2005, 22, 603–626. 
9. Culvenor, C.; Smith, L. Aust. J. Chem. 1967, 20, 2499. 
10. Tasso, B.; Novelli, F.; Sparatore, F.; Fasoli, F.; Gotti, C. J. Nat. Prod. 2013, 76, 
727–731. 
11. Fu, P. P.; Xia, Q.; Lin, G.; Chou, M. W. Drug Metab. Rev. 2004, 36, 1–55. 
12. Sharma, R. A.; Singh, B.; Singh, D.; Chandrawat, P. J. Med. Plants 2009, 3, 1153–
1175. 
13. Takahata, H.; Momose, T. Tetrahedron 1991, 47, 7635–7644. 
14. Stritzke, K.; Schulz, S.; Nishida, R. Synthesis (Stuttg). 2002, 0–8. 
15. Edupuganti, R.; Davis, F. A. Org. Biomol. Chem. 2012, 10, 5021–5031. 
16. Castro, M. A.; del Corral, J. M. M.; García, P. A.; Rojo, M. V.; de la Iglesia-
Vicente, J.; Mollinedo, F.; Cuevas, C.; San Feliciano, A. J. Med. Chem. 2010, 53, 
983–993. 
17. Roeder, E.; Breitmaier, E.; Birecka, H.; Frohlicht, M. Phytochemistry 1991, 30, 
11–14. 
82 
 
18. Asibal, C. F.; Glinski, J. A.; Gelbaum, L. T.; Zalkow, L. H. J. Nat. Prod. 1989, 52, 
109–118. 
19. Katavic, P. L.; Venables, D. A.; Forster, P. I.; Guymer, G.; Carroll, A. R. J. Nat. 
Prod. 2006, 69, 1295–1299. 
20. Kurasaki, H.; Okamoto, I.; Morita, N.; Tamura, O. Org. Lett. 2009, 11, 1179–
1181. 
21. Cuthbertson, J. D.; Godfrey, A. A.; Taylor, R. J. K. Org. Lett. 2011, 13, 3976–
3979. 
22. Senter, T. J.; Fadeyi, O. O.; Lindsley, C. W. 2012, 20–22.  
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
(+)-Amabiline Experimental Methods  
Flame-dried (under vacuum) glassware was used for all reactions. All reagents 
and solvents were commercial grade and purified prior to use when necessary. Thin layer 
chromatography (TLC) was performed on glass-backed silica gel. Visualization was 
accomplished with UV light, and/or the use of anisaldehyde and ceric ammonium 
molybdate solutions followed by charring on a hot-plate. Chromatography on silica gel 
was performed using Silica Gel 60 (230-400 mesh) from Sorbent Technologies. IR 
spectra were recorded as thin films and are reported in wavenumbers (cm
-1
). 
1
H & 
13
C 
NMR spectra were recorded on Bruker DRX-400 (400 MHz) or Bruker AV-NMR (600 
MHz) instrument. Chemical shifts are reported in ppm relative to residual solvent peaks 
as an internal standard set to δ 7.26 and δ 77.0 (CDCl3). Mass spectra were obtained on a 
Micromass Q-Tof API-US mass spectrometer was used to acquire high-resolution mass 
spectrometry (HRMS) data.  The value Δ is the error in the measurement (in ppm) given 
by the equation Δ = [(ME – MT)/ MT] × 10
6
, where ME is the experimental mass and MT is 
the theoretical mass.  The HRMS results were obtained with ES as the ion source and 
leucine enkephalin as the reference.  
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Ethyl 2-(diethoxyphosphoryl)-3-methylbutanoate (2.18) 
Potassium tert-butoxide (6.16g, 55 mmol) was added at 0oC to a stirred solution of ethyl 
2-(diethoxyphosphoryl)acetate (10 mL, 50 mmol) in 40 mL DMSO.  The mixture was 
stirred for 30 min. until potassium tert-butoxide was dissolved. 2-iodopropane (5 mL, 55 
mmol) was then added in a single batch.  The solution was stirred for 90 min. at 60
o
C.   
After reaction complete by LCMS, the reaction was quenched with saturated NH4Cl 
solution and extracted 3 times with diethyl ether.  The organic layers were combined, 
washed once with brine, dried with MgSO4, and concentrated in vacuo to yield a pale 
yellow oil in 12.4g (93%) sufficiently pure to carry forward. 
1
H NMR (400.1 MHz, 
CDCl3) δ (ppm): 4.19 (m, 6H), 2.73 (dd, J= 9, 11 Hz, 1H), 2.37 (m, 1H), 1.32 (m, 9H), 
1.01 (d, J= 6.8 Hz, 3H), 0.99 (d, J= 6.8 Hz, 3H); 
13C NMR (100.6 MHz, CDCl3) δ (ppm): 
169.23, 63.36, 63.34, 54.00, 52.68, 28.24, 21.60, 21.59, 16.24, 14.06; HRMS (TOF,ES+) 
C11H24O5P [M+H]
+
 calc'd 267.1361, found 267.1363. 
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(Z)-ethyl 2-isopropylbut-2-enoate. (2.19) 
A solution of (diethoxyphosphoryl)acetate 1.2.17 (6.0g, 22.56 mmol) in 70 mL 
anhydrous THF was cooled to -78
o
C under argon.  To this solution was added LHMDS 
(26.89 mmol) and then stirred for 10 min, at which time acetaldehyde (1.39 mL, 24.81 
mmol) was added in one batch.  The resulting mixture was stirred at -78
o
C for 90 min.  
The reaction was quenched with saturated NH4Cl solution and extracted 3 times with 
diethyl ether.  The organic layers were combined, washed 1 time with brine, dried with 
MgSO4, and concentrated gently in vacuo.  The crude product was purified by flash 
column chromatography (19:1 pentane/Et2O) to afford the product in 2.75g (78%) as a 
clear oil. 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.81 (q, J= 6.8 Hz, 1H), 4.24 (q, J= 6.8 
Hz, 2H), 2.68 (sept 6.8 Hz, 1H), 1.88 (d, J= 7 Hz, 3H), 1.32 (t, J= 7 Hz, 3H), 1.06 (d, J= 
6.7 Hz, 6H);
 13C NMR (100.6 MHz, CDCl3) δ (ppm): 169.32, 140.17, 129.87, 60.26, 
31.67, 21.99, 15.60, 14.55; HRMS (TOF, ES+) C9H16O2 [M+Na]
+
 calc'd 179.1048, 
found 179.1049. 
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(2S,3S)-ethyl 2,3-dihydroxy-2-isopropylbutanoate (2.20). 
A solution of AD-mix-α (10.43g) in a mixture of tert-butyl alcohol and water (75 mL, 
1:1) was stirred at room temperature for 5 min.  Methanesulfonamide (0.74g, 7.77 mmol) 
and 1.2.18 (1.2g, 7.69 mmol) were then added, and the solution was stirred at 0
o
C for 42 
hours.  Sodium sulfite (10.72g, 85.05 mmol) was added in two batches, and the mixture 
was stirred at room temperature for an addition 30 min. H2O was added and the solution 
was extracted 4 times with ethyl acetate.  The organic layers were combined and washed 
with 1N NaOH and brine.  The organic layer was dried with MgSO4 and the solvent was 
removed in vacuo.  The crude product was purified by flash chromatography to yield the 
product in 1.23g (84%) as a clear oil. [α]D
20
 = -2.9 (c= 10mg/mL, MeOH);  1H NMR 
(400.1 MHz, CDCl3) δ (ppm): 4.29 (q, J= 7 Hz, 2H), 4.00 (q, J=, 6.5 Hz, 1H), 3.48 (br s, 
1H), 2.17 (br s, 1H), 2.16 (sept, J= 6.8 Hz,1H), 1.33 (t, J= 7.25 Hz, 3H), 1.22 (d, J= 6.7 
Hz, 3H), 0.94 (d, J= 6.8 Hz, 3H), 0.93 (d, J= 6.8 Hz, 3H); 
13
C NMR (100.6 MHz, CDCl3) 
δ (ppm): 175.05, 83.14, 70.54, 62.23, 32.49, 17.77, 17.40, 16.36, 14.44; HRMS (TOF, 
ES+) C9H18O4 [M+Na]
+
 calc'd 213.1103, found 213.1102. 
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(2S,3S)-2,3-dihydroxy-2-isopropylbutanoic acid (2.12). 
To a solution of 1.2.19 (0.5g, 2.63 mmol) in 6 mL H2O was added Ba(OH)2▪8H2O 
(0.99g, 3.156 mmol) slowly while stirring.  The solution was heated to 50
o
C and stirred 
for 4 hours. Reaction was then brought to pH 2-3 with 1M HCl, at which time solution 
changed from cloudy white to clear, then extracted 5 times with diethyl ether.  Organic 
layers were combined and concentrated in vacuo, yielding clear/white crystals in 0.40g 
(96%) as a white crystalline solid. [α]D
20
 = -9.7 (c= 10mg/mL, MeOH);   1H NMR (400.1 
MHz, MeOD) δ (ppm):  4.03 (q, J= 6.5 Hz, 1H), 2.16 (sept, J= 6.76 Hz, 1H), 1.25 (d, J= 
6.5 Hz, 3H), 0.98 (d, J= 6.8 Hz, 3H), 0.97 (d, J= 6.8 Hz, 3H); 
13
C NMR (100.6 MHz, 
MeOD) δ (ppm); 84.06, 71.08, 33.70, 18.09, 17.88, 16.73; HRMS (TOF, ES+) C7H14O4 
[M+Na]
+
 calc'd 185.0790, found 185.0791. 
 
 
(4S,5S)-4-isopropyl-2,2,5-trimethyl-1,3-dioxolane-4-carboxylic acid (2.14). 
To a solution of 1.2.10 (0.265g, 1.635 mmol) in 2.615 mL dimethoxypropane was added 
39.21 µL of conc. HCl.  The solution was stirred at room temperature for 2 hours until 
reaction was complete by TLC.  Solution was concentrated in vacuo, and the crude 
product was purified by flash chromatography (1:1 Hex/EtOAc) to yield the product in 
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0.28 g (86%) as a white crystalline solid. [α]D
20
 = -1.20 (c= 10mg/mL, MeOH);   1H 
NMR (400.1 MHz, CDCl3) δ (ppm):  4.30 (q, J= 6.3 Hz, 1H), 2.05 (sept, J= 6.86 Hz, 
1H), 1.58 (s, 3H), 1.43 (s, 3H), 1.39 (d, J= 6.3 Hz, 3H), 1.06 (d, J= 6.86 Hz, 3H), 1.03 (d, 
J= 6.86 Hz, 3H); 
 13C NMR (100.6 MHz, CDCl3) δ (ppm): 172.10, 109.23, 89.92, 77.09, 
34.47, 27.66, 26.01, 18.09, 17.45, 16.83; HRMS (TOF, ES+) C10H19O4 [M+H]
+
 calc'd 
203.1283, found 203.1284. 
 
 
2-(((tert-butyldimethylsilyl)oxy)methyl)prop-2-en-1-ol (2.71): 
To a flame-dried flask was added 350 mL dry THF, followed by addition of NaH (2.74g, 
113.5 mmol).  To this solution at 0
o
C was added 2-methylenepropane-1,3-diol (10g, 
113.5 mmol) drop wise.  Mixture was then brought to room temperature and stirred for 
45 min.  Tert-butyldimethylsilyl chloride (17.11g, 113.5 mmol) was added in one batch 
and stirring was continued for an additional 50 min. until complete by TLC.  Reaction 
quenched with H2O, and extracted 3 times with ethyl acetate, washed with brine, dried 
with anhydrous MgSO4, and concentrated in vacuo.  Purification by  flash 
chromatography (4:1 to 1:1 Hex/EtOAc) yielded the product in 20.66 g (89%) as a clear 
oil:  
1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.08 (d, J= 7.4 Hz, 2H), 4.25 (s, 2H), 4.17 
(d, J= 6 Hz, 2H), 1.92 (t, J= 6 Hz, 1H), 0.92 (s, 9H), 0.09 (s, 6H);
 13
C NMR (100.6 MHz, 
CDCl3) δ (ppm): 147.35, 111.08, 65.07, 64.67, 25.78, 18.21, -5.52; HRMS (TOF, ES+) 
C10H23O2Si [M+H]
+
 calc'd 203.1467, found 203.1466 
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2-(((tert-butyldimethylsilyl)oxy)methyl)acrylaldehyde (2.22). 
In a flame dried flask, monoprotected alcohol 1.2.13 (13.687g, 67.63 mmol) was 
dissolved in 200 mL DCM.  While stirring, MnO2 (29.4g, 338 mmol) was added in two 
batches. Mixture was then stirred for 6 hours, until reaction was determined complete by 
TLC.  Solution was filtered through celite, concentrated in vacuo, and purified by flash 
chromatography (4:1 Hex/EtOAc) to yield product in 12.71g (89%) as a clear oil. :  
1
H 
NMR (400.1 MHz, CDCl3) δ (ppm): 9.62 (s, 1H), 6.52 (s, 1H) 6.11 (s, 1H), 4.40 (s, 2H), 
0.92 (s, 9H), 0.09 (s, 6H); 
13C NMR (100.6 MHz, CDCl3) δ (ppm): 193.86, 149.74, 
133.05, 59.79, 26.06, 18.52, -5.28; HRMS (TOF, ES+) C10H21O2Si [M+H]
+
 calc'd 
201.1311, found 203.1312. 
 
 
(S,E)-N-(2-(((tert-butyldimethylsilyl)oxy)methyl)allylidene)-2-methylpropane-2-
sulfinamide (2.23). 
To a solution of aldehyde 1.2.19 (9.00g, 45mmol) in 400mL DCM was added (R)-2-
methylpropane-2-sulfinamide (6.54g, 54 mmol) and CuSO4 (14.00g, 90 mmol).  Solution 
stirred at room temperature for 16 hours.  Mixture filtered through a pad of celite, with 
DCM as an eluent.  Solution was then concentrated in vacuo and purified by column 
90 
 
chromatography (4:1 Hex/EtOAc) to yield product in 10.75 g (79%). [α]D
20
 = 27.276 (c= 
10mg/mL, MeOH);  
1H NMR (400.1 MHz, CDCl3) δ (ppm): 8.26 (s, 1H), 6.13 (s, 1H), 
5.82 (s, 1H), 4.48 (dt, J=16, 7 Hz, 2H), 1.20 (s, 9H), 0.93 (s, 9H), 0.09 (s, 6H); 
13
C NMR 
(100.6 MHz, CDCl3) δ (ppm):  163.32, 145.25, 127.42, 61.08, 57.62, 26.09, 22.70, 18.57, 
-5.23; HRMS (TOF, ES+) C14H30O2SiS [M+H]
+
 calc'd 304.1767, found 304.1765. 
 
 
(S)-N-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(1,3-dioxan-2-yl)pent-1-en-3-
yl)-2-methylpropane-2-sulfinamide  (2.25). 
In a flame dried flask under Argon gas was added (2-(1,3-dioxan-2-yl)ethyl)magnesium 
bromide (19.8 mL, 0.5M in THF) to 30 mL THF.  Mixture was then cooled to -78
o
 C, and 
aldimine 1.2.20 (1.00g, 3.3 mmol) was added drop wise as a solution in 20 mL THF. 
Reaction was then warmed to -48
o
 C and stirred 16 hours.  Reaction was quenched with 
NH4Cl and brought to room temperature.  Extracted 3 times with ethyl acetate, organic 
layers combined and dried with Na2SO4, concentrated in vacuo to give the crude product 
as >9:1 dr which was then purified by column chromatography (1:1 Hex/EtOAc) to 
afford product in 1.13 g (80%) as a clear oil: [α]D
20
 = 1.596 (c= 10mg/mL, MeOH); 1H 
NMR (400.1 MHz, CDCl3) δ (ppm): 5.30 (s, 1H), 5.20 (s, 1H), 5.07 (s, 1H), 4.50 (t, J= 5 
Hz, 1H), 4.22 (q, J= 13.5, 18.7 Hz, 2H), 4.07 (dd, J= 5, 7 Hz, 2H), 3.76 (m, 3H), 3.70 (d, 
J= 7 Hz, 1H), 2.04 (m, 1H), 1.70 (m, 3H), 1.31 (br d, J= 13.6 Hz, 1H), 1.20 (s, 9H), 0.91 
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(s, 9H), 0.08 (s, 6H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 148.66, 112.74, 102.12, 
67.08, 64.75, 59.33, 56.00, 31.81, 29.48, 26.14, 26.01, 22.92, 18.55, -5.20; HRMS (TOF, 
ES+) C20H42NO4SiS [M+H]
+
 calc'd 420.2604, found 420.2603. 
 
 
(S)-N-allyl-N-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(1,3-dioxan-2-yl)pent-1-
en-3-yl)-2-methylpropane-2-sulfinamide (2.26). 
To sulfinylamine 1.2.22 (0.42 g, 1.00 mmol) in 3.0 mL DMF at -20
o
C was added 
LHMDS (1.75 mL, 1.0M in THF) drop wise.  Mixture stirred at -20
o
C for 20 min, 
followed by addition of allyl bromide (0.61g, 5.0mmol) in a single batch.  Reaction 
stirred for an additional 60 min at -20
o
C, at which time reaction was shown to be 
complete by TLC.  Reaction was quenched with NH4Cl, extracted 3 times with ethyl 
acetate, the organic layers combined and washed once with brine, dried with Na2SO4, and 
concentrated in vacuo.  Purified by column chromatography (1:1 Hex/EtOAc)to yield 
product in 0.46g (100%) as a pale yellow oil: [α]D
20
 = -5.464 (c= 10mg/mL, MeOH); 1H 
NMR (400.1 MHz, CDCl3) δ (ppm): 5.84 (m, 1H), 5.36 (s, 1H), 5.15 (m, 3H), 4.50 (t, J= 
5 Hz, 1H), 4.08 (m, 4H), 3.91 (dd, J= 5, 11.4 Hz, 1H), 3.72 (t, J= 11.6 Hz, 2H), 3.54 (dd, 
J= 4.7, 5.6 Hz, 1H), 3.11 (dd, J= 7.9, 8.5 Hz, 1H), 2.01 (m, 3H), 1.63 (m, 1H), 1.51 (m, 
1H), 1.33 (br d, J= 12.9, 1H), 1.15 (s, 9H), 0.90 (s, 9H), 0.05 (s, 6H); 
13
C NMR (100.6 
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MHz, CDCl3) δ (ppm): 145.52, 136.46, 117.93, 113.03, 102.19, 67.06, 64.98, 61.95, 
57.98, 44.86, 32.76, 26.10, 24.96, 23.71, 18.48, -5.17; HRMS (TOF, ES+) 
C23H46NO4SiS [M+H]
+
 calc'd 460.2917, found 460.2917. 
 
 
(S)-2-(2-(1,3-dioxan-2-yl)ethyl)-3-(((tert-butyldimethylsilyl)oxy)methyl)-1-((S)-tert-
butylsulfinyl)-2,5-dihydro-1H-pyrrole (2.27). 
In a flame-dried flask under Argon, diene 1.2.23 (0.46g, 1.0 mmol) was dissolved into 
300 mL DCM.  Grubbs II (0.042g, 0.05 mmol) was added to the solution in a single batch 
and the mixture was stirred at room temperature for 16 hours.  The solution was then 
concentrated in vacuo and purified by column chromatography (1:1 Hex/EtOAc)to yield 
product in 0.41g (98%) as a pale yellow oil:  [α]D
20
 = 1.876 (c= 10mg/mL, MeOH); 1H 
NMR (400.1 MHz, CDCl3) δ (ppm):  5.61 (s, 1H), 4.59 (br s. 1H), 4.48 (m, 2H), 4.13 (m, 
2H), 4.05 (dd, J= 5, 7 Hz, 2H), 3.73 (t, J= 12.4 Hz, 2H), 3.45 (m, 1H), 2.04 (m, 1H), 1.65 
(m, 3H), 1.51 (m, 1H), 1.34 (br d, J= 13.9 Hz, 1H), 1.21 (s, 9H), 0.90 (s, 9H), 0.05 (s, 
6H);
 13C NMR (100.6 MHz, CDCl3) δ (ppm): 141.72, 121.90, 102.42, 71.75, 67.06, 
60.08, 57.53, 47.76, 29.25, 28.52, 26.08, 24.04, 18.50, -5.26; HRMS (TOF, ES+) 
C21H42NO4SiS [M+H]
+
 calc'd 432.2604, found 432.2604. 
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((R)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-2,5-dihydro-1H-pyrrol-3-
yl)methanol (2.15). 
In a flame dried flask under Argon, 1.2.24 (0.310g, 0.719 mmol) was dissolved in 14.4 
mL THF. Solution was cooled to 0
o
C, and TBAF was slowly added.  Solution was stirred 
at 0
o
C for 10 min, then warmed to room temperature, where stirring was continued 1 hour 
until reaction complete by TLC.  Reaction was quenched by addition of H2O and 
extracted 3 times with ethyl acetate.  Organic layers were combined, washed 1 time with 
brine, dried with Na2SO4, and concentrated in vacuo.  Crude product was purified by 
column chromatography (9:1 DCM/MeOH) to yield desired product in 0.198 g (87%) as 
a pale yellow crystalline solid: [α]D
20
 = 21.11(c= 10mg/mL, MeOH); 1H NMR (400.1 
MHz, CDCl3) δ (ppm): 5.70 (br s, 1H), 4.657 (br s, 1H), 4.51 (m, 2H), 4.12 (m, 2H), 4.06 
(dd, J= 3, 7 Hz, 2H), 3.74 (t, J= 11.5 Hz, 2H), 3.50 (m, 2H), 2.04 (m, 1H), 1.70 (m, 3H), 
1.52 (m, 1H), 1.33 (br d, J= 13.9 Hz, 1H), 1.21 (s, 9H); 
13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 141.98, 123.26, 102.28, 72.02, 67.08, 59.56, 57.59, 47.81, 29.19, 28.38, 25.93, 
23.99; HRMS (TOF, ES+) C15H28NO4S [M+H]
+
 calc'd 318.1739, found 318.1737. 
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((S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-2,5-dihydro-1H-pyrrol-3-
yl)methyl 4-methylbenzenesulfonate (2.28). 
In a flame dried flask under Argon, alcohol 1.2.11 (0.331g, 1.04 mmol) and Et3N 
(0.212g, 2.10 mmol) were dissolved in 2.8 mL DCM and cooled to 0
o
C. p-
Toluenesulfonyl chloride (0.191g, 1.35 mmol) was then dissolved in 2.8 mL DCM and 
added drop wise to reaction mixture.  Stirring was continued at 0
o
C for 1 hour, until 
reaction complete by TLC.  Solution was then filtered through a celite pad using DCM as 
the eluent, and concentrated in vacuo. Crude product was purified by column 
chromatography (4:1 DCM/Et2O) to yield desired product in 0.42g (86%) as a pale 
yellow oil: [α]D
20
 = 6.646 (c= 10mg/mL, MeOH); 1H NMR (400.1 MHz, CDCl3) δ 
(ppm): 7.73 (d, J= 8.2 Hz, 2H), 7.36 (d, J= 8.2 Hz, 2H), 5.73 (s, 1H), 4.52 (m, 5H), 4.05 
(dd, J= 4.13, 7.4 Hz, 2H), 3.72 (dt, J= 2.4, 9.8 Hz, 2H), 3.41 (m, 1H), 2.45 (s, 3H), 2.04 
(m, 1H), 1.60 (m, 4H), 1.33 (br d, J= 13.3 Hz, 1H), 1.18 (s, 9H); 
13
C NMR (100.6 MHz, 
CDCl3) δ (ppm): 145.25, 134.73, 132.98, 130.17, 128.17, 102.04, 71.58, 67.03, 65.78, 
57.70, 47.66, 29.00, 28.04, 25.94, 23.86, 21.88; HRMS (TOF, ES+) C15H34NO6S2 
[M+H]
+
 calc'd 472.1828, found 472.1832. 
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(4S,5S)-((S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-2,5-dihydro-1H-
pyrrol-3-yl)methyl 4-isopropyl-2,2,5-trimethyl-1,3-dioxolane-4-carboxylate (2.27). 
In a flame dried flask under Argon, (4S,5S)-4-isopropyl-2,2,5-trimethyl-1,3-dioxolane-4-
carboxylic acid (1.2.12) (0.237g, 1.175 mmol) was dissolved in 3 mL dry DMF. K2CO3 
was added and mixture stirred at room temperature for 30 min.  Tosylate 1.2.25 (0.461g, 
0.979 mmol) was then added drop wise as a solution in 2 mL DMF, and mixture stirred 
for 90 min at room temperature, at which point reaction was complete by TLC.  Solution 
was diluted with EtOAc, then filtered through a phase separator.  Solution was washed 1 
time with brine, dried with Na2SO4, and concentrated in vacuo.  Crude product was 
purified by column chromatography (1:1 Hex/EtOAc) to yield desired product in 0.46g 
(95%) as a clear oil: [α]D
20
 = 7.4 (c= 10mg/mL, MeOH); 1H NMR (400.1 MHz, CDCl3) δ 
(ppm): 5.81 (s, 1H), 4.75 (d, J= 14 Hz, 1H), 4.65 (br s, 1H), 4.55 (m, 3H), 4.24 (q, J= 6.6 
Hz, 1H), 4.05 (dd, J= 4.7, 6.5 Hz, 2H), 3.74 (t, J= 12.2 Hz, 2H), 3.47 (m, 1H), 2.15 (m, 
1H), 2.04 (m, 1H), 1.70 (m, 2H), 1.60 (s, 3H), 1.51 (m, 1H), 1.40 (s, 3H), 1.33 (br d, J= 
13.3 Hz, 1H), 1.27 (d, J= 6.6 Hz, 6H), 1.23 (s, 9H), 1.01 (d, J= 6.7 Hz, 3H), 0.98 (d, J= 
6.8 Hz, 3H); 
13C NMR (100.6 MHz, CDCl3) δ (ppm): 172.28, 136.41, 126.23, 109.08, 
102.13, 71.93, 67.04, 60.75, 57.69, 47.78, 32.29, 29.13, 28.23, 27.18, 26.76, 25.95, 23.95, 
18.98, 16.98, 16.40; HRMS (TOF, ES+) C25H44NO7S [M+H]
+
 calc'd 502.2839, found 
502.2836. 
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(2S,3S)-((S)-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl)methyl-2,3-dihydroxy-2-
isopropylbutanoate (2.4). 
In a flame dried flask under Argon, ester 1.2.24 (0.100g, 0.20 mmol) was dissolved in 2.0 
mL of 95:5 TFA/H2O at room temperature.  Solution was stirred for 90 min. at room 
temperature until conversion to iminium ion was observed by LC/MS.  Solution was then 
concentrated in vacuo, and resulting residue was dissolved in 3mL DCE.  To this solution 
was added MP-BH(OAc)3 (0.5g, 2.00 mmol/g). The mixture was rotated for 16 hours, 
filtered and concentrated in vacuo.  Crude product was purified by Gilson HPLC to yield 
product as the TFA salt.  Product was converted to the free base by dissolving in DCM 
then adding 5 eq. PS-Carbonate, and rotating for 12 hours.  Solution was filtered and 
concentrated in vacuo to yield desired product in 20 mg (37%) as a clear residue: [α]D
20
 = 
1.7 (c= 10mg/mL, MeOH); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.68 (s, 1H), 4.76 (br 
s, 1H), 4.17 (br s, 2H), 4.01 (q, J= 9.2, 12.8 Hz, 1H), 3.85 (d, J= 16 Hz, 1H), 3.38 (d, J= 
16 Hz, 1H), 3.12 (pent, J= 5.16 Hz, 1H), 2.49 (m, 1H), 2.15 (m, 1H), 2.00 (m, 1H), 1.77 
(m, 2H), 1.53 (m,1H), 1.25 (d, J= 6.52 Hz, 3H), 0.93 (d, J= 6.8 Hz, 3H), 0.88 (d, J= 6.8 
Hz, 3H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 174.75, 137.72, 125.78, 83.48, 71.56, 
70.63, 62.42, 61.90, 56.93, 32.28, 30.26, 25.97, 17.70, 17.31, 16.10; HRMS (TOF, ES+) 
C15H26NO4 [M+H]
+
 calc'd 284.1862, found 284.1862. 
97 
 
 
 
Grandisine D Experimental Methods 
Flame-dried (under vacuum) glassware was used for all reactions. All reagents 
and solvents were commercial grade and purified prior to use when necessary. Thin layer 
chromatography (TLC) was performed on glass-backed silica gel. Visualization was 
accomplished with UV light, and/or the use of anisaldehyde and ceric ammonium 
molybdate solutions followed by charring on a hot-plate. Chromatography on silica gel 
was performed using Silica Gel 60 (230-400 mesh) from Sorbent Technologies. IR 
spectra were recorded as thin films and are reported in wavenumbers (cm
-1
). 
1
H & 
13
C 
NMR spectra were recorded on Bruker DRX-400 (400 MHz) or Bruker AV-NMR (600 
MHz) instrument. Chemical shifts are reported in ppm relative to residual solvent peaks 
as an internal standard set to δ 7.26 and δ 77.0 (CDCl3). Mass spectra were obtained on a 
Micromass Q-Tof API-US mass spectrometer was used to acquire high-resolution mass 
spectrometry (HRMS) data.  The value Δ is the error in the measurement (in ppm) given 
by the equation Δ = [(ME – MT)/ MT] × 10
6
, where ME is the experimental mass and MT is 
the theoretical mass.  The HRMS results were obtained with ES as the ion source and 
leucine enkephalin as the reference.   
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2-(((tert-butyldimethylsilyl)oxy)methyl)prop-2-en-1-ol. (2.72) 
To a flame-dried flask was added 350mL dry THF, followed by addition of NaH (2.74g, 
113.5 mmol).  To this solution at 0
o
C was added 2-methylenepropane-1,3-diol (10g, 
113.5 mmol) drop wise.  Mixture was then brought to room temperature and stirred for 
45 min.  Tert-butyldimethylsilyl chloride (17.11g, 113.5 mmol) was added in one batch 
and stirring was continued for an additional 50 min. until complete by TLC.  Reaction 
quenched with H2O, and extracted 3 times with ethyl acetate, washed with brine, dried 
with anhydrous MgSO4, and concentrated in vacuo.  Purification by  flash 
chromatography (4:1 to 1:1 Hex/EtOAc) yielded the product in 20.66 g (89%) as a clear 
oil:  
1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.08 (d, J= 7.4 Hz, 2H), 4.25 (s, 2H), 4.17 
(d, J= 6 Hz, 2H), 1.92 (t, J= 6 Hz, 1H), 0.92 (s, 9H), 0.09 (s, 6H);
 13
C NMR (100.6 MHz, 
CDCl3) δ (ppm): 147.35, 111.08, 65.07, 64.67, 25.78, 18.21, -5.52; HRMS (TOF, ES+) 
C10H23O2Si [M+H]+ calc'd 203.1467, found 203.1466. 
 
 
2-(((tert-butyldimethylsilyl)oxy)methyl)acrylaldehyde. (2.53) 
In a flame dried flask, alcohol (13.687g, 67.63 mmol) was dissolved in 200 mL DCM.  
While stirring, MnO2 (29.4g, 338 mmol) was added in two batches. Mixture was then 
stirred for 6 hours, until reaction was determined complete by TLC.  Solution was filtered 
through celite, concentrated in vacuo, and purified by flash chromatography (4:1 
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Hex/EtOAc) to yield product in 12.71g (89%) as clear oil. :  
1
H NMR (400.1 MHz, 
CDCl3) δ (ppm): 9.62 (s, 1H), 6.52 (s, 1H) 6.11 (s, 1H), 4.40 (s, 2H), 0.92 (s, 9H), 0.09 
(s, 6H); 
13C NMR (100.6 MHz, CDCl3) δ (ppm): 193.86, 149.74, 133.05, 59.79, 26.06, 
18.52, -5.28; HRMS (TOF, ES+) C10H21O2Si [M+H]+ calc'd 201.1311, found 201.1312. 
 
 
(R)-N-(2-(((tert-butyldimethylsilyl)oxy)methyl)allylidene)-2-methylpropane-2-
sulfinamide (2.51) 
To a solution of aldehyde (9.00g, 45 mmol) in 400 mL DCM was added (R)-2-
methylpropane-2-sulfinamide (6.54g, 54 mmol) and CuSO4 (14.00g, 90 mmol).  Solution 
was stirred at room temperature for 16 hours.  Mixture filtered through a pad of celite, 
with DCM as an eluent.  Solution was then concentrated in vacuo and purified by column 
chromatography (4:1 Hex/EtOAc) to yield product in 10.75 g (79%). [α]D
20
 = 27.276 (c= 
0.01, MeOH);  
1H NMR (400.1 MHz, CDCl3) δ (ppm): 8.26 (s, 1H), 6.13 (s, 1H), 5.82 (s, 
1H), 4.48 (dt, J=16, 7 Hz, 2H), 1.20 (s, 9H), 0.93 (s, 9H), 0.09 (s, 6H); 
13
C NMR (100.6 
MHz, CDCl3) δ (ppm):  163.32, 145.25, 127.42, 61.08, 57.62, 26.09, 22.70, 18.57, -5.23; 
HRMS (TOF, ES+) C14H30O2SiS [M+H]+ calc'd 304.1767, found 304.1765. 
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(S)-N-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(1,3-dioxan-2-yl)pent-1-en-3-
yl)-2-methylpropane-2-sulfinamide.  (2.56) 
In a flame dried flask under Argon gas was added (2-(1,3-dioxan-2-yl)ethyl)magnesium 
bromide (19.8 mL, 0.5M in THF)to 30 mL THF.  Mixture was then cooled to -78
o
 C, and 
aldimine 1.3.23 (1.00g, 3.3 mmol) was added drop wise as a solution in 20 mL THF. 
Reaction was then warmed to -48
o
 C and stirred 16 hours.  Reaction was quenched with 
NH4Cl and brought to room temperature.  Extracted 3 times with ethyl acetate, organic 
layers combined and dried with Na2SO4, concentrated in vacuo, and purified by column 
chromatography (1:1 Hex/EtOAc) to afford product in 1.13 g (80%) as a clear oil: [α]D
20
 
= 1.596 (c= 0.01, MeOH); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.30 (s, 1H), 5.20 (s, 
1H), 5.07 (s, 1H), 4.50 (t, J= 5 Hz, 1H), 4.22 (q, J= 13.5, 18.7 Hz, 2H), 4.07 (dd, J= 5, 7 
Hz, 2H), 3.76 (m, 3H), 3.70 (d, J= 7 Hz, 1H), 2.04 (m, 1H), 1.70 (m, 3H), 1.31 (br d, J= 
13.6 Hz, 1H), 1.20 (s, 9H), 0.91 (s, 9H), 0.08 (s, 6H); 
13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 148.66, 112.74, 102.12, 67.08, 64.75, 59.33, 56.00, 31.81, 29.48, 26.14, 26.01, 
22.92, 18.55, -5.20; HRMS (TOF, ES+) C20H42O4SiS [M+H]+ calc'd 420.2604, found 
420.2603. 
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(S)-N-(but-3-en-1-yl)-N-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(1,3-dioxan-
2-yl)pent-1-en-3-yl)-2-methylpropane-2-sulfinamide (2.57). 
 To a solution of sulfinamide 1.3.28 (100 mg, 0.24 mmol) in 3 mL THF at -78 
o
C was 
added HMPA (83 µL, 0.48 mmol) and 
n
BuLi (94 µL, 2.5 M, 0.48 mmol). The mixture 
was stirred for 30 mins and a pre-cooled solution of but-3-enyl-trifluoromethanesulfonate 
(60 mg, 0.29 mmol) in 1 mL THF was then added slowly to the mixture. The mixture was 
stirred at -78 
o
C for 30 mins.  The reaction was quenched with water and extracted with 
EtOAc (3x).  The combined organic extracts were washed with brine and dried over 
Na2SO4. Filtration and concentration afforded the crude product, which was purified by 
flash chromatography (1:1 Hex/EtOAc) to afford the product as a pale yellow oil (56 mg, 
87% yield brsm): [α]D
20
 = -2.53 (c = 1.00, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ 
(ppm): 5.67-5.77 (m, 1H), 5.32 (brd, J = 1.2  Hz,1H), 5.13 (s, 1H), 5.03 (dd, J = 17.2, 1.6 
Hz, 1H), 5.02 (d, J = 10.0  Hz, 1H),  4.52 (t, J = 4.8  Hz, 1H), 4.05-4.08 (m, 4H), 3.72 (dt, 
J = 12.0, 2.4 Hz, 2H),  3.56 (dd, J = 10.8, 4.4 Hz, 1H), 3.29 (m, 1H), 2.58 (m, 1H), 2.38 
(m, 1H), 2.25 (m, 1H), 1.95-2.23 (m, 3H), 1.67 (m, 1H), 1.50 (m, 1H), 1.32 (dm, J = 13.8 
Hz, 1H), 1.14 (s, 9H), 0.89 (s, 9H), 0.05 (d, J = 8.0 Hz, 6H); 13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 145.6, 135.3, 116.6, 112.9, 102.2, 67.0, 65.0, 61.7, 57.6, 42.2, 34.3, 
32.8, 26.0, 25.9, 24.9, 23.7, 18.4, -5.1, -5.2; HRMS (TOF, ES+) C24H48NO4SiS [M+H]
+
 
calc'd 474.3073, found 474.3074. 
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(S)-6-(2-(1,3-dioxan-2-yl)ethyl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-1-((S)-tert-
butylsulfinyl)-1,2,3,6-tetrahydropyridine. (2.59) 
To a solution of 1.3.29 (1.2 g, 2.54 mmol) in CH2Cl2 (271 mL) was added 2
nd
 Gen. 
Grubbs (107.7 mg, 0.127 mmol). The mixture was refluxed for 1 h and concentrated. The 
resulting crude product was purified by automated flash chromatography (4:1 to 1:1 
Hex/EtOAc) to yield the desired product 1.005 g (89%) as yellow oil: [α]D
20
 = +2.6 (c = 
1.81, CHCl3);  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.75 (s, 1H), 4.49 (t, J= 4.8 Hz, 1 
H), 4.09 (m, 4H), 3.73 (dt, J= 12.0, 2.4 Hz, 3H), 3.53 (dd, J= 14.0, 6.4 Hz, 3H), 3.12 (m, 
1H), 2.45 (m, 1H), 2.05 (m, 1H), 1.87-1.79 (m, 1H), 1.78-1.69 (m, 2H), 1.66-1.58 (m, 
2H), 1.32 (br d, J= 13.2 Hz, 1H), 1.20 (s, 9H), 0.90 (s, 9H), 0.06 (s, 6H);  13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 139.0, 122.3, 102.3, 67.0, 65.6, 58.9, 58.8, 37.8, 32.3, 
27.9, 26.1, 26.0, 25.9, 25.2, 23.8, 18.5, -5.1, -5.3; HRMS (TOF, ES+) C22H44NO4SiS 
[M+H]
+
 calc'd 446.2760, found 446.2762. 
 
 
103 
 
 
((S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-tetrahydropyridin-
3-yl)methanol. (2.72) 
To a solution of silyl ether 1.3.30 (375 mg, 0.84 mmol) in THF (35 mL) under argon was 
added 1.0 M TBAF (1.3 mL, 1.26 mmol) dropwise at 0 
o
C. The mixture was warmed to rt 
and stirred for 2 h. The reaction was quenched with saturated NH4Cl solution and 
extracted with EtOAc (3x).  The combined organic extracts were washed with water and 
the dried over Na2SO4. Filtration and concentration afforded the crude product, which 
was purified by flash chromatography (9:1 CH2Cl2/MeOH) to afford the product as 
yellow oil (267 mg, 96%): [α]D
20
 = +5.45 (c = 4.7, CHCl3);   
1
H NMR (400.1 MHz, 
CDCl3) δ (ppm): 5.82 (br s, 1H), 4.52 (t, J= 4.8 Hz, 1H), 4.04 (m, 4H), 3.81 (br d, J= 7.2 
Hz, 1H), 3.74 (dt, J= 2.4, 10 Hz, 2H), 3.57 (q, J= 7.2 Hz, 1H), 3.13 (m, 1H), 2.49 (m, 
1H), 2.17 (m, 2H), 1.88 (m, 2H), 1.77 (m, 2H), 1.62 (m, 1H), 1.33 (d, J= 11 Hz, 1H), 
1.21 (s, 9H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 139.81, 124.20, 102.17, 67.05, 
65.46, 59.43, 58.97, 37.43, 32.33, 27.80, 25.88, 25.23, 23.87; HRMS (TOF, ES+) 
C16H30NO4S [M+H]
+
 calc'd 332.1896, found 332.1898 
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(S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-tetrahydropyridine-
3-carbaldehyde (2.50). 
 To a solution of alcohol 1.3.40 (1.69 g, 5.11 mmol) in THF (300 mL) under argon was 
added MnO2 (8.87 g, 102.1 mmol). The mixture was stirred at rt overnight. Filtration 
over celite and concentration afforded the pure product in 99% yield: [α]D
20
 = +40.0 (c = 
0.3, CHCl3);   
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 9.34 (s, 1H), 6.91 (t, J= 4 Hz, 1H), 
4.51 (t, J= 4.4 Hz, 1H), 4.05 (m, 3H), 3.70 (m, 3H), 3.23 (m, 1H), 2.84 (m, 1H), 2.17 (dt, 
J= 5.2, 20 Hz, 1H), 2.04 (m, 1H), 1.7 (m, 4H), 1.32 (br d, J= 12.4 Hz, 1H), 1.20 (s, 9H) ;  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 192.05, 150.64, 143.48, 102.11, 67.02, 59.36, 
57.12, 36.48, 32.67, 28.57, 26.76, 25.88, 23.50; HRMS (TOF, ES+) C16H28NO4S [M+H]
+
 
calc'd 330.1739, found 330.1741. 
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(5S,6R)-6-((S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-
tetrahydropyridine-3-carbonyl)-5-methylcyclohex-2-enone (2.60) 
To a solution of (S)-5-methylcyclohex-2-enone (1.3.7) (43.5 mg, 0.395 mmol) in CH2Cl2 
(2 mL) at -78 
o
C was added N-ethyl-N-isopropylamine (iPr2NEt) (0.103 mL, 0.592 
mmol) and 
n
Bu2BOTf (0.592 mL, 0.592 mmol). The mixture was stirred at 78 
o
C for 1 h. 
Aldehyde 1.3.22 (86.6 mg, 0.263 mmol) dissolved in CH2Cl2 (2 mL) was added 
dropwise. The mixture was warm to rt and stir for 1.5 h. The reaction mixture was cooled 
to -78 
o
C and quenched with 0.1 mL each of MeOH and H2O2, diluted with NaHCO3 and 
extracted with CH2Cl2 (3x).  The combined organic extracts were washed with water and 
the dried over Na2SO4. Filtration and concentration afforded the crude product, which 
was used in the next step without purification.  
To a stirred solution of DMSO (38 μL, 0.53 mmol) in CH2Cl2 (7 mL) at -78 ºC was 
added drop-wise trifluoroacetic anhydride (50 μL, 0.35 mmol). After stirring at -78 ºC for 
30 mins, a pre-cooled solution of the crude alcohol dissolved in CH2Cl2 (4 mL). The 
reaction mixture was stirred at -78 ºC for 1 h, then Et3N (0.18 mL, 1.32 mmol) was added 
drop-wise. The solution was further stirred at −78 ºC for a further 20 min, then warmed to 
rt and held for 1 h. The reaction was quenched by the addition of saturated aqueous 
NaHCO3 and the aqueous layer was extracted with CH2Cl2 (5x), dried over Na2SO4, 
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filtered, concentrated in vacuo to give the crude product, which was then purified by  
flash chromatography (1:20 MeOH/EtOAc) to yield 50 in 5:1 dr., 88.4 mg (77% over 2-
steps) as a pale yellow oil: [α]D
20
 = +3.4 (c = 1.55, CHCl3);   
1
H NMR (400.1 MHz, 
CDCl3) δ (ppm):  6.84 (m, 1H), 6.02 (d, J= 9.7 Hz, 1H), 5.91 (t, J = 3.8 Hz, 1H), 4.52 (m, 
1H), 4.21 (m, 1H), 4.07 (m, 2H), 3.73 (m, 2H), 3.61 (m, 2H),  3.20 (m, 1H), 2.66 (m, 
1H), 2.53 (m, 1H), 2.40 (m, 1H), 2.34 (m, 1H), 2.10-2.09 (m, 2H), 1.87-1.73 (m, 3H), 
1.61 (m, 1H), 1.33 (d, J= 13.4 Hz, 1H), 1.20 (s, 9H), 1.08 (d, J= 6.88, 3H);   13C NMR 
(100.6 MHz, CDCl3) δ (ppm):  200.98, 200.90, 147.6, 141.5, 128.9, 125.0, 102.2, 72.4, 
67.3, 60.2, 59.2, 57.7, 36.34, 32.29, 30.95, 30.09, 27.97, 25.65, 23.53, 19.72 ; HRMS 
(TOF, ES+) C23H36NO5S [M+H]
+
 calc'd 438.2371, found 438.2373. 
 
 
Grandisine D (2.32) 
 1.3.31 (43.7 mg, 0.1 mmol) was dissolved in 95:5 TFA : H2O to a final concentration of 
0.1 M. After stirring for 1.5 h, the mixture was concentrated in vacuo and the residue was 
dissolved in DCE and PS-NaBH(OAc)3 (0.5 g, 0.5 mmol) was added and placed on a 
shaker for 2 h. The beads were filtered off and the solvent was concentrated in vacuo to 
give the crude product. Purification by flash chromatography (28% NH3-MeOH-AcOEt, 
1:10:50) gave grandisine D as a pale yellow oil (12.2 mg, 47%). To a solution of the 
grandisine D (41) (9 mg, 0.034 mmol) in DCM (1 mL) at 0 ºC was added dropwise TFA 
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(3.6 μL, 0.051 mmol). The solution was held at 0 ºC for 30 min, then warmed to rt and 
held for 1 h. The pale yellow solution was concentrated in vacuo to afford TFA salt of 
grandisine D (12.1 mg, Quant.) as pale yellow oil; [α] D
20
 +68.8 (c 0.09, MeOH); 1H 
NMR (400.1 MHz, DMSO) δ (ppm): 10.47 (br s, 1H), 7.32 (bdd, J = 4.0, 4.0 Hz, 1H), 
7.16 (ddd, J = 10.0, 6.0, 2.4 Hz, 1H), 5.94 (dd, J = 10.0, 2.4 Hz, 1H), 4.42 (dd, J = 8.8, 
8.8 Hz, 1H), 4.36 (d, J = 12.0 Hz, 1H), 3.58-3.51 (m, 1H), 3.41-3.29 (m, 2H), 3.20-3.06 
(m, 1H), 2.67-2.59 (m, 2H), 2.53-2.33 (m, 3H), 2.27-2.18 (m, 1H), 2.08-1.98 (m, 2H), 
1.77-1.67 (m, 1H) 0.86 (d, J = 6.0 Hz, 3H); δC (100 MHz, DMSO) 198.4, 196.9, 151.9, 
140.0, 137.3, 128.3, 59.1, 58.0, 52.7, 43.0, 32.7, 32.3, 28.0, 22.4, 20.4, 19.1; HRMS 
(TOF, ES+) C16H22NO2 [M+H]
+
 calc'd 260.1651, found 260.1650. 
 
 
(S)-N-(3-(1,3-dioxan-2-yl)propylidene)-2-methylpropane-2-sulfinamide (2.61):  
To a solution of 3-(1,3-dioxan-2-yl)propanal (10.1 g, 70.1 mmol) in CH2Cl2 (500 mL) 
was added (S)-2-methylpropane-2-sulfinamide (10.17 g, 84.1 mmol) and CuSO4 (44.6 g, 
280.4 mmol). The reaction mixture was stirred at rt overnight. The mixture was filtered 
through a celite pad and washed with CH2Cl2. Concentration in vacuo gave the crude 
product which was purified by automated flash chromatography (4:1 to 1:1 Hex/EtOAc) 
to yield the desired product 15.6 g (90%) as yellow oil: [α]D
20
 = +209.3 (c = 0.86, 
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CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 8.11 (t, J = 4.0 Hz, 1H), 4.62 (t, J = 4.8 
Hz, 1H), 4.10 (dd, J = 6.0, 4.8 Hz, 2H), 3.76 (m, 2H), 2.64 (sextet, J = 4.0 Hz, 2H), 2.07 
(m, 1H), 1.93 (m, 2H), 1.32 (dm, J = 13.8 Hz, 1H), 1.18 (s, 9H);  13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 169.1, 101.0, 67.0, 56.7, 30.8, 30.7, 25.8, 22.5; HRMS (TOF, ES+) 
C11H22NO3S [M+H]
+
 calc'd 248.1320, found 248.1319. 
 
 
(S)-N-((S)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-2-methylpropane-2-sulfinamide (2.62):   
Indium-mediated allylation was done according to procedures published by Lin and co-
workers. To a reaction flask containing sulfinimine 1.3.32 (14.5 g, 58.7 mmol) and 
indium powder (27.0 g, 234.8 mmol) was added saturated aqueous NaBr solution (1174 
mL, (1062.4 g of NaBr)) followed by the allyl bromide (36.8 mL, 234.8 mmol). The 
resulting suspension stirred at rt for 24 h. The reaction was quenched by the addition of 
saturated aqueous NaHCO3 and filtered through a pad of celite. The aqueous layer was 
extracted with EtOAc (3x), dried over Na2SO4, filtered, concentrated in vacuo to give the 
crude product as >19:1 dr, which was then purified by  flash chromatography (1:1 
Hex/EtOAc) to yield the allylation product in 14.7 g (87%) as a pale yellow oil: [α]D
20
 = 
+38.9 (c = 1.43, CHCl3);
 1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.77 (m, 1H), 5.16 (d, J 
= 4 Hz, 1H), 5.13 (s, 1H), 4.51 (t, J = 4.5 Hz, 1H), 4.08 (dd, J = 5, 6.3 Hz, 2H), 3.74 (dt, 
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J = 10, 2.2 Hz, 2H), 3.30 (m, 1H), 3.23 (d, J = 6.5 Hz, 1H), 2.37 (m, 2H), 2.05 (m, 1H), 
1.63 (m, 3H), 1.33 (br, J = 14 Hz, 1H), 1.19 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 133.9, 119.0, 101.9, 66.8, 55.8, 55.0, 40.5, 31.3, 29.2, 25.7, 22.6;  HRMS (TOF, 
ES+) C14H28NO3S [M+H]
+
 calc'd 290.1790, found 290.1790. 
 
 
(S)-N-((S)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-N-(2-(((tert-
butyldimethylsilyl)oxy)methyl)allyl)-2-methylpropane-2-sulfinamide (2.64):  
To a solution of sulfinamide 1.3.33 (1.4 g, 4.84 mmol) in 25 mL DMF at -20 
o
C was 
added LiHMDS (9.7 mL, 1 M in THF,) and the mixture was stirred for 20 mins at -20 
o
C 
and 20 mins at rt. The mixture was cooled back to -20 
o
C and 2.62 (3.83 g, 14.83 mmol) 
was then added slowly to the mixture and the reaction was stirred at -20 
o
C for 30 mins 
and rt overnight.  The reaction was quenched with saturated NH4Cl solution and extracted 
with EtOAc (3x).  The combined organic extracts were washed with water and  dried over 
Na2SO4. Filtration and concentration afforded the crude product, which was purified by 
flash chromatography (4:1 to 1:1 Hex/EtOAc) to afford the product as a pale yellow oil 
(2.06 g, 90%): [α]D
20
 = -2.3 (c = 0.85, CHCl3); 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 
5.74-5.84 (m, 1H), 5.23 (s, 1H), 5.14 (s, 1H), 5.03 (m, 1H), 4.48 (t, J = 5.2  Hz, 1H), 4.05 
(m, 4H), 3.94 (brd, J = 17.2 Hz, 1H), 3.72 (dt, J = 12.0, 2.4 Hz, 2H), 3.14 (d, J = 17.2 Hz, 
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1H), 2.96 (q, J = 7.2 Hz, 1H), 2.40 (dq, J = 28.2, 6.8 Hz, 2H), 1.89-2.09 (m, 2H), 1.61-
1.80 (m, 3H), 1.32 (dm, J = 13.8 Hz, 1H), 1.29 (s, 9H), 1.19 (s, 9H), 0.06 (s, 6H); 13C 
NMR (100.6 MHz, CDCl3) δ (ppm): 145.2, 136.3, 117.2, 111.7, 102.2, 67.0, 66.9, 64.8, 
62.6, 58.0, 53.6, 45.5, 39.5, 33.3, 27.3, 26.0, 25.9, 23.8, 18.5, -5.2, -5.3; HRMS (TOF, 
ES+) C24H48NO4SiS [M+H]
+
 calc'd 474.3073, found 474.3076. 
 
 
(S)-2-(2-(1,3-dioxan-2-yl)ethyl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-1-((S)-tert-
butylsulfinyl)-1,2,3,6-tetrahydropyridine (2.67): 
To a solution of 1.3.35 (1.0 g, 2.11 mmol) in CH2Cl2 (260 mL) was added 2
nd
 Gen. 
Grubbs (89.5 mg, 0.106 mmol). The mixture was refluxed for 1 h and concentrated. The 
resulting crude product was purified by automated flash chromatography (4:1 to 1:1 
Hex/EtOAc) to yield the desired product 0.845 g (90%) as a yellow oil: [α]D
20
 = -1.7 (c = 
0.0181, CHCl3);  
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 5.62 (d, J= 4.8 Hz, 1H), 4.51 (t, 
J= 4.8 Hz, 1 H), 4.09 (dd, J= 4, 7.6 Hz, 2H), 4.03 (d, J= 4 Hz, 1H), 3.73 (m, 3H), 3.34 
(m, 2H), 2.52 (m, 1H), 2.06 (m, 1H), 1.89 (dd, J= 6, 12.4 Hz, 1H), 1.80 (m, 1H), 1.68 (m, 
2H), 1.57 (m, 2H), 1.33 (br, d, J= 12.4 Hz, 1H), 1.16 (s, 9H), 0.89 (s, 9H), 0.05 (s, 6H);  
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 135.3, 118.3, 102.3, 67.0, 65.5, 58.7, 56.8, 37.2, 
32.9, 28.0, 27.0, 26.1, 25.9, 23.5, 18.5, -5.2; HRMS (TOF, ES+) C22H44NO4SiS [M+H]
+
 
calc'd 446.2760, found 446.2764. 
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((S)-6-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-tetrahydropyridin-
3-yl)methanol (2.72) 
 To a solution of 1.3.36 (300 mg, 0.67 mmol) in THF (27 mL) under argon was added 1.0 
M TBAF (1.01 mL, 1.01 mmol) dropwise at 0 
o
C. The mixture was warmed to rt and 
stirred for 2 h. The reaction was quenched with saturated NH4Cl solution and extracted 
with EtOAc (3x).  The combined organic extracts were washed with water and then dried 
over Na2SO4.  Filtration and concentration afforded the crude product, which was 
purified by flash chromatography (9:1 CH2Cl2/MeOH) to afford the product as a yellow 
oil (210 mg, 95%): [α]D
20
 = -116.1 (c = 4.7, CHCl3);   
1
H NMR (400.1 MHz, CDCl3) δ 
(ppm): 5.64 (br d, J= 4.8 Hz,  1H), 4.49 (t, J= 4.8 Hz, 1H), 4.05 (dd, J= 11.6, 4.0 Hz,  
2H), 3.91 (m, 3H), 3.71 (tt, J= 12.0, 3.6, Hz, 2H), 3.33 (m, 2H), 2.96 (br s, 1H), 2.52 (br 
d, J= 17.6 Hz, 1H), 2.04 (m, 1H), 1.87 (br dd, J= 17.6, 5.2, Hz, 1H), 1.79-1.68 (m, 2H), 
1.59-1.49 (m, 2H), 1.31 (d, J= 12.4 Hz, 1H), 1.14 (s, 9H); 13C NMR (100.6 MHz, CDCl3) 
δ (ppm): 135.7, 119.8, 101.9, 66.8, 65.2, 58.6, 56.9, 36.6, 32.6, 27.7, 26.8, 25.7, 23.3; 
HRMS (TOF, ES+) C16H30NO4S [M+H]
+
 calc'd 332.1896, found 332.1897. 
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(S)-6-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-tetrahydropyridine-
3-carbaldehyde (2.68) 
 To a solution of alcohol (150 mg, 0.45 mmol) in THF (30 mL) under argon was added 
MnO2 (796 mg, 9.16 mmol). The mixture was stirred at rt overnight. Filtration over celite 
and concentration afforded the pure product in Quant. yield: [α]D
20
 = -8.1 (c = 1, MeOH);   
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 9.34 (s, 1H), 6.91 (d, J= 5.2 Hz, 1H), 4.51 (t, J= 
4.4 Hz, 1H), 4.12 (m, 3H), 3.72 (tt, J= 12.0, 2.8 Hz, 2H), 3.49 (m, 2H), 2.79 (dm, J= 3.2 
Hz, 1H), 2.22 (ddd, J= 19.2, 6.0, 2.0 Hz, 1H), 2.06 (m, 1H), 1.75-1.51 (m, 4H), 1.32 (br 
d, J= 12.4 Hz, 1H), 1.18 (s, 9H) ;  13C NMR (100.6 MHz, CDCl3) δ (ppm): 191.9, 146.5, 
138.7, 101.5, 66.7, 58.7, 56.6, 33.6, 32.3, 29.3, 26.8, 25.6, 23.2; HRMS (TOF, ES+) 
C16H28NO4S [M+H]
+
 calc'd 330.1739, found 330.1739. 
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(5S,6R)-6-((S)-6-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-
tetrahydropyridine-3-carbonyl)-5-methylcyclohex-2-enone (2.69)  
To a solution of (S)-5-methylcyclohex-2-enone 1.3.7 (43.5 mg, 0.395 mmol) in CH2Cl2 
(2 mL) at -78 
o
C was added N-ethyl-N-isopropylpropylamine (iPr2NEt) (0.103 mL, 0.592 
mmol) and 
n
Bu2BOTf (0.592 mL, 0.592 mmol). The mixture was stirred at -78 
o
C for 1 h. 
Aldehyde 1.3.37 (86.6 mg, 0.263 mmol) dissolved in CH2Cl2 (2 mL) was added 
dropwise. The mixture was warmed to rt and stirred for 1.5 h. The reaction mixture was 
cooled -78 
o
C and quenched with 0.1 mL each of MeOH and H2O2, diluted with NaHCO3 
and extracted with CH2Cl2 (3x).  The combined organic extracts were washed with water 
and the dried over Na2SO4. Filtration and concentration afforded the crude product, 
which was used in the next step without purification.  
To a stirred solution of DMSO (38 μL, 0.53 mmol) in CH2Cl2 (7 mL) at -78 ºC was 
added drop-wise trifluoroacetic anhydride (50 μL, 0.35 mmol).  After stirring at -78 ºC 
for 30 mins, a pre-cooled solution of the crude alcohol was dissolved in CH2Cl2 (4 mL). 
The reaction mixture was stirred at -78 ºC for 1 h, then Et3N (0.18 mL, 1.32 mmol) was 
added dropwise. The solution was further stirred at −78 ºC for a further 20 min, then 
warmed to rt and held for 1 h. The reaction was quenched by the addition of saturated 
aqueous NaHCO3 and the aqueous layer was extracted with CH2Cl2 (5x), dried over 
Na2SO4, filtered, concentrated in vacuo to give the crude product, which was then 
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purified by  flash chromatography (1:20 MeOH/EtOAc) to yield the desired product 57, 
77.0 mg (67% over 2-steps) as a pale yellow oil: [α]D
20
 = +3.6 (c = 0.27, CHCl3);   
1
H 
NMR (400.1 MHz, CDCl3) δ (ppm): 6.96 (m, 1H), 6.86 (br d, J= 5.2 Hz, 1H), 6.02 (d, J= 
10 Hz, 1H), 4.51 (m, 1H), 4.08 (m, 3H), 3.82 (m, 1H), 3.72 (m, 3H), 3.53 (br d, J=  18.8 
Hz, 1H), 3.39 (m, 1H), 2.77 (m, 1H), 2.67 (m, 1H), 2.56 (m, 1H), 2.09 (m, 3H), 1.75 (m, 
1H), 1.59 (m, 2H), 1.32 (br d, J= 12.4 Hz, 1H), 1.16 (s, 9H), 0.99 (d, J= 6.4 Hz, 3H);  13C 
NMR (100.6 MHz, CDCl3) δ (ppm): 197.73, 196.79, 149.98, 138.64, 129.34, 101.97, 
67.00, 59.85, 58.91, 56.27, 34.79, 33.08, 32.90, 32.62, 29.04, 27.28, 25.88, 23.39, 22.86, 
20.20; HRMS (TOF, ES+) C23H36NO5S [M+H]
+
 calc'd 438.2371, found 438.2371. 
 
 
(5S,6R)-6-((S)-1,2,3,5,8,8a-hexahydroindolizine-6-carbonyl)-5-methylcyclohex-2-
enone (2.70): 
 1.3.38 (40.7 mg, 0.093 mmol) was dissolved in 95: 5 (TFA: H2O) to a final 
concentration of 0.1 M. After stirring for 1.5 h, the mixture was concentrated in vacuo, 
the residue was dissolved in DCE and PS-NaBH(OAc)3 (0.5 g, 0.465 mmol) and was 
added and placed on a shaker for 2 h. The beads were filtered off and the solvent was 
concentrated in vacuo to give the crude product. Purification by flash chromatography 
(28% NH3-MeOH-AcOEt, 1:10:50) gave 1.3.39 as pale yellow oil (11.8 mg, 49%). To a 
solution of 1.3.39 (10 mg, 0.0386 mmol) in DCM (1 mL) at 0 ºC was added dropwise 
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TFA (4.1 μL, 0.058 mmol). The solution was held at 0 ºC for 30 min, then warmed to rt 
and held for 1 h. The pale yellow solution was concentrated in vacuo to afford TFA salt 
of 1.3.39 (13.7 mg, Quant.) as a pale yellow oil; [α] D
20
 +2.1 (c 0.05, MeOH);  
1H NMR (600.1 MHz, DMSO) δ (ppm): 10.27 (br s, 1H), 7.33 (m, 1H), 7.15 (ddd, J = 
10.2, 6.6, 2.4 Hz, 1H), 5.96 (dd, J = 10.2, 2.4 Hz, 1H), 4.35 (d, J = 12.0 Hz, 1H), 4.30 (d, 
J = 16.2 Hz, 1H), 3.80 (m, 1H), 3.74-3.68 (m, 1H), 3.30 (br s, 1H), 3.12-3.09 (m, 1H), 
2.89 (dt, J = 19.8, 4.2, Hz, 1H), 2.55-2.44 (m, 3H), 2.32-2.27 (m, 1H), 2.32-2.27 (m, 1H), 
2.24-2.19 (m, 1H), 2.06-1.99 (m, 1H), 1.97-1.91 (m, 1H), 1.64 (q, J = 10.2 Hz, 1H) 0.87 
(d, J = 6.0 Hz, 3H); δC (150.9 MHz, DMSO) 198.0, 196.8, 151.9, 140.9, 134.6, 128.4, 
60.4, 59.5, 52.2, 47.8, 32.7, 32.6, 28.7, 27.6, 19.9, 19.2; HRMS (TOF, ES+) C16H22NO2 
[M+H]
+
 calc'd 260.1651, found 260.1651. 
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 CHAPTER III 
 
GENERAL ACCESS TO CHIRAL N-ALKYL TERMINAL AZIRIDINES AND 2-
SUBSTITUTED AZETIDINES VIA ORGANOCATALYSIS 
 
3.1. Introduction to Aziridines 
3.1.1. General properties of aziridines: 
Aziridines represent an important class of nitrogen heterocycles that have been 
met with increasing interest in both synthetic chemistry and pharmacology over the past 
two decades.  The synthetic utility of the aziridine group lies primarily in both its stability 
and ability to undergo highly regio- and stereoselective transformations.  This reactivity 
is due to a combination of Baeyer strain of the three-membered heterocycle and 
electronegativity of the heteroatom, resulting in similar reactivity to that of its oxygen-
containing cousin epoxides (Table 3.1).  Diminished electronegativity of the nitrogen 
compared to that of oxygen, as well as the additional valency of nitrogen make aziridines 
less prone to ring-opening reactions. However, there is still a plentiful collection of this 
chemistry.  In addition, aziridines can exhibit antitumor or antibiotic activity, as well as 
other biological properties which make them attractive synthetic targets in medicinal 
chemistry and the total synthesis of natural products.
1
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Table 3.1. Physical properties of 3-member ring moieties 
 
As the chemistry surrounding aziridines has been developed over the last fifty 
years, aziridines have been classified as either activated or non-activated.  This 
classification has been made according to whether or not nucleophilic ring-opening 
reactions proceed without a positive charge at the nitrogen.  Activated aziridines are 
typically N-substituted with groups that stabilize the amide-like anion that results from 
ring-opening. This is achieved through resonance or inductive effects (sulfonyl, carbonyl, 
phosphoryl).  Non-activated aziridines are N-substituted with alkyl or aryl groups, and 
nucleophilic ring-opening usually requires activation through Lewis acid catalysis, 
protonation, or quaternization of the nitrogen. 
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3.2. Synthesis of Aziridines: 
3.2.1. Introduction 
While aziridines share many structural similarities with epoxides, there is a 
marked disparity in the range of synthetic methods available to construct aziridines. 
While aziridines synthesis, and especially asymmetric synthesis, has been slower to 
develop than epoxides, there are several strategies currently available to synthetic 
chemists.  The first synthesis of an aziridine was reported by Gabriel in 1888.
2
  Gabriel’s 
synthesis of ethylenimine was accomplished by the nucleophilic ring closure of vicinal 
haloamines under basic conditions. 
 
 
Scheme 3.1. Gabriel-Marckwald Ethylenimine Synthesis 
 
Similarly, in 1935, an approach was developed by Wenker where vicinal 
aminoalcohol 3.3 was first treated with sulfuric acid to form a sulfonate salt 3.4, which 
was subsequently reacted with sodium hydroxide to form the resulting aziridine (Scheme 
3.1).
3
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Scheme 3.1. Wenker Aziridine Synthesis 
 
Since these seminal publications on the synthesis of aziridines, a tremendous 
amount of progress has been made in approaches for the formation of aziridines that are 
relatively mild and stereoselective.  Modern methods include addition to alkenes (nitrene 
transfer, addition/elimination), addition to imines (carbene and ylide methods, aza-
Darzens strategies), and intramolecular nucleophilic substitution (Figure 3.1).
4
 
 
Figure 3.1. Synthetic Approaches to Aziridines 
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3.2.2. Aziridine Synthesis by Addition to Alkenes 
A traditional approach for the direct aziridination of alkenes involves the addition 
of nitrenes.  Nitrenes are typically generated by thermal or photochemical decomposition 
of azides, as well as oxidation of hydrazines.  These methods require harsh reaction 
conditions, and, in many cases, the desired products are formed with poor 
stereoselectivity.
1
  In the 1990s, attention was directed towards the use of metal-stabilized 
nitrenes in alkene aziridination, which, in the presence of chiral ligands, can provide a 
method for enantioselective aziridination of a wide range of alkenes.  
In 1993, the Evans group developed the first copper-mediated enantioselective 
aziridination of trans olefins 3.5 with chiral bis(oxazoline) ligands 3.6 (Figure 3.2).5  The 
Jacobsen group concurrently optimized chiral 1,2 diimine derivatives 3.9 with copper(II) 
salts and found high enantioselectivities for cis olefins 3.8 containing at least one 
aromatic substituent.
6
  These two systems are complimentary in their substrate scope, 
however both lack good enantioselectivity for simple alkenes, and typically require up to 
five equivalents of alkene to achieve the reported yields. 
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Figure 3.2. Complimentary methods of Cu-catalyzed aziridination utilizing 
bis(oxazoline) and di-imine ligands 
 
Dodd and co-workers took advantage of a Michael addition-elimination sequence 
in their total synthesis of an unnatural enantiomer of polyoxamic acid 3.14 (Scheme 
3.3).
7
  The unsaturated lactone 3.11 was reacted with 3,4-dimethoxybenzylamine (3.12) 
to afford the aziridine 3.13 as a single diastereomer. 
 
Scheme 3.2. Synthesis of polyoxamic acid via Michael addition-elimination sequence 
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Catalytic asymmetric Mn-catalyzed aziridinations using an optimized Manganese 
salen complex 3.16 have been developed by Nishikori and Katsuki.  The aziridination of 
styrene with TsN=IPh and 3.16 proceeded in high yield and enantiomeric excess 
(Scheme 3.3).
8,9
 
 
Scheme 3.3. Mn- catalyzed aziridination of styrene 
 
3.2.3. Aziridine Synthesis by Addition to Imines 
Alternatively to the addition of nitrenes to alkenes, carbenes (or ylides) can 
undergo addition to imines, thus simultaneously forming one C-C bond and one C-N 
bond.  The first enantioselective azirdination of imines was accomplished by Jacobsen 
and co-workers in 1995.
10
  This involved the addition of a metallocarbene derived from 
ethyl diazoacetate and copper(I)hexafluorophosphate adding to N-arylaldimines 3.18. 
123 
 
 
Scheme 3.4. Jacobsen azirdination of imines 
 
An analogous strategy to the carbene methods previously described is the reaction 
of sulfur and iodine ylides with imines to generate the desired aziridines (Scheme 3.6).  
These ylides react with imines to give β-sulfo- or iodonium amide anions which 
subsequently undergo nucleophilic ring closure to provide aziridines.  Aggarwal and 
coworkers have been very active in this area, utilizing chiral sulfides such as 3.23 to 
access trans disubstituted aziridines 3.24.
11
  This strategy avoids the need to use 
potentially hazardous diazoester by generating reactive chiral sulfonium intermediates 
from tosylhydrazones. 
 
Scheme 3.5. Chiral aziridination using sulfur ylides 
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The aza-Darzens reaction is a well-studied and efficient azirdine-forming 
reaction.  In 1999, Zhang and co-workers reported that S-chiral sulfinylimines 3.25 and 
achiral bromoenolates 3.26 undergo an asymmetric aza-Darzens reaction to form the 
desired un-activated aziridines 3.27 in excellent yield and stereocontrol (Scheme 3.7).
12
 
 
Scheme 3.6. Aziridination of sulfinylimines with bromoenolates via aza-Darzens reaction 
 
In 2004, Johnston and co-workers reported a mild protocol for the synthesis of 
cis-aziridines utilizing Bronsted acid catalysis.13  This approach facilitates the 
construction of functionally diverse N-alkyl aziridines such as 3.31 with excellent 
diastereoselectivitiy.  This method has been applied in an approach to the aziridine-
containing natural product mitomycin c, providing efficient access to the aziridine 
intermediate (Scheme 3.8).
14
 
 
Scheme 3.7. Bronsted acid-catalyzed aza-Darzens en route to Mitomycin C 
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3.2.4. Aziridine Synthesis by Intramolecular Substitution 
Due to extensive research on the preparation of chiral epoxides, there has been 
considerable interest in the multistep preparation of azetidines via chiral 1,2 
azidoalcohols.  Borch and co-workers demonstrated an approach to N-protected 
aziridines 3.33 by the intramolecular substitution of an O-mesylate generated from the 
monoacetate to access chiral aziridines (Scheme 3.9).
15
  Similarly, Savoia and coworkers 
reported the activation of a 1,2-aminoalcohol 3.34 under Mitsunobu conditions followed 
by intramolecular substitution to access substituted aziridines.  Both of these methods 
require α-chiral amines.16 
 
Scheme 3.8. Synthesis of aziridines via 1,2-aminoalcohols 
 
In 2007, Cordova and co-workers reported an organocatalytic aziridination of α,β-
unsaturated aldehydes with acylated hydroxycarbamates.
17,18
  Utilizing a chiral silyl-
protected pyrrolidine alcohol 3.38 as an organocatalyst, 2-formylaziridines 3.39 were 
accessed in moderate yields with moderate to high diastereoselectivities and 
enantioselectivities (Scheme 3.10). 
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Scheme 3.9. Organocatalytic aziridination of α,β-unsaturated aldehydes 
 
3.3. Introduction to Azetidines: 
3.3.1. General Properties of Azetidines: 
Azetidines comprise a very important class of nitrogen-containing heterocycles 
due to both their biological importance and increasing use in medicinal chemistry, as well 
as their value to synthetic chemists in the asymmetric synthesis of complex natural 
products. Since the discovery of penicillin by Fleming, and the subsequent structure 
elucidation by Dorothy Hodgkin, azetidines have received considerable attention in the 
biological and medical chemistry communities due to their potential value as 
antibiotics.
19
  Despite their utility, they have received relatively little attention from the 
chemical community compared to their higher homologous counterparts.
20
 The problems 
encountered with azetidine synthesis have been posed in various ways by different 
natural product families, making general and versatile methods for their preparation 
difficult.   The natural products mugineic acid, penaresidins, penicillins, and the partial 
nAChR agonist tebanicline contain an azetidine moiety in their core structure (Figure 
3.3).
21
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Figure 3.3. Azetidine-based natural products and pharmaceuticals 
 
From a synthetic standpoint, the structural features of azetidine ring systems are 
of great importance, as they provide information on reliable ways of constructing and 
manipulating the strained bonds of four membered rings.  The sp3 configurations of the 
ring components should give a certain degree of flexibility in the orthogonally twisted σ-
bonds with the deformation angle of 19.5°.
22
  This results in a preference for the azetidine 
ring to adopt a puckered conformation with a barrier of inversion that can lead to the 
observance of conformational isomers (Figure 3.4).  The thermodynamic stability of the 
relatively flexible ring structures allows synthetic access to numerous azetidine 
derivatives through strategies involving cyclization and cycloaddition methodologies, and 
further transformations can be conducted on azetidine subunits to achieve target-directed 
synthesis. 
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Figure 3.4. Geometric configuration of azetidine 
 
3.4. Enantioselective Synthesis of Azetidine Rings: 
3.4.1. Introduction: 
An increase in activity in the area of azetidine synthesis over the last two decades 
has been driven in large part by their applications in both natural product total synthesis 
and medicinal chemistry.
22
  The azetidine ring is a challenging ring systems to form due 
to ring strain of the desired product, making the ring closure significantly uphill in 
energy.
20
  Although there are multiple reported methods for the synthesis of azetidines, 
few are generally applicable to form diverse arrangements of substituents, and most lack 
stereocontrol.
23
 
The general methodologies available for the preparation of azetidines can be 
divided into two categories: intramolecular cyclization and intermolecular [2+2] 
cycloaddition.  The former category typically employs the nucleophilic attack of 
deprotonated amines onto reactive γ-carbon atoms bearing a suitable leaving group, or 
through carbon-carbon bond formation.  The latter category consists of metal-catalyzed 
[2+2] cycloadditions of imines to enol ethers, similar to a Staudinger reaction. 
24
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3.4.2. Azetidine Synthesis via intramolecular cyclization 
Cyclization of a pre-formed chain by nucleophilic displacement of a leaving 
group by a nitrogen nucleophile is the most common method to produce azetidines.  
Amines are the most common nitrogen nucleophile; the main drawback of this approach 
being competing elimination due to the strained nature of the forming azetidine ring.
23
  
Halogens such as chlorides and bromides are the most often encountered leaving groups 
in this class of cyclization, although iodines, sulfonic esters (mesylate, tosylate, triflate), 
epoxides, aziridines, haloniums, and diazo groups have also seen use in the literature.
20
 
In 2006, Yu and co-workers reported the cyclization of aniline with 1,3-
dichloropropane (Scheme 3.11).  The reaction was carried out in water with microwave 
irradiation to afford the aryl azetidine 3.47 in 54% yield.
25
 
 
Scheme 3.10. Cyclization of aniline with 1,3-dichloropropane 
 
In 2009, Yus and coworkers demonstrated the base-induced cyclization of 
enantiopure (2-aminoalkyl)oxirane 3.49, forming 2(hydroxymethyl)azetidine 3.50 
stereospecifically (Scheme 3.12).
26
  By altering the reaction conditions, either the 
azetidine or pyrrolidine 3.48 could be accessed from a key intermediate. 
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Scheme 3.11. Synthesis of pyrrolidines and azetidines from enantiomerically pure 
oxiranes 
 
Activation of the hydroxyl group of a γ-amino alcohol through Mitsunobu 
conditions can also facilitate cyclization to the azetidine ring (Scheme 3.13).  In 2004, 
Christmann and co-workers reported a novel cyclization of γ-amino alcohol 3.51 obtained 
by a stereoselective Mannich reaction, leading to the synthesis of enantiopure cis-2,3-
disubstituted azetidine 3.53.
27
 
 
Scheme 3.12. Mitsunobu-activated cyclization 
 
In 2010, Fossey and coworkers described an iodine-mediated cyclization of 
homoallyl amines 3.54 that provided access to cis-2,4-azetidines 3.55 through a 4-exo-
trig cyclization (Scheme 3.14).
28
  These iodoazetidines were unstable even at 4°C, and 
underwent ring expansion to the pyrrolidine 3.56, retaining the cis configuration.  
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However, displacement of the iodide with a protected amine afforded the relatively stable 
amino azetidine 3.57 in substantially higher yield. 
 
Scheme 3.13. 2,4-cis-azetidine formation by iodocyclization of homoallylamines 
 
In 2012, Chen and coworkers reported the synthesis of azetidines 3.59 via 
palladium-catalyzed intramolecular amination of C-H bonds of picolinamide (PA) 
protected amine substrates 3.58.
29
 2,3-disubstituted azetidines could be accessed in good 
yield.  Attempts to access 2-substituted azetidines with this PA-directed C-H activation 
methodology suffered from the formation of an acetoxylated byproduct. 
 
Scheme 3.14. Synthesis of azetidines via intramolecular amination of γ-C(sp3)-H bonds 
  
3.4.3. Azetidine Synthesis via Cycloaddition 
Several variations of azetidine synthesis through [2+2] cycloaddition have been 
recently demonstrated, allowing access to azetidines containing diverse substitution 
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patterns.  Historically, the cycloaddition chemistry for four-membered ring systems 
involved the synthesis of β-lactams, from which azetidines were obtained by reduction of 
the amide.  However throughout the last decade, there have been major advances in 
synthetic methodology surrounding the direct synthesis of azetidines through 
cycloaddition chemistry. 
In 2003, Shi and co-workers reported an interesting DABCO-catalyzed 
regioselective formal [2+2] cycloaddition of N-tosylamines with allenoates during their 
investigation of the aza-Baylis-Hillman reaction.
30
  This inspired Zhu and co-workers in 
2011 to report the first examples of the catalytic enantioselective [2+2] cycloaddition 
between allenoates 3.62 and N-sulfonylimines 3.61 to give enantioenriched 2-
alkylideneazetidines 3.63.
31
 This methodology utilized a cinchona alkaloid quinidine 
amide as the organocatalyst. 
 
Scheme 3.15. Azetidine synthesis via organocatalyzed [2+2] cycloaddition 
 
In 2010, Fan and co-workers demonstrated the stereoselective synthesis of highly 
functionalized azetidines from a [2+2] cycloaddition of 2-aminomalonates 3.64 with 
chalcones 3.65 via a grind-promoted, solvent-free Michael addition and a PhIO/Bu4NI 
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mediated oxidative cyclization.
32
  These trans-2,3,4-trisubstituted azetidines 3.66 were 
synthesized in moderate to good yields with excellent diastereoselectivities. 
 
Scheme 3.16. Synthesis of trans-2,3,4-trisubstituted azetidines via [2+2] cycloaddition 
 
In addition, several examples of [4+2] cycloadditions utilizing the building block 
N-acetyl-2-azetine have been shown in the literature.  One such example from Osbourne 
and coworkers in 2004 demonstrated a Lewis acid-catalyzed [4+2] cycloaddition of N-
acetyl-2-azetine 3.68 with aromatic imines 3.67 to access bicyclic azetidine ring 
systems.
33
 
 
 
Scheme 3.17. Synthesis of bicyclic azetidines through [4+2] cycloaddition 
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3.5. Azetidines in Medicinal Chemistry 
Saturated heterocycles present a liability to the DMPK properties of potential 
therapeutics due to the metabolic susceptibility of the position adjacent to or directly on 
the heteroatom.  Both lipophilicity and charge influence metabolism, and strategies have 
been implemented with success to block the site of metabolism through changing the 
electronics of the ring and reducing hydrophobicity.
34
  Of the saturated heterocycles 
containing one heteroatom, azetidines and oxetanes are the least lipophilic, and have 
shown in some cases to be more metabolically stable than their larger homologous 
counterparts. 
 
Table 3.2. cLogP, cLogD, and pKa values of common saturated heterocycles 
 
While the recent approaches to the enantioselective synthesis of azetidines have 
made great strides in the ability to access various types of azetidines, 2-alkyl substituted 
azetidines are notably scarce in literature.  In a review of functional group occurrences in 
compounds with biological activity by Roughley and co-workers in 2011, it was noted 
that, although aliphatic amines comprised 43% of compounds in this data set, azetidines 
135 
 
made up 1.4% of this subset, and there were no occurrences of secondary azetidin-2-yl 
compounds.
35
  This may demonstrate a need by the medicinal chemistry community for a 
general, facile, and enantioselective approach to access azetidin-2-yl compounds for the 
synthesis of pharmacologically active compounds. 
 
3.6. Organocatalytic Enantioselective Synthesis of Aziridines and Azetidines 
3.6.1. Introduction: 
Many of the classical methods for aziridine synthesis typically incorporate an 
electron withdrawing group as the N-substituent, and the synthesis of terminal aziridines 
with diversity at the N-substituent is rare. In 2007, Kocovsky and co-workers developed 
an expedient protocol for the enantioselective synthesis of diaryl aziridines relying on the 
organocatalyzed reduction of α-chloroimines.36  While this work was a notable advance, 
it was lacking in generality and substrate scope, as only N-arylaziridines could be 
accessed with this approach.  Due to the fact that there were few synthetic methods in the 
literature for the enantioselective synthesis of N-alkylaziridines, we were motivated to 
develop a synthetic methodology to access N-alkyl terminal aziridines enantioselectively.  
Seminal work in this area by our lab in the organocatalytic synthesis of β- fluoroamines 
was inspired by the work of MacMillan and Jorgensen, reporting the enantioselective α-
chlorination of aldehydes via organocatlysis (Scheme 3.19). 
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Scheme 3.18. Organocatalytic enantioselective synthesis of α-chloroaldehydes and β-
fluoroamines 
 
 Based on this and previous work involving the enantioselective synthesis of β-
fluoramines, we envisioned a three-step, one-pot protocol involving the enantioselective 
α-chlorination of aldehydes, followed by reductive amination with a primary amine and 
subsequent SN2 displacement to afford previously unattainable chiral terminal aziridines 
with a wide range of N-substituents (Scheme 3.20). 
 
Scheme 3.19. General access to chiral N-alkyl terminal azirdines via organocatalysis 
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Initial efforts utilized the Jorgensen route to access α-chloroaldehydes, where 
NCS was the chlorinating agent and the optimized solvent was DCE, which made a one-
pot α-chlorination / reductive elimination feasible.  However, first attempts at the 
reductive elimination led to epimerization and loss of enantiomeric excess.  It was 
determined that the room-temperature reductive amination was the source of 
epimerization and a direct correlation was found between temperature and epimerization.  
Reducing the temperature to -78°C resolved the epimerization problem and, with the β-
chloroamine in hand, a base screen was utilized to determine optimal conditions for the 
aziridine ring closure.  The optimal conditions were determined to be KOH in THF/H2O 
(1:1).  This sequence resulted in the enantioselective synthesis of N-alkyl terminal 
aziridines in 40-65% overall yield and 56-96% ee.  Overall, this new approach represents 
the effective addition of a primary amine across an olefin to form aziridines and is a 
notable extension of the linchpin catalysis concept to access chiral epoxides reported by 
MacMillan.
37
 
While this work represents a significant improvement in the art to access 
aziridines, there were notable improvements to be made to this methodology.  Modest 
enantiomeric excess was reported in some cases, presumably due to epimerization of the 
α-chloraldehyde 2.77.  Furthermore, the reductive amination step is not amenable for 
access to larger homologous ring sizes.  Given our interest in a more general, linchpin 
approach for the synthesis of aza-moieties and our desire to improve upon our previous 
methodology, we envisioned a new approach involving an in situ  reduction of the α-
chloraldehyde to the 1,2-chloroalcohol 3.79 (Scheme 3.21).  Intermolecular SN2 
displacement with either an amine or nitrile could afford access to β-chloro or γ-
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chloroamines, respectively.  Cyclization would then allow access to either the azirdine 
3.78 or azetidine 3.80 from a common advanced intermediate. 
 
Scheme 3.20. Envisioned route to chiral N-alkyl terminal aziridines and 2-alkylazetidines 
 
3.6.2.  An Improved Synthesis of Jorgensen’s Catalyst 
Before pursuing our aziridination studies further, it was necessary to obtain the 
pyrrolidine organocatalyst described by the Jorgensen group for use in enantioselective α-
chlorination.  Unfortunately, the catalyst was no longer commercially available.  We 
attempted to prepare the organocatalyst according to literature precedent; however, we 
found that for several reactions the yields were low and variable, notably including the 
final allyl deprotection of the pyrrolidine ring.  Also importantly, the literature 
preparations resulted in an inseparable mixture of isomers of the final catalyst, including 
>18% of the meso isomer.  We found that this caused deleterious effects in the α-
chlorination reaction, affecting both the reaction rate and increasing the ratio of 
dichlorination vs. monochlorination.  Recrystallization of the final product was achieved, 
successfully increasing the purity of the desired isomer to >92%. However, these 
conditions limited the scale and required careful regulation of temperature of the entire 
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apparatus (recrystallization was performed in cold room, with temperature <4 °C).  
Therefore, we sought to improve the synthesis to both increase the yield and reliability of 
the synthesis, with the goal of being able to rapidly obtain the pyrrolidine catalyst on 
multi-gram scale.   
We were able to optimize the synthetic route, as outlined in Scheme 3.22.  
Notably, we found that flash column chromatography of the penultimate intermediate 
3.84 with a 7:3 hexanes/toluene solvent system provided excellent separation of the 
desired isomer.  Additionally, increasing the amount of Wilkinson’s catalyst in the allyl 
deprotection to 10 mol% reliably improved reaction yield to 71% from <50%.  These 
improvements allowed for the gram-scale production of catalyst 3.71 in >54% overall 
yield, and >97% purity. 
 
Scheme 3.21. Scalable synthesis of pyrrolidine organocatalyst 3.71 
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3.6.3. Studies Toward the Enantioselective Synthesis of Aziridines 
With sufficient organocatalyst for α-chlorination in hand, our efforts now focused 
on developing a protocol for the asymmetric synthesis of N-alkyl terminal azirdines.  
Utilizing previous efforts by the Jorgensen lab, organocatylzed α-chlorination with 
pyrrolidine catalyst 3.71, followed by in situ reduction with NaBH4 afforded the α-chloro 
alcohol 3.86 in excellent yield (Scheme 3.23). 
 
 
Scheme 3.22. One pot α-chlorination/reduction sequence 
 
The alcohol was then displaced with a primary amine, facilitated by an in situ 
triflate formation followed by SN2 displacement to afford the secondary β-chloroamine 
3.87 (Scheme 3.24).  This was followed by cyclization which was achieved by heating 
with KOH in THF:H2O (1:1) to cleanly afford the desired chiral N-alkyl terminal 
aziridine 3.88 in 78% overall yield from the aldehyde and 94% enantiomeric excess.  
Enantiomeric excess was determined by chiral SFC LCMS with a racemic sample for 
comparison.   
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Scheme 3.23. Amine displacement and intramolecular SN2 cyclization 
 
In order to determine the scope of this methodology, we prepared several N-alkyl 
terminal aziridines from commercially available aldehydes.  As shown in Figure 3.5, this 
sequence was general and well-tolerated across various alkyl/aryl groups, as well as 
heteroatom-containing substrates and protecting groups.  Overall yields for substrates in 
the two-pot sequence ranged from 50-73%, with up to 94% ee.  This method compares 
favorably with previous routes to access aziridines described by our group.
38
  With 
similar substrates, yields are improved by up to 20% while retaining similar 
enantioselectivity.  These conditions also avoid the problem of racemization of the α-
chloro aldehyde intermediate used previously for reductive amination.  By effecting in 
situ reduction of this intermediate, the route described avoids the need to maintain 
extremely cold temperatures and avoids the potential for racemization in subsequent 
reaction steps. 
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3.6.4. Studies Towards the Enantioselective Synthesis of Azetidines 
With an efficient method to for the enantioselective synthesis of aziridines 
optimized, our attention then turned to the enantioselective synthesis of secondary 2-
alkylazetidines.  In line with our desire to extrapolate our linchpin approach for the 
functionalization of aldehydes, the α-chloroalcohol 3.86 was prepared as previously 
described.  We next sought to displace the alcohol with a nitrile group through activation 
of the alcohol as a triflate.  Initial conditions using CH2Cl2, THF, or acetonitrile as the 
solvent with potassium cyanide led to poor conversion at room temperature and 
elimination at elevated temperature.  However, we found the acetonitrile with potassium 
cyanide and 18-crown-6 as an additive was effective in conversion to the desired nitrile 
after 24 hours at room temperature. Under these optimized conditions, displacement of 
 Figure 3.5. Enantioselective synthesis of N-alkyl terminal 
aziridines 
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the in situ prepared triflate with potassium cyanide facilitated formation of the desired β-
chloronitrile 3.93 in 83% yield.  While this substrate was relatively stable at room 
temperature in CH2Cl2 solution, elevated temperatures resulted in the formation of an 
elimination byproduct.  Similarly, the oil was highly prone to elimination, and 
decomposed within hours at room temperature. 
  Initial attempts to subsequently reduce the nitrile with standard reducing 
conditions were unsuccessful, however an InCl3 mediated reduction with NaBH4 was 
sufficient to cleanly afford the γ-chloroamine 3.94 in excellent yield. 
 
 
Scheme 3.25. Synthesis of γ-chloroamine 
 
With the γ-chloroamine in hand, we focused on the cyclization conditions to afford the 
desired azetidine.  We initially attempted the same conditions that were successful in 
facilitating the 3-exo-tet cyclization of the β-chloroamine to aziridines.  However, 
treatment with KOH in THF/H2O led to minimal consumption of the γ-chloroamine 
starting material. Additionally, when other conditions were tried, we observed substantial 
elimination to an undesired byproduct. To find conditions that might be able to affect the 
4-exo-tet cyclization, we performed a screen of a broad selection of organic and inorganic 
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bases, solvents, and temperatures.  These are summarized in Table 3.3.  Unfortunately, 
the competing elimination pathway remained problematic through all conditions 
attempted.  This can be rationalized by the high energetic requirements necessary to 
enable ring closure to the highly strained 4-member azetidine ring.  We also found that 
compounds that contained branched substituents, aryl groups, or heteroatoms β to the 
chlorine group led to nearly full conversion to the elimination product under tested 
conditions.  However, we were able to find conditions that were able to promote 
cyclization favored in a 3:1 ratio with the competing elimination pathway.  KOH in 
THF/H2O (1:1), under high thermal conditions (170 °C) was effective in conversion to 
the desired azetidine 3.95.  Microwave irradiation for 1 hour at this temperature resulted 
in full consumption of the γ-chloroamine starting material.   
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Table 3.3.  Base screen for azetidine cyclization 
 
The optimized conditions afforded the desired azetidine 3.95 in 60% yield and 
92% enantiomeric excess as determined by chiral HPLC.  The overall sequence provided 
access to the secondary 2-alkyl azetidine in 44% overall yield from a commercially 
available aldehyde (Scheme 3.26).  
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Scheme 3.26. Cyclization of γ-chloroamine to access 2-alkylazetidines 
 
In order to determine the scope of this methodology, we prepared several 2-alkyl 
azetidines from commercially available aldehydes.  β-chloro nitriles were readily 
accessed from a range of β-chloro alcohols in good overall yield.  Of note, these 
compounds were all prone to elimination as their isolated final products.  Substrates with 
branched alkyl groups or aryl groups neighboring the chlorine were especially susceptible 
to elimination, as reflected in the lower yield of compounds 3.100 and 3.98.   
 
 
Figure 3.6.  Enantioselective synthesis of β-chloronitriles 
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With the desired β-chloro nitriles in hand, we next subjected them to the 
optimized conditions for intramolecular cyclization to access the desired azetidines.  
Elimination was once again problematic across all substrates, owing to the high 
temperatures and basic conditions used.  Elimination was observed across all substrates, 
with branched or aryl substituents increasing the ratio of elimination byproduct relative to 
the desired azetidine.  The desired azetidines were isolated in 44-55% yield, and 84-92% 
ee for substrates investigated.  However, the compound 3.103, with a β-aryl substituent, 
led to an increase in the ratio of eliminated side product, with less than 5% of the desired 
azetidine product recovered. 
 
 
Figure 3.7.  Intramolecular cyclization for the synthesis of 2-substituted azetidines. 
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3.6.5. Synthesis of an Azetidine CaSR Antagonist 
To highlight the utility of this methodology, we sought to synthesize several 
current biologically active compounds that contain 2-substituted azetidines.  One such 
compound, 3.103, is a calcium sensing receptor (CaSR) antagonist under development by 
Daiichi Sankyo Pharmaceuticals (Scheme 3.27).  The current synthesis of this compound 
requires the use of expensive chiral starting materials and the use of toxic tin reagents to 
effect conversion to the desired azetidine.  Furthermore, yields for this sequence were 
low, with an overall yield of 8.7%. 
 
Scheme 3.27. Daiichi Sankyo synthesis of CaSR antagonist 2.99 
 
Our proposed synthesis of 3.103 began with a heck reaction of commercially 
available 3.115 with allyl alcohol to access aldehyde 3.115.  Asymmetric α-chlorination 
followed by reduction provided 3.116, which was subsequently alkylated to the β-
chloronitrile 3.100.  Reduction of the nitrile followed by intramolecular ring closure 
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afforded the desired azetidine 3.103. This approach requires fewer transformations, 
allows for greater control over stereochemistry, and avoids the use of prohibitively 
expensive starting materials.  However, improvements are currently ongoing to optimize 
the yield of the final intramolecular cyclization step. 
 
Scheme 3.28. Proposed synthesis of CaSR antagonist 3.103 
 
In summary, we have developed an optimized three-step procedure for the 
enantioselective synthesis of N-alkyl terminal aziridines and azetidines with alkyl 
substitutions at the C2 position of each heterocycle via organocatalysis.  This 
methodology allows for the rapid preparation of the functionalized aziridines in 50-73% 
overall yields and 88-94% ee, and unfunctionalized azetidines in 22-32% overall yields 
and 84-92% ee.  This new methodology addresses deficiencies in our first generation 
approach for the synthesis of aziridines while facilitating the synthesis of azetidines 
through a common advanced intermediate.  Alternative methods to access azetidines that 
do not rely on the chiral pool is a demonstrated need  in natural products synthesis and 
medicinal chemistry applications, and the ability to employ simple aldehydes and 
organocatalysts towards their synthesis allows for straightforward access to either 
150 
 
enantiomer.  Additional refinements and applications of this methodology to the synthesis 
of biologically relevant small molecules are currently being investigated. 
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Experimental Methods 
General Methods:  All NMR spectra were recorded on a Bruker 400, 500 or 600 MHz 
instrument.  
1
H chemical shifts are reported in  values relative to residual solvent signals 
in ppm.    Data are reported as follows:  chemical shift, integration, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, br = broad resonance, m = multiplet), 
coupling constant (Hz).  Low resolution mass spectra were obtained on an Agilent 1200 
series 6130 mass spectrometer.  High resolution mass spectra were recorded on a Waters 
Q-TOF API-US plus Acuity system with ES as the ion source.  Analytical thin layer 
chromatography was performed on Sorbent Technologies 250 micron silica plates.  
Visualization was accomplished via UV light, and/or the use of potassium permanganate 
solution followed by application of heat.  Analytical HPLC was performed on an HP1100 
with UV detection at 214 and 254 nm along with ELSD detection, LC/MS (J-Sphere80-
C18, 3.0 x 50 mm, 4.1 min gradient, 7%[0.1%TFA/H2O] : 93%[CH3CN].  Preparative 
RP-HPLC purification was performed on a custom HP1100 automated purification 
system with collection triggered by mass detection or using a Gilson Inc. preparative UV-
based system using a Phenomenex Luna C18 column (50 x 30 mm I.D., 5 m) with an 
acetonitrile (unmodified)-water (0.5 mL/L NH4OH) custom gradient.  Normal-phase 
silica gel preparative purification was performed using an automated Combi-flash 
Companion from ISCO.  Semi-preparative purifications were carried out via stacked 
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injections on a Waters Investigator SFC using a 10 x 250 mm Chiral Technologies 
CHIRALPAK ID column heated to 40 degrees Celsius.  Analytical separations were 
carried out on an Agilent 1260 Infinity SFC using a 4.6 x 250 mm Chiral Technologies 
CHIRALPAK ID column heated to 40 degrees Celsius.  Solvents for extraction, washing 
and chromatography were HPLC grade.  All reagents were purchased from Aldrich 
Chemical Co. and were used without purification.  All polymer-supported reagents were 
purchased from Argonaut Technologies and Biotage. 
 
 
(S)-2-Chloro-4-(4-methoxyphenyl)butan-1-ol (3.86). 
To a flame dried round bottom flask equipped with a stir bar, aldehyde 2.81 (0.25g, 1.40 
mmol) was dissolved into CH2Cl2 (2.81 mL) at 0°C and to the stirring solution was added 
catalyst 3.71 (31 mg, 0.14 mmol) and then N-chlorosuccinimide (0.24g, 1.82 mmol).  
Solution was maintained at 0 °C, and stirring was continued for 12 hours, at which point 
starting material was consumed by 
1
H NMR.  Reaction was diluted with MeOH (7.0 mL) 
and cooled to 0°C, then NaBH4 (0.26g, 7.02 mmol) was slowly added while stirring.  The 
reaction was stirred for an additional 30 min. at the same temperature, then quenched 
with H2O and extracted three times with EtOAc.  Organic fractions were combined, 
washed with brine, and dried over Na2SO4.  The organic layer was concentrated in vacuo 
and a crude oil was purified by column chromatography (4:1 Hex/EtOAc) to yield the 
desired product as a clear oil in 0.21g (77%).  
1
H NMR (400.2 MHz, CDCl3) δ (ppm): 
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7.12 (d, J= 8 Hz, 2H), 6.84 (d, J= 8 Hz, 2H), 3.97 (m, 1H), 3.79 (s, 3H), 3.75 (m, 1H), 
3.68 (dd, J= 11.5, 6.5 Hz, 1H), 2.84 (dt, J= 14, 6.5 Hz, 1H), 2.71 (dt, 14, 8 Hz, 1H), 2.01 
(m, 2H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 158.2, 132.7, 129.5, 114.1, 67.2, 64.4, 
55.4, 36.1, 31.5; HRMS (TOF, ES+) C11H15ClO2 [M+H]
+
 calc'd 275.1887, found 
275.1886; Specific rotation [α]23/D = -31.7° (c = 1, CH3Cl). 
 
 
(S)-2-chloro-4-phenylbutan-1-ol (3.117). 
To a flame dried round bottom flask equipped with a stir bar, 4-phenylbutanal (0.35 g, 
2.36 mmol) was dissolved into CH2Cl2 (4.73 mL) at 0°C and to the stirring solution was 
added catalyst 3.71 (0.053 g, 0.0.24 mmol) and then N-chlorosuccinimide (0.410 g, 3.07 
mmol).  Solution was maintained at 0 °C, and stirring was continued for 12 hours, at 
which point starting material was consumed by 
1
H NMR.  Reaction was diluted with 
MeOH (4.73 mL) and cooled to 0°C, then NaBH4 (0.447 g, 11.82 mmol) was slowly 
added while stirring.  The reaction was stirred for additional 30 min. at the same 
temperature, then quenched with H2O and extracted three times with EtOAc.  Organic 
fractions were combined, washed with brine, and dried over Na2SO4.  The organic layer 
was concentrated in vacuo and a crude oil was purified by column chromatography (4:1 
Hex/EtOAc) to yield desired product as a clear oil in 0.311 g (72%).  
1
HNMR (400.2 
MHz, CDCl3) δ (ppm): 7.30 (t, J= 8.0 Hz, 2H), 7.21 (m, 3H), 3.98 (m, 1H), 3.78 (dd, J= 
12.1, 4.0 Hz, 1H), 3.69 (dd, J= 12.1, 6.5 Hz, 1H), 2.90 (quint, J= 7.1 Hz, 1H), 2.76 
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(quint, J= 7.1 Hz, 1H), 2.07 (m, 2H); 13C NMR (100.6 MHz, CDCl3) δ (ppm): 140.5, 
128.5, 128.4, 126.2, 66.95, 64.2, 62.6, 35.7, 32.3;  [α]23/D = -26.2° (c = 1, CH3Cl). 
 
 
(S)-2-chlorodecan-1-ol (3.118). 
To a flame dried round bottom flask equipped with a stir bar, decanal (0.25 g, 1.60 mmol) 
was dissolved into CH2Cl2 (8.01 mL) at 0°C and to the stirring solution was added 
catalyst 3.71 (0.036 g, 0.16 mmol) and then N-chlorosuccinimide (0.278 g, 2.08 mmol). 
Solution was maintained at 0 °C, and stirring was continued for 12 hours, at which point 
starting material was consumed by 
1
HNMR.  Reaction was diluted with MeOH (8.01 mL) 
and cooled to 0°C, then NaBH4 (0.303 g, 8.01 mmol) was slowly added while stirring.  
The reaction was stirred for an additional 30 min. at the same temperature, then quenched 
with H2O and extracted three times with EtOAc.  The organic fractions were combined, 
washed with brine, and dried over Na2SO4.  The organic layer was concentrated in vacuo 
and a crude oil was purified by column chromatography (4:1 Hex/EtOAc) to yield 
desired product as a clear oil in 0.22 g (70%).  
1
HNMR (400.2 MHz, CDCl3) δ (ppm): 
4.00 (m, 1H), 3.77 (dd, J= 11.9, 3.5 Hz), 3.65 (dd, J= 11.9, 7.1 Hz, 1H), 2.18 (br s, 1H), 
1.73 (m, 2H), 1.51 (m, 1H), 1.40 (m, 1H), 1.41 (m, 1H), 1.27 (m, 10H), 0.87 (t, J= 7.0 
Hz, 3H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 67.2, 65.5, 34.4, 31.9, 29.5, 29.3, 29.2, 
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26.5, 22.8, 14.2; HRMS (TOF, ES+) Did not ionize on positive or negative ion detection 
mode; Specific rotation [α]23/D = +5.9° (c = 1.1, CH3Cl). 
 
 
 
(S)-2-chloro-3-(3-fluoro-4-methylphenyl)propan-1-ol (3.119). 
To a flame dried round bottom flask equipped with a stir bar, 3-(3-fluoro-4-
methylphenyl)propanal (0.340 g, 2.05 mmol) was dissolved into CH2Cl2 (5.85 mL) at 
0°C and to the stirring solution was added catalyst 3.71 (0.046 g, 0.20 mmol) and then N-
chlorosuccinimide (0.355 g, 2.66 mmol).  Solution was maintained at 0 °C, and stirring 
was continued for 12 hours, at which point starting material was consumed by 
1
HNMR.  
The reaction was diluted with MeOH (5.85 mL) and cooled to 0°C, then NaBH4 (0.387 g, 
10.24 mmol) was slowly added while stirring.  The reaction was stirred for an additional 
30 min. at the same temperature, then quenched with H2O and extracted three times with 
EtOAc.  The organic fractions were combined, washed with brine, and dried over 
Na2SO4.  The organic layer was concentrated in vacuo and a crude oil was purified by 
column chromatography (4:1 Hex/EtOAc) to yield desired product as a clear oil in 0.234 
g (58%).  
1
HNMR (400.2 MHz, CDCl3) δ (ppm): 6.97 (t, J= 8.4 Hz, 1H), 6.76 (s, 1H), 
6.74 (d, J= 4.0 Hz, 1H), 4.04 (m, 1H), 3.65 (dd, J= 12.0, 4.0 Hz, 1H), 3.53 (dd, J= 12.0, 
6.0 Hz, 1H), 2.95 (dd, J= 13.7, 6.5 Hz, 1H), 2.85 (dd, J= 13.7, 7.5 Hz, 1H), 2.10 (s, 3H), 
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1.76 (br s, 1H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 161.2 (JCF = 247 Hz), 136.5 (JCF 
= 7 Hz), 131.4 (JCF = 6 Hz), 124.6 (JCF = 4 Hz), 123.4 (JCF = 18 Hz), 115.8 (JCF = 20 Hz), 
65.7, 64.4, 39.9, 14.2 (JCF = 4 Hz); Specific rotation [α]
23
/D = -18.8° (c = 1, CH3Cl). 
 
 
(S)-2-chloro-4-(5,5-dimethyl-1,3-dioxan-2-yl)butan-1-ol (3.120). 
To a flame dried round bottom flask equipped with a stir bar, 4-(5,5-dimethyl-1,3-dioxan-
2-yl)butanal (0.25 g, 1.34 mmol) was dissolved in CH2Cl2 (3.84 mL) at 0°C and to the 
stirring solution was added catalyst 3.71 (0.03 g, 0.13 mmol) and then N-
chlorosuccinimide (0.233 g, 1.75 mmol).  Solution was maintained at 0 °C, and stirring 
was continued for 12 hours, at which point starting material was consumed by 
1
HNMR.    
The reaction was diluted with MeOH (3.84 mL) and cooled to 0°C, then NaBH4 (0.254 g, 
6.72 mmol) was slowly added while stirring.  The reaction was stirred for additional 30 
min. at the same temperature, then quenched with H2O and extracted three times with 
EtOAc.  The organic fractions were combined, washed with brine, and dried over 
Na2SO4.  The organic layer was concentrated in vacuo and a crude oil was purified by 
column chromatography (4:1 Hex/EtOAc) to yield desired product as a clear oil in 0.23 g 
(76%).  
1
HNMR (400.2 MHz, CDCl3) δ (ppm): 4.49 (t, J= 4.4 Hz, 1H), 4.08 (m, 1H), 
3.81 (dd, J= 12.2, 4.0 Hz, 1H), 3.69 (dd, J= 11.7, 7.0 Hz, 1H), 3.62 (d, J= 10.8 Hz, 2H), 
3.44 (d, J= 10.8 Hz, 2H), 2.05 (s, 1H), 2.00-1.74 (m, 4H), 1.20 (s, 3H), 0.74 (s, 3H); 13C 
NMR (100.6 MHz, CDCl3) δ (ppm): 101.2, 76.6, 66.8, 64.7, 31.2, 30.1, 28.3, 22.9, 21.7; 
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HRMS (TOF, ES+) C10H19ClO3 [M+H]
+
 calc'd 222.1021, found 222.1020; Specific 
rotation [α]23/D = -3.0° (c = 1, CH3Cl). 
 
 
N-Benzyl-2-chloro-4-(4-methoxyphenyl)butan-1-amine (3.121). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.86 (0.30 g, 1.40 
mmol) and 2,6-lutidine (0.751 g, 7.01 mmol) were dissolved in CH2Cl2 (7.01 mL) and 
cooled to 0°C.  Tf2O (1.68 mL, 1M in CH2Cl2, 1.68 mmol) was then added dropwise, and 
the solution was left to stir at 0°C for 30 minutes. At this time, the triflate solution was 
taken up by syringe and added dropwise to a stirring solution of benzylamine (1.52 g, 
14.01 mmol) in CH2Cl2 (1.5 mL) at 0°C.  The flask containing the triflate solution was 
washed 2 times with CH2Cl2 (1 mL) and added to the reaction.  The solution was then 
slowly warmed to ambient temperature and stirred overnight.  The reaction was quenched 
with NaHCO3, diluted with CH2Cl2, and extracted 3 times with CH2Cl2.  The organic 
layers were combined and washed with brine. The organic layer was dried over Na2SO4 
and concentrated in vacuo to yield the crude product as a yellow oil.  Purification by flash 
column chromatography (9:0.9:0.1 CH2Cl2/MeOH/NH4OH) to yield the desired product 
as a pale yellow oil in 0.22g, (88%).  Instead of flash column chromatography, crude 
reaction product could also be directly carried forward to the next step.  
1
HNMR (400.2 
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MHz, CDCl3) δ (ppm): 7.33 (m, 4H), 7.26 (m, 1H), 7.10 (d, J= 9 Hz, 2H),  6.83 (d, J= 9 
Hz, 2H), 4.03 (m, 1H), 3.80 (dd, 14, 13 Hz, 2H), 3.79 (s, 3H), 2.86 (dd, 6, 3 Hz, 2H), 
2.80 (m, 1H), 2.01 (m, 2H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 157.94, 132.82, 
129.39, 129.22, 128.42, 128.15, 128.07, 127.06, 120.12, 113.86, 113.80, 62.48, 55.34, 
55.21, 53.25, 37.97, 31.52, 24.41. 
                                                            
 
(S)-N-benzyl-2-chloro-4-phenylbutan-1-amine (3.122). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.117 (0.075 g, 0.41 
mmol) and 2,6-lutidine (0.218 g, 2.04 mmol) were dissolved in CH2Cl2 (2.04 mL) and 
cooled to 0°C.  Tf2O (0.49 mL, 1M in CH2Cl2, 0.49 mmol) was then added dropwise, and 
the solution was left to stir at 0°C for 30 minutes. At this time, the triflate solution was 
taken up by syringe and added dropwise to a stirring solution of benzylamine (0.44 g, 
4.07 mmol) in CH2Cl2 (0.5 mL) at 0°C.  The flask containing the triflate solution was 
washed 2 times with CH2Cl2 (0.5 mL) and added to the reaction.  The solution was then 
slowly warmed to ambient temperature and stirred overnight.  The reaction was quenched 
with NaHCO3, diluted with CH2Cl2, and extracted 3 times with CH2Cl2.  The organic 
layers were combined and washed with brine. The organic layer was dried over Na2SO4 
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and concentrated in vacuo to yield the crude product.  The crude product was isolated as 
a pale yellow oil quantitatively and carried forward directly to the next step.   
 
 
(S)-N-benzyl-2-chlorodecan-1-amine (3.123). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.118 (0.12 g, 0.60 
mmol) and 2,6-lutidine (0.32 g, 2.99 mmol) were dissolved in CH2Cl2 (2.99 mL) and 
cooled to 0 °C.  Tf2O (0.72 mL, 1M in CH2Cl2, 0.72 mmol) was then added dropwise, 
and the solution left to stir at 0°C for 30 minutes. At this time, the triflate solution was 
taken up by syringe and added dropwise to a stirring solution of benzylamine (0.64 g, 
5.99 mmol) in CH2Cl2 (1.0 mL) at 0°C.  The flask containing the triflate solution was 
washed 2 times with CH2Cl2 (1 mL) and added to reaction.  The solution was then slowly 
warmed to ambient temperature and stirred overnight.  The reaction was quenched with 
NaHCO3, diluted with CH2Cl2, and extracted 3 times with CH2Cl2.  The organic layers 
were combined and washed with brine. The organic layer was dried over Na2SO4 and 
concentrated in vacuo to yield the crude product.  The crude product was isolated as a 
pale yellow oil quantitatively and carried forward directly to the next step.   
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(S)-N-benzyl-2-chloro-3-(3-fluoro-4-methylphenyl)propan-1-amine (3.124). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.119 (0.20 g, 1.00 
mmol) and 2,6-lutidine (0.53 g, 4.9 mmol) were dissolved in CH2Cl2 (4.9 mL) and cooled 
to 0°C.  Tf2O (1.19 mL, 1M in CH2Cl2, 1.19 mmol) was then added dropwise, and the 
solution was left to stir at 0°C for 30 minutes. At this time, the triflate solution was taken 
up by syringe and added dropwise to a stirring solution of benzylamine (1.06 g, 9.90 
mmol) in CH2Cl2 (1.5 mL) at 0°C.  The flask containing the triflate solution was washed 
2 times with CH2Cl2 (1 mL) and added to reaction.  The solution was then slowly warmed 
to ambient temperature and stirred overnight.  The reaction was quenched with NaHCO3, 
diluted with CH2Cl2, and extracted 3 times with CH2Cl2.  The organic layers were 
combined and washed with brine. The organic layer was dried over Na2SO4 and 
concentrated in vacuo to yield the crude product.  The crude product was isolated as a 
pale yellow oil quantitatively and carried forward directly to the next step.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
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(S)-N-benzyl-2-chloro-4-(5,5-dimethyl-1,3-dioxan-2-yl)butan-1-amine (3.125). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.120 (0.10 g, 0.45 
mmol) and 2,6-lutidine (0.241 g, 2.25 mmol) were dissolved in CH2Cl2 (2.25 mL) and 
cooled to 0°C.  Tf2O (0.54 mL, 1M in CH2Cl2, 0.54 mmol) was then added dropwise, and 
the solution was left to stir at 0°C for 30 minutes. At this time, the triflate solution was 
taken up by syringe and added dropwise to a stirring solution of benzylamine (0.48 g, 
4.50 mmol) in CH2Cl2 (1.00 mL) at 0°C.  The flask containing the triflate solution was 
washed 2 times with CH2Cl2 (1.00 mL) and added to reaction.  The solution was then 
slowly warmed to ambient temperature and stirred overnight.  The reaction was quenched 
with NaHCO3, diluted with CH2Cl2, and extracted 3 times with CH2Cl2.  The organic 
layers were combined and washed with brine. The organic layer was dried over Na2SO4 
and concentrated in vacuo to yield the crude product.  The crude product was isolated as 
a pale yellow oil quantitatively and carried forward directly to the next step. 
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(R)-1-Benzyl-2-(4-methoxyphenethyl)aziridine (3.88). 
In an open microwave vial equipped with a stir bar, amine 3.121 (0.12g, 0.41 mmol) was 
dissolved in 1:1 THF/H2O (2.71 mL), followed by the addition of KOH (0.15g, 2.64 
mmol).  The microwave vial was sealed and stirred overnight at 65 °C. The reaction 
mixture was allowed to cool to ambient temperature, then extracted 3 times with EtOAc.  
The organic layers were combined and dried over Na2SO4, then concentrated in vacuo to 
give the crude product as a pale yellow oil. Purification by flash column chromatography 
(1:1 Hex/EtOAc) afforded the desired product as a colorless oil in 0.10 g, (95%). 
1
HNMR 
(400.2 MHz, CDCl3) δ (ppm): 7.35 (m, 4H), 7.27 (m, 1H), 7.02 (d, J= 8.4 Hz, 2H), 6.80 
(d, J= 8.4 Hz, 2H), 3.78 (s, 3H), 3.50 (d, J= 13.0 Hz, 1H), 3.31 (d, J= 13.0 Hz, 1H), 2.56 
(m, 2H), 1.69 (m, 2H), 1.63 (d, J= 3.5 Hz, 1H), 1.48 (m, 1H), 1.39 (d, J= 6.6 Hz, 1H); 13C 
NMR (100.6 MHz, CDCl3) δ (ppm): 157.9, 139.6, 134.1, 129.4, 128.5, 128.4, 127.2, 
113.8, 65.1, 55.4, 39.3, 35.1, 34.2, 32.9;  HRMS (TOF, ES+) C18H21NO [M+H]
+
 calc'd 
267.1622, found 267.1622; Specific rotation [α]23/D = +25.6° (c = 1.2, CH3Cl). 
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(R)-1-benzyl-2-phenethylaziridine (3.89). 
In an open microwave vial equipped with a stir bar, amine 3.122 (0.17 g, 0.62 mmol) was 
dissolved in 1:1 THF/H2O (4.1 mL), followed by the addition of KOH (0.23 g, 4.04 
mmol).  The microwave vial was sealed and stirred overnight at 65 °C. The reaction 
mixture was allowed to cool to ambient temperature, then extracted 3 times with EtOAc.  
The organic layers were combined and dried over Na2SO4, then concentrated in vacuo to 
give the crude product as a pale yellow oil. Purification by flash column chromatography 
(1:1 Hexs/EtOAc) afforded the desired product as a colorless oil in 0.13 g, (89%). 
1
HNMR (400.2 MHz, CDCl3) δ (ppm): 7.25 (m, 4H), 7.15 (m, 3H), 7.06 (m, 1H), 7.01 (d, 
J= 7.6 Hz, 2H), 3.40 (d, J= 13.0 Hz, 1H), 3.20 (d, J= 13.0 Hz, 1H), 2.53 (m, 1H), 1.64 
(m, 2H), 1.54 (d, J= 3.8 Hz, 1H), 1.39 (m, 1H), 1.31 (d, J= 6.2 Hz, 1H); 13C NMR (100.6 
MHz, CDCl3) δ (ppm): 142.0, 139.5, 128.5, 128.4, 128.3, 128.2, 127.2, 125.8, 65.1, 39.3, 
34.8, 34.2, 33.8;  HRMS (TOF, ES+) C17H19N [M+H]
+
 calc'd 193.0656, found 193.0656; 
Specific rotation [α]23/D = +11.0° (c = 0.9, CH3Cl). 
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(R)-1-benzyl-2-octylaziridine (3.91). 
In an open microwave vial equipped with a stir bar, amine 3.123 (0.17 g, 0.60 mmol) was 
dissolved in 1:1 THF/H2O (4.0 mL), followed by the addition of KOH (0.22 g, 3.92 
mmol).  The microwave vial was sealed and stirred overnight at 65 °C. The reaction 
mixture was allowed to cool to ambient temperature, then extracted 3 times with EtOAc.  
The organic layers were combined and dried over Na2SO4, then concentrated in vacuo to 
give the crude product as a pale yellow oil. Purification by flash column chromatography 
(1:1 Hex/EtOAc) afforded the desired product as a colorless oil in 0.18 g, (81%).  
1
HNMR (400.2 MHz, CDCl3) δ (ppm): 7.20 (m, 5H), 3.42 (d, J= 12.9 Hz, 1H), 3.24 (d, 
J= 12.9 Hz, 1H), 1.53 (d, J= 3.7 Hz, 1H), 1.33 (m, 4H), 1.15 (m, 12H), 0.81 (t, J= 7.0 Hz, 
3H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 139.6, 128.4, 128.3, 127.1, 65.2, 39.9, 
34.2, 33.2, 31.9, 29.7, 29.5, 29.4, 29.3, 27.6, 22.8, 14.2; HRMS (TOF, ES+) C17H27N 
[M+H]
+
 calc'd 245.2144, found 245.2144; Specific rotation [α]23/D = +17.6° (c = 0.9, 
CH3Cl). 
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(R)-1-benzyl-2-(3-fluoro-4-methylbenzyl)aziridine (3.92). 
In an open microwave vial equipped with a stir bar, amine 3.124 (0.08 g, 0.29 mmol) was 
dissolved in 1:1 THF/H2O (1.94 mL), followed by the addition of KOH (0.11 g, 1.89 
mmol).  The microwave vial was sealed and stirred overnight at 65 °C. The reaction 
mixture was allowed to cool to ambient temperature, then extracted 3 times with EtOAc.  
The organic layers were combined and dried over Na2SO4, then concentrated in vacuo to 
give the crude product as an oil. Purification by flash column chromatography (1:1 
Hex/EtOAc) afforded the desired product as a pale yellow oil in 0.06 g, (84%).  
1
HNMR 
(400.2 MHz, CDCl3) δ (ppm): 7.20 (m, 5H), 6.94 (t, J= 8.0 Hz, 1H), 6.76 (s, 1H), 6.74 (d, 
J= 5.0 Hz, 1H), 3.34 (d, J= 12.1Hz, 1H), 3.29 (d, J= 12.1 Hz, 1H), 2.66 (dd, J= 14.0, 6.6 
Hz, 1H), 2.54 (dd, J= 14.0, 6.6 Hz, 1H), 2.15 (s, 3H), 1.65 (m, 2H), 1.39 (d, dd, J= 6.7 
Hz, 1H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 161.3 (d, JCF = 247 Hz), 139.1 (d, JCF = 
8 Hz), 139.0, 131.1 (d, JCF = 6 Hz), 128.2, 128.0, 126.9, 123.9 (d, JCF = 3.6 Hz), 122.2 (d, 
JCF = 20 Hz), 115.0 (d, JCF = 22 Hz), 64.7, 40.3, 38.6, 33.7, 14.1 (d, JCF = 4 Hz); Specific 
rotation [α]23/D = -1.1° (c = 1, CH3Cl). 
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(R)-1-benzyl-2-octylaziridine (3.90). 
In an open microwave vial equipped with a stir bar, amine 3.125 (0.14 g, 0.45 mmol) was 
dissolved in 1:1 THF/H2O (2.99 mL), followed by the addition of KOH (0.16 g, 2.92 
mmol).  The microwave vial was sealed and stirred overnight at 65 °C. The reaction 
mixture was allowed to cool to ambient temperature, then extracted 3 times with EtOAc.  
The organic layers were combined and dried over Na2SO4, then concentrated in vacuo to 
give the crude product a pale yellow oil. Purification by flash column chromatography 
(1:1 Hex/EtOAc) afforded the desired product as pale yellow oil in 0.11 g, (85%).  
1
HNMR (400.2 MHz, CDCl3) δ (ppm): 7.23 (m, 5H), 4.28 (t, J= 5.0 Hz, 1H), 3.50 (d, J= 
10.8 Hz, 2H), 3.43 (d, J= 13.6 Hz, 1H), 3.27 (m, 3H), 1.61 (m, 2H), 1.55 (d, J= 3.4 Hz, 
1H), 1.47 (m, 3H), 1.32 (d, J= 6.0 Hz, 1H), 1.10 (s, 3H), 0.63 (s, 3H); 13C NMR (100.6 
MHz, CDCl3) δ (ppm): 139.5, 128.4, 128.3, 127.0, 101.7, 77.3, 65.1, 39.5, 34.0, 32.6, 
30.2, 27.6, 23.1, 21.9; HRMS (TOF, ES+) C17H25NO2 [M+H]
+
 calc'd 275.1886, found 
275.1886; Specific rotation [α]23/D = +4.0° (c = 1, CH3Cl). 
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(S)-3-Chloro-5-(4-methoxyphenyl)pentanenitrile (3.93). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.86 (0.50 g, 2.34 
mmol) and 2,6-lutidine (1.25 g, 11.68 mmol) were dissolved in CH2Cl2 (11.68 mL) and 
cooled to 0°C.  Tf2O (2.80 mL, 1M in CH2Cl2, 2.80 mmol) was then added dropwise, and 
the solution was left to stir at 0°C for 30 minutes. The reaction was diluted with CH2Cl2 
and washed with H2O.  The organic fraction was washed with brine, dried over Na2SO4, 
and concentrated in vacuo.  The crude oil was carried forward directly to the next step.   
The crude triflate was dissolved in MeCN (11.68 mL), then 18-C-6 (0.12 g, 0.47 mmol) 
was added to the mixture and allowed to dissolve.  KCN (1.52 g, 23.36 mmol) was then 
added, and the reaction was allowed to stir for 12 h at ambient temperature.  The reaction 
was then quenched with NaHCO3 and extracted three times with CH2Cl2.  The organic 
fractions were combined and dried over Na2SO4. The organic layer was concentrated in 
vacuo, and purification by flash chromatography (4:1 Hex/EtOAc) to afford the desired 
product as a clear/rose colored oil in 0.43 g (83%).  
1
HNMR (400.2 MHz, CDCl3) δ 
(ppm): 7.11 (d, J= 8.5 Hz, 2H), 6.85 (d, J= 8.5 Hz, 2H), 3.97 (quint, J=6.5 Hz, 1H), 3.79 
(s, 3H), 2.84 (m, 1H), 2.80 (dd, J= 5.6, 1Hz, 2H), 2.72 (m, 1H), 2.12 (dd, J= 14, 7 Hz, 
2H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 158.4, 131.7, 129.6, 116.2, 114.3, 55.4, 
54.8, 39.3, 31.5, 27.8;  HRMS (TOF, ES+) C12H14ClNO [M+H]
+
 calc'd 223.0762, found 
223.0760; Specific rotation [α]23/D = +10.1° (c = 0.9, CH3Cl). 
 
170 
 
 
(S)-3-chloro-5-phenylpentanenitrile (3.97). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.117 (0.15, 0.82 
mmol) and 2,6-lutidine (0.44 g, 4.1 mmol) were dissolved in CH2Cl2 (4.10 mL) and 
cooled to 0°C.  Tf2O (0.98 mL, 1M in CH2Cl2, 0.98 mmol) was then added dropwise, and 
the solution was left to stir at 0°C for 30 minutes. The reaction was diluted with CH2Cl2 
and washed with H2O.  The organic fraction was washed with brine, dried over Na2SO4, 
and concentrated in vacuo.  The crude oil was carried on directly to the next step.   
The crude triflate was dissolved in MeCN (4.10 mL), then 18-C-6 (0.04 g, 0.16 mmol) 
was added to the mixture and allowed to dissolve.  KCN (0.53 g, 8.20 mmol) was then 
added, and the reaction was allowed to stir for 12 h at ambient temperature.  The reaction 
was then quenched with NaHCO3 and extracted three times with CH2Cl2.  The organic 
fractions were combined and dried over Na2SO4. The organic layer was concentrated in 
vacuo, and purification by flash chromatography (4:1 Hex/EtOAc) afforded the desired 
product as a clear/rose colored oil in 0.14 g (86%).  
1
HNMR (400.2 MHz, CDCl3) δ 
(ppm): 7.31 (t, J= 7.7 Hz, 2H), 7.22 (m, 3H), 3.99 (ddt, J= 9.7, 5.9, 5.6 Hz, 1H), 2.92 (m, 
1H), 2.81 (dd, J= 5.9, 2.5 Hz, 2H), 2.78 (m, 1H), 2.16 (m, 2H); 13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 139.75, 128.84, 128.60, 128.66, 116.17, 54.80, 39.03, 32.35, 27.80; 
HRMS (TOF, ES+) C11H12ClN [M+H]
+
 calc'd 193.0656, found 193.0656; Specific 
rotation [α]23/D = +2.4° (c = 1, CH3Cl). 
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(S)-3-chloroundecanenitrile (3.99). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.118 (0.50 g, 2.60 
mmol) and 2,6-lutidine (1.39 g, 13.01 mmol) were dissolved in CH2Cl2 (13.01 mL) and 
cooled to 0°C.  Tf2O (3.12 mL, 1M in CH2Cl2, 3.12 mmol) was then added dropwise, and 
the solution was left to stir at 0°C for 30 minutes. The reaction was diluted with CH2Cl2 
and washed with H2O.  The organic fraction was washed with brine, dried over Na2SO4, 
and concentrated in vacuo.  The crude oil was carried on directly to the next step.   
The crude triflate was dissolved in MeCN (13.01 mL), then 18-C-6 (0,137 0.52 mmol) 
was added to the mixture and allowed to dissolve.  KCN (0.578g, 8.88 mmol) was then 
added, and the reaction was allowed to stir for 12 h at ambient temperature.  The reaction 
was then quenched with NaHCO3 and extracted three times with CH2Cl2.  The organic 
fractions were combined and dried over Na2SO4. The organic layer was concentrated in 
vacuo, and purification by flash chromatography (4:1 Hex/EtOAc) afforded the desired 
product as a clear/rose colored oil in 0.33 g (66%).  
1
HNMR (400.2 MHz, CDCl3) δ 
(ppm): 4.05 (m, 1H), 2.82 (dd, J= 6.0, 1.3 Hz, 2H), 1.85 (m, 2H), 1.52 (m, 1H), 1.42 (m, 
1H), 1.28 (m 12H), 0.87 (t, J= 6.5 Hz, 3H); 13C NMR (100.6 MHz, CDCl3) δ (ppm): 
116.4, 55.8, 37.5, 31.9, 29.4, 29.2, 28.9, 27.7, 26.3, 22.7, 14.2; Specific rotation [α]23/D = 
+0.9° (c = 1, CH3Cl). 
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(S)-3-chloro-4-(3-fluoro-4-methylphenyl)butanenitrile (3.100). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.119 (0.16 g, 0.81 
mmol) and 2,6-lutidine (0.44g, 4.06 mmol) were dissolved in CH2Cl2 (4.06 mL) and 
cooled to 0°C.  Tf2O (0.97 mL, 1M in CH2Cl2, 0.97 mmol) was then added dropwise, and 
the solution was left to stir at 0°C for 30 minutes. The reaction was diluted with CH2Cl2 
and washed with H2O.  The organic fraction was washed with brine, dried over Na2SO4, 
and concentrated in vacuo.  The crude oil was carried on directly to the next step.   
The crude triflate was dissolved in MeCN (4.06 mL), then 18-C-6 (0.04 g, 0.16 mmol) 
was added to the mixture and allowed to dissolve.  KCN (0.53 g, 8.12 mmol) was then 
added, and the reaction was allowed to stir for 12 h at ambient temperature.  The reaction 
was then quenched with NaHCO3 and extracted three times with CH2Cl2.  The organic 
fractions were combined and dried over Na2SO4. The organic layer was concentrated in 
vacuo, and purification by flash chromatography (4:1 Hex/EtOAc) afforded the desired 
product as a clear/rose colored oil in 0.15g (75%).  
1
HNMR (400.2 MHz, CDCl3) δ 
(ppm): 7.15 (t, J= 8.0 Hz, 1H), 6.90 (m, 2H), 4.23 (pent, J= 6.2 Hz, 1H), 3.13 (dq, J= 
13.0, 6.8 Hz, 2H), 2.76 (dq, J= 17.0, 6.0 Hz, 2H), 2.26 (s, 3H); 13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 161.3 (d, JCF = 247 Hz), 135.2 (d, JCF = 8 Hz), 131.9 (d, JCF = 6 Hz), 
124.7 (d, JCF = 4 Hz), 124.3 (d, JCF =  18 Hz), 116.1, 115.8 (d, JCF = 21 Hz), 53.4, 42.9, 
26.5, 14.3 (d, JCF = 4 Hz); HRMS (TOF, ES+) C11H11ClFN [M+H]
+
 calc'd 211.0562, 
found 211.0561; Specific rotation [α]23/D = -13.3° (c = 1, CH3Cl). 
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(S)-3-chloro-5-(5,5-dimethyl-1,3-dioxan-2-yl)pentanenitrile (3.98). 
To a flame dried round bottom flask equipped with a stir bar, alcohol 3.120 (0.19g, 0.89 
mmol) and 2,6-lutidine (0.48g, 4.44 mmol) were dissolved in CH2Cl2 (4.4 mL) and 
cooled to 0°C.  Tf2O (0.30g, 1.07 mmol) was then added dropwise, and solution left to 
stir at 0°C for 30 minutes. Reaction was diluted with CH2Cl2 and washed with H2O.  The 
organic fraction was washed with brine, dried over Na2SO4, and concentrated in vacuo.  
The crude oil was carried on directly to the next step.   
The crude triflate was dissolved in MeCN (4.4 mL), then 18-C-6 (0.05g, 0.18 mmol) was 
added to the mixture and allowed to dissolve.  KCN (0.578g, 8.88 mmol) was then added, 
and the reaction was allowed to stir for 12 h at ambient temperature.  The reaction was 
then quenched with NaHCO3 and extracted three times with CH2Cl2.  The organic 
fractions were combined and dried over Na2SO4. The organic layer was concentrated in 
vacuo, and purification by flash chromatography (4:1 Hex/EtOAc) afforded the desired 
product as a clear/rose colored oil in 0.11 g (70%).  
1
HNMR (400.2 MHz, CDCl3) δ 
(ppm): 4.45 (dd, J= 10.4, 1.6 Hz, 1H, (tt, J= 10.2, 3.5 Hz, 1H), 3.60 (m, 2H), 3.38 (d, J= 
8.9 Hz, 1H), 3.20 (m, 3H), 2.54 (m, 1H), 2.07 (m, 2H), 1.71 (dt, J= 15.4, 5.0 Hz, 1H), 
0.85 (s, 3H), 0.82 (s, 3H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 117.9, 75.9, 75.7, 
72.7, 68.5, 53.86, 36.7, 35.4, 28.2, 23.2, 23.1; HRMS (TOF, ES+) C11H18ClNO2 [M+H]
+
 
calc'd 231.1025, found 231.1025; Specific rotation [α]23/D = +6.4° (c = 1.1, CH3Cl). 
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(S)-2-(4-Methoxyphenethyl)azetidine (3.94) 
To a flame dried microwave vial with magnetic stir bar was added InCl3 (0.12 g, 0.54 
mmol) and NaBH4 (0.06 g, 1.63 mmol).  Anhydrous THF (1.2 mL) was added and the 
heterogeneous mixture was stirred under argon for 1h.  3.93 (0.12 g, 0.54 mmol) was then 
slowly added as a solution in THF (1.2 mL).  The reaction mixture was allowed to stir at 
ambient temperature for 4 h.  The reaction was quenched by dropwise addition 
(CAUTION: results in rapid generation of gas) of H2O (1.5 mL) and the solution was 
heated to 75 °C for 30 min.  MeOH (1.5 mL) was then slowly added, and stirring 
continued at 75 °C for 30 min. The reaction mixture was allowed to cool to room 
temperature, then filtered through a celite pad to remove solid indium byproducts.  The 
resulting colorless solution was concentrated in vacuo and the residue was carried 
forward directly to the next step. 
 To an open microwave vial equipped with a stir bar, the crude residue from the previous 
step was dissolved in a solution of 1:1 THF/H2O (3.52 mL) and KOH (0.16g, 2.86 mmol) 
was then added. The vial was sealed and submitted to microwave irradiation at 170°C. 
for 1 h. The biphasic solution was extracted three times with EtOAc and washed with 
brine.  The organic fractions were combined, dried over Na2SO4, and concentrated in 
vacuo.  Purification by flash column chromatography (9:0.9:0.1 CH2Cl2/MeOH/NH4OH) 
afforded desired product as a light yellow oil in 40 mg (48%).
1
HNMR (400.2 MHz, 
CDCl3) δ (ppm): 7.09 (d, J= 8.2 Hz, 2H), 6.82 (d, J= 8.2 Hz, 2H), 3.88 (quint, J= 7.6 Hz, 
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1H), 3.75 (s, 3H), 3.60 (q, J= 8.3 Hz, 1H), 2.50 (m, 2H), 2.30 (m, 1H), 2.03 (m, 1H), 1.87 
(m, 2H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 159.4, 135.0, 130.3, 114.8, 59.7, 55.7, 
43.6, 40.9, 31.8, 28.2; [α]D
20
 = +0.8 (c = 1.0, CHCl3). 
 
 
(S)-2-phenethylazetidine (3.101) 
To a flame dried microwave vial with magnetic stir bar was added InCl3 (0.09 g, 0.39 
mmol) and NaBH4 (0.04 g, 1.17 mmol).  Anhydrous THF (0.86 mL) was added and the 
heterogeneous mixture was stirred under argon for 1h.  3.97 (0.08 g, 0.39 mmol) was then 
slowly added as a solution in THF (0.86 mL).  The reaction mixture was allowed to stir at 
ambient temperature for 4 h.  The reaction was quenched by dropwise addition 
(CAUTION: results in rapid generation of gas) of H2O (0.86 mL) and the solution was 
heated to 75 °C for 30 min.  MeOH (1.6 mL) was then slowly added, and stirring 
continued at 75 °C for 30 min. The reaction mixture allowed to cool to room temperature, 
then filtered through a celite pad to remove solid indium byproducts.  The resulting 
colorless solution was concentrated in vacuo and the residue was carried forward directly 
to the next step. 
 To an open microwave vial equipped with a stir bar, the crude residue from the previous 
step was dissolved in a solution of 1:1 THF/H2O (3.13 mL) and KOH (0.14 g, 2.54 
mmol) was then added. The vial was sealed and submitted to microwave irradiation at 
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170°C. for 1 h. The biphasic solution was extracted three times with EtOAc and washed 
with brine.  The organic fractions were combined, dried over Na2SO4, and concentrated 
in vacuo.  Purification by flash column chromatography (9:0.9:0.1 
CH2Cl2/MeOH/NH4OH) afforded the desired product as a colorless oil in 28 mg (44%). 
1
HNMR (400.2 MHz, CDCl3) δ (ppm): 7.25 (t, , J= 7.8 Hz, 2H), 7.17 (m, 3H), 3.85 (pent, 
, J= 7.4 Hz, 1H), 3.57 (q, , J= 8.3 Hz, 1H), 3.31 (m, 3H), 2.56 (m, 2H), 2.29 (m, 1H), 
2.03 (m, 1H), 1.90 (m, 2H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 143.1, 129.4, 126.8, 
59.7, 43.6, 40.7, 32.7, 28.2; specific rotation [α]D
20
 = 9.6 (c = 1.0, CHCl3). 
 
 
(S)-2-octylazetidine (3.102) 
To a flame dried microwave vial with magnetic stir bar was added InCl3 (0.07 g, 0.29 
mmol) and NaBH4 (0.03 g, 0.88 mmol).  Anhydrous THF (0.65 mL) was added and the 
heterogeneous mixture was stirred under argon for 1h.  3.99 (0.06 g, 0.29 mmol) was then 
slowly added as a solution in THF (0.65 mL).  The reaction mixture was allowed to stir at 
ambient temperature for 4 h.  The reaction was quenched by dropwise addition 
(CAUTION: results in rapid generation of gas) of H2O (0.65 mL) and the solution was 
heated to 75 °C for 30 min.  MeOH (1.3 mL) was then slowly added, and stirring 
continued at 75 °C for 30 min. The reaction mixture was allowed to cool to room 
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temperature, then filtered through a celite pad to remove solid indium byproducts.  The 
resulting colorless solution was concentrated in vacuo and the residue was carried 
forward directly to the next step. 
 To an open microwave vial equipped with a stir bar, the crude residue from the previous 
step was dissolved in a solution of 1:1 THF/H2O (2.34 mL) and KOH (0.11 g, 1.90 
mmol) was then added. The vial was sealed and submitted to microwave irradiation at 
170°C. for 1 h. The biphasic solution was extracted three times with EtOAc and washed 
with brine.  The organic fractions were combined, dried over Na2SO4, and concentrated 
in vacuo.  Purification by flash column chromatography (9:0.9:0.1 
CH2Cl2/MeOH/NH4OH) afforded the desired product as a light yellow oil in 22 mg 
(45%). 
1
HNMR (400.2 MHz, CDCl3) δ (ppm): 3.96 (pent, J= 7.6 Hz, 1H), 3.67 (q, J= 8.4 
Hz, 1H), 3.40 (td, J= 9.0, 4.3 Hz, 1H), 3.40 (pent, J= 7.8 Hz, 1H), 3.33 (pent, J= 1.6 Hz, 
1H), 2.36 (m, 1H), 2.07 (m, 1H), 1.65 (m, 1H), 1.33 (m, 12H), 0.88 (t, J= 6.5 Hz, 3H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 59.3, 42.1, 36.8, 31.6, 29.2, 29.0, 28.9, 26.5, 
24.8, 22.2, 12.9; HRMS (TOF, ES+) C11H23N [M+H]
+
 calc'd 169.1829, found 169.1828; 
specific rotation [α]D
20
 = +6.2 (c = 1.0, CHCl3) 
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(S)-1-benzyl-2-octylazetidine (3.126) 
To a 0.5-2 mL microwave vial containing 3.102 (0.04 g, 0.23 mmol), benzaldehyde (0.06 
g, 0.35 mmol) and acetic acid (0.124, 1.15 mmol) in CH2Cl2 (1.15 mL) were added, 
followed by MP-Cyanoborohydride (0.279 g, 0.58 mmol, 2.08 mmol/g).  The vial was 
capped and heated to 110 °C for 7 min under microwave irradiation.  After cooling, the 
vial was decapped and the solid phase reagent was filtered off and washed with 5 mL 
CH2Cl2. The resulting solution washed with 5 mL sat. NaHCO3 and 5 mL H2O.  The 
organic phase was separated and dried over Na2SO4, filtered and concentrated in vacuo. 
The crude residue was purified by flash column chromatography (1:1 Hex/EtOAc) to 
afford the desired product as a colorless oil in 45 mg (75%). 
1
HNMR (400.2 MHz, 
CDCl3) δ (ppm): 7.25 (m, 5H), 3.73 (s, 2H), 3.53 (dt, J= 8.4, 3.0 Hz, 1H), 3.35 (m, 1H), 
2.97 (q, J= 8.8 Hz, 1H), 2.04 (m, 1H), 1.93 (m, 1H), 1.44 (m, 2H), 1.14 (m, 12H), 0.85 (t, 
J= 7.0 Hz, 3H); 13C NMR (100.6 MHz, CDCl3) δ (ppm): 135.1, 129.5, 128.8, 127.8, 67.0, 
60.7, 50.4, 34.4, 31.8, 29.3, 29.3, 29.1, 25.1, 23.7, 22.6, 14.0 
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(S)-2-(3-fluoro-4-methylbenzyl)azetidine (3.103) 
To a flame dried microwave vial with magnetic stir bar was added InCl3 (0.12 g, 0.54 
mmol) and NaBH4 (0.06 g, 1.63 mmol).  Anhydrous THF (1.2 mL) was added and the 
heterogeneous mixture was stirred under argon for 1h.  3.100 (0.12 g, 0.54 mmol) was 
then slowly added as a solution in THF (1.2 mL).  The reaction mixture was allowed to 
stir at ambient temperature for 4 h.  The reaction was quenched by dropwise addition 
(CAUTION: results in rapid generation of gas) of H2O (1.5 mL) and the solution was 
heated to 75 °C for 30 min.  MeOH (1.5 mL) was then slowly added, and stirring 
continued at 75 °C for 30 min. The reaction mixture was allowed to cool to room 
temperature, then filtered through a celite pad to remove solid indium byproducts.  The 
resulting colorless solution was concentrated in vacuo and the residue was carried 
forward directly to the next step. 
 To an open microwave vial equipped with a stir bar, the crude residue from the previous 
step was dissolved in a solution of 1:1 THF/H2O (2.1 mL) and KOH (0.16g, 2.86 mmol) 
was then added. The vial was sealed and submitted to microwave irradiation at 170°C. 
for 1 h. The biphasic solution was extracted three times with EtOAc and washed with 
brine.  The organic fractions were combined, dried over Na2SO4, and concentrated in 
vacuo.  Purification by flash column chromatography (9:0.9:0.1 CH2Cl2/MeOH/NH4OH) 
afforded desired product as a light yellow oil in <5% yield.  
1
HNMR (400.2 MHz, 
CDCl3) δ (ppm): 7.23 (t, , J= 8.0 Hz, 1H), 7.00 (m, 2H), 4.71 (pent, , J= 8.0 Hz, 1H), 4.06 
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(q, , J= 9.4, 1H), 3.89 (m, 1H), 3.17 (dd, , J= 7.8, 4.0 Hz, 2H), 2.50 (m, 2H), 2.25 (s, 3H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 161.1 (d, JCF =  250 Hz), 134.6 (d, JCF =  8 Hz), 
131.6 (d, JCF =  7 Hz), 124.0 (d, JCF =  4 Hz), 123.5 (d, JCF =  18 Hz), 114.8 (d, JCF =  22 
Hz), 61.2, 42.3, 38.3, 24.4, 12.6 (d, JCF =  4 Hz); [α]D
20
 = -2.5 (c = 1.0, CHCl3); HRMS 
(TOF, ES+) C11H14FN [M+H]
+
 calc'd 179.1109, found 179.1108 
 
 
(S)-2-(3-fluoro-4-methylbenzyl)azetidine (3.104) 
To a flame dried microwave vial with magnetic stir bar was added InCl3 (0.10 g, 0.43 
mmol) and NaBH4 (0.05 g, 1.30 mmol).  Anhydrous THF (1.0 mL) was added and the 
heterogeneous mixture was stirred under argon for 1h.  3.98 (0.10 g, 0.43 mmol) was then 
slowly added as a solution in THF (1.0 mL).  Reaction mixture was allowed to stir at 
ambient temperature for 4 h.  The reaction was quenched by dropwise addition 
(CAUTION: results in rapid generation of gas) of H2O (1.0 mL) and the solution was 
heated to 75 °C for 30 min.  MeOH (2.0 mL) was then slowly added, and stirring 
continued at 75 °C for 30 min. The reaction mixture was allowed to cool to room 
temperature, then filtered through a celite pad to remove solid indium byproducts.  The 
resulting colorless solution was concentrated in vacuo and the residue was carried 
forward directly to the next step. 
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 To an open microwave vial equipped with a stir bar, the crude residue from the previous 
step was dissolved in a solution of 1:1 THF/H2O (3.40) and KOH (0.16 g, 2.76 mmol) 
was then added. The vial was sealed and submitted to microwave irradiation at 170°C. 
for 1 h. The biphasic solution was extracted three times with EtOAc and washed with 
brine.  The organic fractions combined, dried over Na2SO4, and concentrated in vacuo.  
Purification by flash column chromatography (9:0.9:0.1 CH2Cl2/MeOH/NH4OH) 
afforded desired product as a light yellow oil in 45 mg (55%). 
1
HNMR (400.2 MHz, 
MeOD) δ (ppm): 3.89 (dd, J= 12.5, 3.6 Hz, 1H), 3.63 (m, 1H), 3.62 (d, J= 12.0 Hz, 1H), 
3.57 (d, J= 12.0 Hz, 1H), 3.35 (m, 3H), 1.97 (m, 1H), 1.79 (d, J= 7.0 Hz, 1H), 1.50 (m, 
4H), 1.35 (d, J= 3.4 Hz, 1H), 0.94 (s, 3H), 0.88 (s, 3H); 13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 81.8, 81.0, 79.3, 77.2, 38.1, 29.6, 29.3, 29.1, 24.1, 23.0, 22.6; [α]D
20
 = +1.7 (c = 
1.0, CHCl3);  HRMS (TOF, ES+) C11H22NO3S [M+H]
+
 calc'd 199.1574, found 199.1575  
 
 
(S)-1-(4-bromobenzyl)-2-(2-(5,5-dimethyl-1,3-dioxan-2-yl)ethyl)azetidine (3.127) 
To a flame dried vial with magnetic stir bar, 3.104 (0.04 g, 0.18 mmol) was dissolved in 
THF (1.76 mL).  At ambient temperature was added triethylamine (0.03 g, 0.18 mmol) 
followed by 1-bromo-4-(bromomethyl)benzene (0.04 g, 0.18 mmol).  Stirring was 
continued at room temperature for 12 hours, during which time the solution became 
opaque with white precipitant.  After completion of reaction by LCMS, the reaction was 
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quenched with water, and extracted 3 times with EtOAc.  Organic layers were combined, 
washed with brine, and dried over Na2SO4.  Concentration in vacuo provided the crude 
colorless oil, which was purified by flash column chromatography (1:1 Hex/EtOAc) to 
provide the desired product as a clear oil in 102 mg (80%). 
1
HNMR (400.2 MHz, CDCl3) 
δ (ppm): 7.44 (d, J= 10.3 Hz, 2H), 7.21 (d, J= 9.4 Hz, 2H), 3.75 (dd, J= 12.4, 4.0 Hz, 
1H), 3.57 (d, J= 12.0 Hz, 1H), 3.53 (d, J= 12.0 Hz, 1H), 3.44 (m, 3H), 3.25 (m, 5H), 1.62 
(d,  J= 12.0 Hz, 1H), 1.54 (m, 1H), 1.40 (m, 2H), 1.27 (m, 1H), 0.91 (s, 3H), 0.86 (s, 3H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 138.3, 131.3, 129.8, 120.8, 81.9, 81.4, 79.8, 
64.1, 53.3, 39.3, 38.6, 34.0, 29.1, 28.6, 24.1, 23.8. 
 
 
(1S,4S)-1,4-diphenylbutane-1,4-diol (3.83) 
To a solution of (R)-diphenyl(pyrrolidin-2-yl)methanol (638 mg, 2.52 mmol) in THF 
(15.7 mL, 0.16 M) was added distilled trimethylborate (0.14 mL, 25 mol %, 3.15 mmol) 
at ambient temperature. After 1 h, borane-dimethyl sulfide complex (2.4 mL, 25.2 mmol) 
was added, followed by a solution of 1,4-diphenylbutane-1,4-dione (3.00 g, 12.6 mmol) 
in THF (50 mL, 0.25 M) over 30 min. After 1 h, the mixture was quenched with 2M 
aqueous HCl (80 mL) slowly. The organic solvent was removed under reduced pressure 
and the resulting residue was diluted with ethyl acetate and water. The layers were 
separated and the aqueous layer was extracted with ethyl acetate. The combined organic 
layers were washed with water and brine, dried (MgSO4), filtered, and concentrated. The 
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resulting oil was then purified by column chromatography 60% EtOAc/Hex to afford a 
colorless, viscous oil which solidified upon standing. The resulting white solid was then 
recrystallized in DCM/ Hexanes to afford 3.02 g (99%) as long white needles. m.p. 74.8 – 
75.2 °C; 
1
H NMR (400.2 MHz, CDCl3) 𝛿 (ppm): 7.27 (m, 7H), 7.20 (m, 3H), 4.65 (m, 
2H), 2.09 (br s, 2H), 1.88 (m, 2H), 1.76 (m, 2H); 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 
144.5, 128.4, 127.5, 125.7, 74.6, 35.7. 
 
(2R,5R)-1-allyl-2,5-diphenylpyrrolidine (3.84) 
To a cooled solution of (1S,4S)-1,4-diphenylbutane-1,4-diol (2.00 g, 8.26 mmol) in 68 
mL DCM (0.24 M) at -20 °C, was added dry triethylamine (3.46 mL, 24.8 mmol) 
followed by distilled methanesulfonyl chloride (1.60 mL, 20.6  mmol) dropwise. After 
1.5 hr, dry allylamine (62.0 mL, 8.26 mmol) was added and the mixture was allowed to 
warm to room temperature overnight. Excess allyamine was removed under reduced 
pressure and the crude mixture was diluted with ether and water. The layers were 
separated and the aqueous layer was extracted with ether and the combined organic 
extracts were washed with sat. NaHCO3 and brine, dried (MgSO4), filtered, and 
concentrated to give a yellow oil. The crude oil was purified by column chromatography 
using first a gradient system of Hex ➞ 20% Tol/Hex until the undesired meso compound 
eluted, followed by 5% Et2O/Hex to give the desired product in 1.67 g (77%, 85:15 dr) as 
a clear, light yellow oil. 
1
H NMR (400 MHz, CDCl3) 𝛿 (ppm): 7.50 (d, J= 7.2 Hz, 4H), 
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7.35 (t, J= 7.5 Hz, 4H), 7.26 (m, 2H), 5.72 (m, 1H), 4.90 (m, 2H), 3.87 (t, J= 5.4 Hz, 2H), 
3.06 (d, J= 6.8 Hz, 2H), 2.20 (m, 2H), 1.82 (m, 2H); 13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 144.9, 133.7, 128.2, 127.4, 126.7, 117.2, 66.6, 52.6, 34.5. 
 
 
(2R,5R)-2,5-diphenylpyrrolidine (3.71) 
To a solution of (2R,5R)-1-allyl-2,5-diphenylpyrrolidine (910 mg, 3.45 mmol) in a 
solvent mixture of degassed acetonitrile and water (84:16, 5 mL) at RT was added 
Tris(triphenylphosphine)rhodium (I) chloride (160 mg, 0.17 mmol). The mixture was 
refluxed at 100 ˚C for 5 hr and upon completion the reaction was concentrated (to ca. 1/2 
volume). The resulting residue was diluted with Et2O and water. The layers were 
separated and the aqueous layer was extracted with Et2O. The combined organic extracts 
were dried (MgSO4), filtered, and concentrated. The crude oil was purified by flash 
chromatography (10% Et2O/Hex) to afford XX g (71%) as a white solid. 
1
H NMR (400 
MHz, CDCl3) 𝛿 (ppm):  7.35 (d, J= 7.2 Hz, 4H), 7.27 (t, J= 7.5 Hz, 4H), 7.16 (m, 2H), 
4.48 (t, J = 6.8 Hz, 2H), 2.33 (m, 2H), 1.83 (m, 2H). 
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CHAPTER IV 
 
 
DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF THE MENIN-
MIXED-LINEAGE LEUKEMIA INTERACTION 
 
 
4.1. Introduction 
4.1.1. Protein-protein Interactions as Therapeutic Targets 
Protein-protein interactions (PPIs) represent a vast class of therapeutic targets 
located both inside and outside the cell.  PPIs play a critical role in nearly all biological 
processes and are dysregulated in a broad spectrum of human diseases, including cancer,
1
 
and small molecule modulators of PPIs are highly desired to serve as chemical tools and 
potential therapeutics.  Despite the importance of PPIs in biology, identification of small 
molecule inhibitors of PPIs is considered challenging for several reasons, including large 
interaction areas, lack of well-defined binding pockets, and flexibility of residues on PPI 
interfaces.
2,3
  Discovery of cell-permeable small molecule inhibitors of PPIs provides an 
additional challenge due to increased molecular weight of PPI inhibitors often required to 
achieve high potency.
4
  This has significantly limited successful development of PPI 
modulators, which, twenty years ago, led to the idea that PPIs were “intractable” 
therapeutic targets.  However, over the past 15 years, the emergence of powerful 
techniques such as fragment-based lead discovery (FBLD) and structure-based drug 
design have provided recent successes with a number of PPI inhibitors
3,5-8
.   This has 
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demonstrated that some PPIs are amenable to inhibition by small molecules. More 
importantly, advancing small molecule inhibitors of PPIs into clinical trials, such as the 
Bcl-2 protein family inhibitor ABT-263 (Navitoclax)
9
 and the MDM2 inhibitor 
RG7112
10
, provides an important proof-of-principle that small molecule inhibitors of 
PPIs may serve as novel therapeutic agents and justifies the efforts in developing novel 
PPIs inhibitors. 
 
4.1.2. Menin-MLL interaction 
The protein-protein interaction between menin and Mixed Lineage Leukemia (MLL) 
plays a critical role in acute leukemias with translocations of the MLL gene.11  Fusion of 
MLL with one out of  over 60 partner genes results in expression of chimeric MLL fusion 
proteins, which enhances proliferation of hematopoietic cells and blocks hematopoietic 
differentiation, ultimately leading to acute leukemias.
12
  The MLL leukemias represent a 
heterogeneous group of acute myeloid leukemias (AML) and acute lymphoblastic 
leukemias (ALL), accounting for about 5-10% of acute leukemias in adults
13
 and ~70% 
of acute leukemias in infants.
14
  Patients with leukemias harboring MLL translocations 
have a very poor prognosis with existing therapies (20% event-free survival at 3 years), 
and novel targeted therapies are urgently needed to treat these leukemias. 
12,15
  
The MLL fusion proteins preserve the N-terminal MLL fragment of approximately 
1400 amino acids fused with the fusion partner.
15-18
 Importantly, the N-terminal fragment 
of MLL, retained in all MLL fusion proteins, is involved in the interactions with the 
scaffold protein menin, which is a highly specific binding partner. 
11,19,20
 This interaction 
plays a critical role in the MLL-fusion protein-mediated leukemogenic 
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transformations.
11,21
 MLL fusion proteins are required for regulation of target gene 
expression, including HOXA9 and MEIS1 genes, both of which are essential for 
leukemogenic activity of MLL fusions.
11
 Therefore, menin represents a critical oncogenic 
cofactor of MLL fusion proteins in acute leukemias, and disruption of the protein-protein 
interaction between menin and MLL with small molecules represents a possible 
therapeutic strategy to develop new targeted drugs for mixed-lineage leukemia patients. 
  
 
Figure 4.1. A. Schematic of MLL wild type (top) and MLL fusion proteins (bottom). B. 
Role of menin in recruitment of MLL wild type and MLL fusion to the Hoxa9 promoter. 
Inhibition of the menin-MLL interaction by small molecules (red stars) should down-
regulate expression of Hoxa9 and Meis1. 
 
Menin interacts with two MLL fragments located within the N-terminal region, with 
MBM1 (menin-binding motif 1 corresponding to MLL4-15) representing the high affinity 
menin binding motif.
19
  The group of Jolanta Grembecka at the University of Michigan 
previously reported a high resolution crystal structure of the menin-MBM1 complex, 
which demonstrated that MLL binds to a large central cavity on menin.
22,23
  
 
188 
 
 
 
 
Figure 4.2. X-ray co-crystal structure of MLL peptide (magenta) in complex with menin 
(PDB 4GQ6) 
 
4.1.3.  Classes of Menin-MLL Inhibitors 
To date, several inhibitors of the menin-MLL interaction have been developed.  
These include peptidomimetics such as MCP-1 and multiple classes of small molecule 
inhibitors including the thienopyrimidines and hydroxymethylpiperidines (Figure 4.3).  
However, no systemically available menin-MLL inhibitor tool compounds have been 
described.  Historically, PPI inhibitors have higher molecular weights and increased 
lipophilicity compared to typical orally available drugs. 22 Two commonly employed 
metrics to compare or assess the drug-like properties of compounds include ligand 
efficiency (LE = ΔG/HA), and lipophilic ligand efficiency (LLE = pIC50 - logP).  The LE 
of published PPI compounds (0.24) have been lower than desired for systemically 
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available drugs (>0.3), and the LLE is typically below the desired value of >5. 
22
  
Although these metrics are not definitively predictive of systemic availability, the 
limitations highlight the unique challenges presented in the development of PPI 
inhibitors.   
 
 
Figure 4.3. Recently developed small molecule menin-MLL PPIs 
 
The lack of systemically available compounds, together with the pressing need to 
develop menin-MLL inhibitors suitable for in vivo studies in animal models of MLL 
leukemia, emphasizes a clear demand for identification of novel menin-MLL inhibitors 
with distinct chemical scaffolds suitable for optimization of potency and physicochemical 
properties.  The development of potent small molecule inhibitors of the menin-MLL 
interaction with reduced off-target ancillary pharmacology and improved metabolic 
stability could allow for systemic administration to animals.  This would greatly help 
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facilitate studies into the biological consequences of inhibiting the menin-MLL 
interaction and its impact on leukemia development. 
 
4.2. Identification of Novel Inhibitors of the Menin-MLL PPI 
4.2.1. High Throughput Screen to Identify Novel Menin-MLL Inhibitors 
To identify new inhibitors of the menin-MLL interaction, we performed a high 
throughput screen of ~288,000 small molecules at the NIH MLPCN (Molecular Libraries 
Probe Centers Network, https://mli.nih.gov/mli) using a fluorescence polarization (FP) 
assay with a fluorescein-labeled MLL-derived peptide, MBM1.
19
  A stepwise procedure, 
including FP assay for primary screening, followed by HTRF (Homogenous Time 
Resolved Fluorescence) assay for secondary screening and NMR STD (Saturation 
Transfer Difference) experiments to validate direct binding of compounds to menin, was 
applied to identify menin-MLL inhibitors.  The most potent compound identified in the 
screen was 4.1, belonging to the hydroxymethylpiperidine class, which exhibited a half 
maximal inhibitory concentration (IC50) value of 12.8 µM for inhibition of the menin-
MLL interaction (Figure 4.4a).  We validated direct binding of 4.1 to menin using STD 
NMR experiments, resulting in a strong STD effect (Figure 4.4b). Importantly, addition 
of the MLL peptide strongly decreased the STD effect observed for 4.1, demonstrating 
that 4.1 and MLL compete for binding to menin. These results confirm reversible and 
specific binding of 4.1 hydroxymethylpiperidine compound to menin. 
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Figure 4.4. (a) Structure and activity of the most potent hit from HTS, 4.1. (b) NMR 
STD experiments demonstrating binding of 4.1 to menin and competition with MLL 
(competition STD). (c) Structure and activity for 4.2 
 
4.2.2. Determination of the Minimal Pharmacophore  
After identifying 4.1 as a novel menin-MLL inhibitor, we performed synthetic 
efforts to identify a minimal pharmacophore within 4.1 required for efficient inhibition of 
the menin-MLL interaction. The HTS hit 4.1, 4.5, and 4.6, were readily prepared starting 
from either diphenyl(piperidin-4-yl)methanol or  4-benzhydrylpiperidine using a one-pot 
two-step procedure.
24
  Our initial strategy, involving pre-installation of the nitrile tail 
group prior to Grignard addition led to final products contaminated with trace amounts of 
an inseparable side-product presumed to result from Grignard addition to the nitrile (R3 = 
CN). To circumvent this issue, we performed a selective alkylation of piperidines 4.3a-b 
using 1-bromo-3-chloropropane to afford chloride intermediates 4.4a-b in good yield 
(Scheme 4.1).   
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Scheme 4.1. General synthesis of hydroxymethyl piperidine compounds. 
 
Addition of Grignard reagents to 4.4a-b provided the crude carbinol chlorides in 
high conversion.  Subsequent alkylation using the appropriate phenol reagent led to final 
target compounds.  We found that removal of the hydroxyl group from 4.1 in the linker 
region, resulting in compound 4.2, slightly increased the activity (IC50 = 10.8µM). Thus, 
to facilitate synthesis and reduce the number of resulting stereoisomers, we eliminated 
the central hydroxyl group from subsequent analogs.  In contrast, removal of the 
hydroxyl group from the quaternary carbon in the head group region resulted in 4.5 with 
decreased inhibitory activity by more than 20-fold, emphasizing the importance of this 
group in binding to menin (Table 4.1). Similarly, the binding affinity was markedly 
decreased by removing the nitrile within the tail group region, which resulted in 4.6 with 
an IC50 > 250 µM.  Based on this data, we concluded that 4.2 represents the minimal 
pharmacophore for the hydroxymethylpiperidine class of menin-MLL inhibitors.  
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Compound R2 -X R3 R4 IC50 
(µM) 
 
4.1 
 
 
 
-OH 
 
-CN 
 
 
 
 
12.8 ± 1.6  
 
4.2 
 
 
 
-OH 
 
-CN 
 
 
 
 
10.8 ± 0.2 
 
4.5  
 
-H 
 
-CN 
-H 
 
205 ± 63 
 
4.6  
 
-OH 
 
-H 
-H 
 
>250 
 
4.7 
 
-H 
 
-OH 
 
-CN 
-H 
 
234 ± 22 
 
4.8 
 
 
 
-OH 
 
-CN -H 
 
295 ± 50 
 
4.9  
 
-OH 
 
-CN 
-H 
 
15.3 ± 3.8 
 
4.10 
 
 
-OH 
 
-CN 
-H 
 
11.2 ± 3.9 
 
4.11  
 
-OH 
 
-CN 
-H 
 
4.1 ± 0.6 
 
4.12  
 
-OH 
 
-CN 
-H 
 
4.0 ± 1.4 
 
4.13 
(MIV-3) 
 
 
 
-OH 
 
-CN -H 
 
0.39 ± 
0.04 
 
4.14  
 
-OH 
 
-CN 
-H 
 
1.7± 0.6 
 
Table 4.1. Activity of hydroxymethyl piperidine menin-MLL inhibitors 
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4.3. Lead Optimization of the Hydroxymethyl Piperidine Class 
4.3.1. Probing the Hydrophobic Head Group Region  
Compound 4.2 was used as a lead for medicinal chemistry optimization to 
improve potency of hydroxymethylpiperidine class. First, we explored replacement of 
one of the phenyl rings at the head group region of 4.2 with different hydrophobic groups 
(Table 4.1). Interestingly, we found a pronounced structure-activity relationship (SAR) 
for modifications at this site.  The inhibitory activity of 4.7, with a hydrogen replacing the 
phenyl group, was weak (IC50 = 234 µM), and the potency did not improve upon addition 
of a methyl group at this position (4.8). Introducing more bulky hydrophobic substituents 
resulted in increased inhibition of the menin-MLL interaction. For example, n-butyl (4.9) 
or cyclopropyl (4.11) substituents yielded about a 20-fold increase in activity versus 4.8 
(Table 4.1). Furthermore, analogues with iso-propyl (4.11) and cyclobutyl (4.12) groups 
had further improved IC50 values (IC50 = 4.1 µM and 4.0 µM, respectively). Finally, 
cyclopentyl was identified as the most optimal saturated carbocycle at this position, 
resulting in compound 4.13 (MIV-3),
24
 with an IC50 of 390 nM measured for the racemic 
mixture.  Further increase in ring size decreased activity, as cyclohexyl analogue 4.14 
was about four-fold less active than MIV-3. Based on this data, we concluded that 
cyclopentyl was the preferred hydrophobic group at the R2 position.   MIV-3 was 
declared as a first generation MLPCN probe for the menin-MLL interaction, and was 
given the designation ML227.  In light of the promising in vitro activity of MIV-3, it was 
characterized for tier 1 drug metabolism and pharmacokinetic (DMPK) properties, and 
screened in a Eurofins radioligand binding panel of over 60 G protein-coupled receptors, 
ion channels, and transporters at a concentration of 10 µM.  These studies revealed that 
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MIV-3 possessed several limitations, precluding its use in animal models of mixed-
lineage leukemia.  These included a high predicted hepatic clearance at near the rate of 
hepatic blood flow, and a low fraction unbound value from plasma proteins of 
approximately 1% (PPB fu = 0.004, 0.013).  Additionally, MIV-3 was a low micromolar 
inhibitor of multiple CYP450 isoforms, as well as possessed significant off-target 
activity, most notably, binding to the human ether-a-go-go (hERG) potassium channel. 
 
 
Figure 4.5.  Physical and DMPK properties of MIV-3. 
 
MIV-3 represents a racemic mixture, and to assess the activity of individual 
enantiomers, the racemic mixture was separated by chiral SFC. Interestingly, the R 
enantiomer, MIV-3R, was only about 2-fold more potent than the S enantiomer (MIV-
3S) as assessed by the FP assay (IC50 = 270 nM and 529 nM for MIV-3R and S, 
respectively). The dissociation constants (Kd) for binding of both enantiomers of MIV-3 
to menin using Isothermal Titration Calorimetry (ITC) were determined, and it was found 
that they both bind to menin with nanomolar affinities (Kd =  285 nM and 952 nM for R 
and S isomers, respectively), consistent with the IC50 values (Figure 4.6). Overall, 
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development of MIV-3R represents a more than 40-fold improvement in activity 
compared to the parent compound 4.1. Interestingly, there was a relatively small 
difference observed in inhibition of the menin-MLL interaction by both enantiomers of 
MIV-3. 
  
 
Figure 4.6. (a) Structure and activity for MIV-3 and two individual enantiomers (b, c) 
ITC experiments demonstrating direct and specific binding of both enantiomers of MIV-3 
to menin. N corresponds to the stoichiometry of ligand binding to menin 
 
4.3.2. Structural Investigation of MIV-3 -menin Interaction 
In order to establish the molecular basis for the binding of MIV-3 to menin and 
understand the similar binding affinity between the two enantiomers, the crystal 
structures of menin in complex with both enantiomers of MIV-3 were determined 
(Figure 4.7). 
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Figure 4.7. Crystal structures of menin in complex with MIV-3R (a) and MIV-3S (b) 
with 2Fo-Fc electron density maps for ligands contoured at the 1 level. Menin is shown 
in surface representation and location of F9, P10 and P13 pockets is labeled. 
 
It was discovered that both enantiomers bind in similar conformations to the MLL 
binding site on menin, and occupy three hydrophobic pockets: F9, P10 and P13 (Figure 
4.8). There is close overlap of the binding modes of both enantiomers of MIV-3, with the 
only difference being an alternate positioning of the head group substituents between the 
F9 and P10 hydrophobic pockets on menin. 
The menin-MIV-3 interactions are predominately mediated by the hydrophobic 
contacts, with only one direct hydrogen bond formed between the nitrile group of both 
enantiomers of MIV-3 and the indole nitrogen of Trp341 on menin (Figure 4.8). An 
additional water-mediated hydrogen bond involves a hydroxyl at the head group region of 
MIV-3 and the Asp180 side chain on menin. 
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Figure 4.8. Superposition of the menin-MIV-3R and menin-MIV-3S crystal structures 
showing binding mode of ligands and key protein residues in the binding site. 
 
The importance of the hydrogen bonds involving the head group hydroxyl and tail 
group nitrile is reflected by a more than 20-fold decrease in the activity of the analogues 
deficient in the corresponding functional groups, such as compounds 4.5 and 4.6 (Table 
4.1). Of note, binding of MIV-3 to menin does not induce conformational changes of the 
protein. 
In the co-crystal structure with the more potent enantiomer, MIV-3R, the phenyl ring 
occupies the F9 pocket on menin formed by the side chains of hydrophobic residues 
Leu177, Phe238, Ser155, Met278 and backbone of Asp180 and His181 (Figure 4.8). The 
cyclopentyl ring occupies to the P10 pocket and interacts with the side chains of Ala242, 
Cys241, Tyr276, Phe238 and Ser155. In case of the MIV-3S enantiomer, the positions of 
the cyclopentyl and phenyl rings are swapped between these two pockets on menin. The 
piperidine ring and tail groups in both enantiomers of MIV-3 bind to menin in the same 
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manner, extending towards the P13 pocket and Trp341. The alkoxy portion of the linker 
fits into the P13 pocket formed by Tyr319 and Tyr323, while the benzonitrile moiety 
extends beyond the P13 pocket, where it approaches Met322 and Glu363 side chains to 
form a hydrogen bond with the side chain of Trp341. The interaction of the benzonitrile 
moiety is of particular interest as this region of the binding site is not occupied by the 
MLL peptide or the previously identified thienopyrimidine class of menin-MLL 
inhibitors (Figure 4.9).   
The novel interaction identified for the new hydoxymethylpiperidine class offered 
the possibility to introduce additional contacts with menin to further improve affinity 
through rationally designed modifications, and this structural information explains the 
SAR data for this class of menin-MLL inhibitors (Table 4.1). 
 
Figure 4.9.  Superposition of the crystal structures of menin-MIV-3R (green carbons) 
and the menin-MLL (blue carbons, PDB code 4GQ6) complexes. 
  
In our previous studies, we found that three hydrophobic residues in the MLL-derived 
peptide MBM1, namely Phe9, Pro10 and Pro13, have the most critical contributions for 
binding to menin and their mutation to alanine residues reduce binding affinity by 30-
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1000 fold.
19,22
  Superposition of the MLL MBM1 peptide and both enantiomers of MIV-
3 bound to menin demonstrates a close overlap of these small molecule inhibitors with 
the critical residues of MLL required for potent binding to menin (Figure 4.9). 
Specifically, the phenyl ring in the head group of the more potent enantiomer, MIV-3R, 
overlaps with the phenyl side chain of Phe9 in MLL, while the cyclopentyl ring in MIV-
3R adopts a similar position and conformation as the Pro10 side chain in MLL.  This 
closely mimics the critical MLL interactions with menin. Furthermore, the alkoxy portion 
of the linker in MIV-3R mimics the interactions of MLL Pro13 with menin, while the 
benzonitrile moiety extends beyond the P13 pocket towards a previously unexplored 
region of the binding site. Overall, the potent activity of MIV-3R results from mimicking 
key interactions of MLL with menin in F9, P10 and P13 pockets, as well as additional 
contacts beyond the P13 pocket, which provides further opportunity for optimization of 
these compounds.  
 
4.4. Structure-based design of nanomolar inhibitors of the menin-MLL interaction  
4.4.1. Optimization of Hydrophobic Head Group 
The crystal structure of menin in complex with both enantiomers of MIV-3 was 
used for rational design of new analogues to further improve potency and 
physicochemical properties of this class of compounds. Four regions in MIV-3 were 
explored for modifications to rationally design new compounds based upon structural 
data, as described in Figure 4.5. 
Synthesis of cyclopentyl hydroxymethyl piperidines, MIV-3 and 4.17-4.21, is 
outlined in Scheme 4.2.  In order to circumvent low yields due to competing reduction of 
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the sterically hindered ketones by alkyl Grignard reagents
25
 we employed a strategy 
involving introduction of the saturated cycloalkyl followed by a second aryl or alkyl 
group.  Thus, initial introduction of the cycloalkyl was accomplished using a known two-
step procedure starting from N-benzylpiperidine-4-carbonitrile to give a key starting 
aminoketone 4.23.
26
  
 
 
Scheme 4.2.  Synthesis of cyclopently-containing hydroxymethyl piperidine compounds. 
 
Subsequent one-pot double alkylation using 4.22 and 1-bromo-3-chloropropane 
afforded piperidine 4.23 in 78% yield. Grignard or stabilized aryl lithium additions 
afforded final target compounds 4.13, 4.24-4.27 in moderate to good yield.  Over-
addition of these aryl Grignard and lithium reagents to the nitrile was not evident for 
substrate 4.23 and all final compounds displayed excellent purity (>98 %). 
First, we explored additional optimization of R1 substituents that bind to the F9 
pocket on menin (Figure 4.10a). As demonstrated above, the phenyl ring in MIV-3R 
closely mimics the interactions of MLL Phe9 with menin, and therefore it was used to 
design further modifications. In the crystal structure of menin in complex with the MI-2-
2 thienopyrimidine inhibitor we found a favorable C-F---C=O dipolar interaction between 
a fluorine atom in MI-2-2 and the backbone of His181.
22
 Based on the menin-MIV-3R 
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co-crystal structure, we anticipated that introducing a fluorine into position 3 of the 
phenyl ring should result in similar contacts and improved activity.    
 
Figure 4.10.  (a) General structure of the hydroxymethylpiperidine class. (b) Inhibitory 
activities of MIV-3 analogues. (c) Crystal structure of menin in complex with 4.24. (d) 
Structures and activities for analogues with modifications introduced simultaneously at 
R1 and R2. (e) Crystal structure of menin in complex with 4.27. 
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Introduction of a 3-fluoro to give compound 4.24 resulted in a 2-fold 
improvement in potency versus MIV-3 (Figure 4.10b). The binding mode of 4.24 to 
menin was confirmed by solving the crystal structure of the complex (Figure 4.10c) 
which confirmed the presence of a dipolar interaction between the fluorine atom in 4.24 
and the backbone amide of His181 on menin. Introducing a chloro substituent at the same 
position (4.26) or incorporation of an additional fluorine to the phenyl ring (4.25) resulted 
in a weaker inhibitory activity (Figure 4.10b).  As a result of the structure guided-design, 
we found that the 3-fluoro substituted phenyl represents the preferred substituent 
identified to interact with the F9 pocket on menin.  
 We next performed optimization of the R2 substituent that interacts with the P10 
pocket. In the complex of menin with MIV-3R, this pocket is occupied by the 
cyclopentyl ring, which is not optimal for further derivitization and contributes 
significantly to the lipophilic character and oxidative metabolism of the molecule.  The 
analysis of the apo structure of menin and the complex with MIV-3 revealed the presence 
of a water molecule, which forms a hydrogen bond with Tyr 276, located in proximity to 
the ortho position of the phenyl ring in MIV-3. Therefore, we introduced a nitrogen atom 
via replacement of phenyl with a pyridine or thiazole ring to engage in favorable 
interactions with this structural water molecule.  
 These efforts resulted in 4.27 and 4.28, both of which showed improved potency 
and increased polarity versus MIV-3. The existence of a water-mediated hydrogen bond 
between 4.27 and Tyr276 was confirmed by solving the crystal structure of the complex 
(Figure 4.10). Testing separated enantiomers of 4.27, showed a ~4-fold greater inhibitory 
activity for the S enantiomer (IC50 = 195 nM). The optimal substituents identified to 
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interact with F9 and P10 pockets were then combined, and we synthesized the hybrid 3-
fluorophenyl-2-pyridyl congener 4.15, with ~3-fold improved IC50 value (IC50 = 90 nM 
for R enantiomer of 4.15) (Figure 4.10d). Importantly, introduction of a heterocyclic 
instead of phenyl ring to occupy the P10 pocket substantially increased polarity, 
decreasing the cLogP by a full order of magnitude.  
 
4.4.2. Optimization of Tertiary Carbinol 
 The crystal structure of MIV-3 enantiomers with menin revealed that the solvent 
exposed hydroxyl group in the head group region is involved in a water-mediated 
hydrogen bond with Asp180 (Figure 4.11b). Based on structural data, it was anticipated 
that introducing a positively charged group, such as an amino moiety, would result in 
additional favorable electrostatic interactions with adjacent Asp180 and other acidic 
residues located in this region of the binding site (e.g. Asp153, Glu 359). 
Preparation of tertiary carbinamine compound 4.29 was accomplished via 
solvolysis of carbinol 4.13 in the presence of sodium azide in chloroform and sulfuric 
acid (Scheme 4.3).   
 
 
 
Scheme 4.3.  Synthesis of aminomethyl piperidine 4.29. 
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The crude azide was reduced using palladium on carbon with atmospheric 
hydrogen in EtOH to afford amine 4.29.  Despite efforts to screen for alternative 
conditions to improve solvolysis and formation of the azide intermediate, facile formation 
of a major elimination side product leading to the olefin elimination byproduct remained 
problematic. Resolution of racemic 4.29 was accomplished using chiral SFC to afford 
single enantiomers 4.29S and 4.29R for which the stereochemical configuration was 
subsequently inferred on the basis of the absolute configuration observed in the electron 
density map of the X-ray structure of the respective menin complex with 4.29. 
Compound 4.29 showed an almost 6-fold increase in inhibition of the menin-MLL 
interaction (IC50 = 67nM for racemic mixture) versus MIV-3 (Figure 4.11). The binding 
mode of 4.29 was not affected by incorporating the amino group, as validated by the 
crystal structure of menin in complex with 4.29R enantiomer. 
4.29R represents the most potent inhibitor of the menin-MLL interaction reported 
for this class (IC50 = 56 nM), which binds to menin with a Kd = 85 nM. These results 
demonstrate the importance of considering long range electrostatic interactions in 
designing protein ligands to achieve efficient binding. 
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Figure 4.11.  (a) Structures and activities of analogues with substitution at the head 
group region. (b) Comparison of the crystal structures of menin in complex with 4.29R 
(bottom) and MIV-3R (top) (c) Structures and activities of analogues with substitution of 
nitrile at the tail group region. (d) Comparison of the crystal structures of menin in 
complex with 4.31 (bottom) and 4.27 (top). 
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4.4.3. Optimization of the Tail Group 
The crystal structure of menin with 4.27 was utilized to guide replacement of the 
nitrile, with the goal of further improving polarity while retaining the hydrogen bond with 
Trp341 (Figure 4.11d). Based on the menin-4.27 structure, we screened several polar 
substituents at the 4-position of the aryl tail group. Compounds such as the sulfonamide 
analogue 4.31 were prepared according to Scheme 4.4. 
Preparation of 4.31 began with 2-pyridyl lithium addition to the benzyl protected 
ketone 4.32 to provide 4.33 in excellent yield (Scheme 4.4). Hydrogenolysis of the N-
benzyl of 4.33 using Pearlman’s catalyst overnight in ethanol with heating, followed by 
alkylation of the crude deprotected piperidine using chloride 4.34, afforded target 
sulfonamide 4.31. 
 
 
Scheme 4.4.  Synthesis of sulfonamide containing hydroxymethyl piperidine 4.31. 
 
The sulfonamide analogue 4.31 showed ~3-fold improved inhibitory activity (IC50 
= 114nM) versus the corresponding nitrile analogue 4.29, while 4.16 demonstrated a 
modest ~1.5-fold improvement in IC50 versus the corresponding nitrile derivative 4.15 
(Figure 4.11d). The binding mode of 4.31 to menin was validated by crystallographic 
studies, confirming the existence of the  hydrogen bonds with the side chain of Trp341 
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and also the presence of an additional water-mediated hydrogen bond with Glu366, 
resulting in increased potency. This suggests that the sulfonamide is a viable replacement 
for the nitrile in this class of menin-MLL inhibitors, which allows for significant increase 
in polarity relative to the nitrile analogues. 
 
4.5. Biological Characterization of Menin-MLL Inhibtitors 
4.5.1. Disruption of Fusion Protein Interaction in Cells and Expression of 
Downstream Targets 
To assess the mechanism of action of this new class of menin-MLL inhibitors, 
they were evaluated for their effect on blocking the activity of MLL fusion proteins in 
leukemia cells. For these studies the most potent inhibitor developed, 4.29, and the 
corresponding hydroxyl analogue, MIV-3R, were selected.  A co-immunoprecipitation 
(co-IP) experiment was performed in HEK-293 cells transfected with Flag-MLL-AF9 
which showed that low micromolar concentrations of both 4.29 and MIV-3R effectively 
disrupt the menin-MLL-AF9 interaction (Figure 4.12a).  
 
 
Figure 4.12.  (a) Co-immunoprecipitation experiment in HEK293 cells transfected with 
MLL-AF9. (b) Quantitative real-time PCR performed in MLL-AF9-transformed murine 
bone marrow cells after 6 days of treatment with compounds. 
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Importantly, the expression levels of menin and MLL-AF9 were not affected upon 
treatment. This data demonstrates that both 4.29 and MIV-3R can reach the target protein 
and effectively disrupt the menin-MLL fusion protein interaction in human cells.    
The menin-MLL fusion protein interaction is required for the maintenance of high 
expression level of HOXA9 and MEIS1 in MLL leukemia cells and for leukemic 
transformation by MLL fusions.
11
 To assess whether 4.29 and MIV-3R affect the 
expression level of HOXA9 and MEIS1, real time quantitative PCR (qRT-PCR) 
experiments were performed in MLL-AF9 transformed murine bone marrow cells 
(BMC). Treatment with both 4.29 and MIV-3R resulted in a dose-dependent reduction in 
the expression level of Hoxa9 and Meis1 as compared to the DMSO control, with a 50% 
decrease in Hoxa9 levels upon treatment with 3µM 4.29 (Figure 4.12b). The effects on 
expression level of target genes correlates well with the in vitro inhibition observed for 
these compounds as 4.29 showed about 4-fold more pronounced effect on Hoxa9 
expression. Importantly, the negative control compound, 4.7, which is a weak menin-
MLL inhibitor (IC50 = 234 µM), did not show any effect on Hoxa9 and Meis1 expression. 
These results demonstrate that 4.29 and MIV-3R inhibit the menin-MLL fusion protein 
interaction in cells which results in a decrease in MLL-fusion protein-dependent gene 
expression.  This suggests on-target effects for these compounds and validates their 
mechanism of action.  
 
4.5.2. Proliferation and Differentiation in MLL Leukemia Cells 
Disruption of the menin-MLL fusion protein interaction is expected to result in 
growth arrest and differentiation of MLL leukemia cells.
11,27
 Therefore, the activity of 
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4.29 and MIV-3R were tested in murine BMCs transformed with either MLL-AF9 or 
Hoxa9/Meis1 (HM-2), with the later serving as a negative control.  
 
 
Figure 4.13.  (a) Titration curves from MTT cell viability assay performed for 4.29 and 
MIV-3R after 7 days of treatment of MLL-AF9 and Hoxa9/Meis1 (HM-2) transformed 
murine BMCs.  (b) Titration curves from MTT cell viability assay performed for 4.29 
and MIV-3R after 7 days of treatment of human MLL leukemia cell lines (MV4;11 and 
MOLM-13) and control cell line HL-60 (non-MLL leukemia cell line) 
 
A strong and dose-dependent inhibition of cell proliferation was observed for both 
compounds in MLL-AF9 transformed BMCs (Figure 4.13a), with GI50 = 1.1 µM for 
4.29, which showed a 4-fold more pronounced effect than MIV-3R (GI50 = 4.5 µM), 
consistent with its higher in vitro activity. In contrast, these two compounds have a 
limited effect on proliferation of Hoxa9/Meis1 transformed BMCs, demonstrating 
selectivity towards MLL fusion-transformed cells. Similar effects were observed in 
human MLL leukemia cell lines. Treatment of MV4;11 and MOLM13 cells harboring 
MLL-AF4, MLL-AF9 fusion proteins, respectively, with 4.29 and MIV-3R resulted in 
dose-dependent inhibition of cell proliferation, with a more pronounced effect observed 
for 4.29 (Figure 4.13b). Marginal effects on cell proliferation were observed upon 
treatment of HL-60 promyelocytic leukemia cells, which served as a negative control cell 
line.  
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 Finally, the effect of hydroxy- and aminomethylpiperidine compounds on 
differentiation of MLL fusion protein-dependent cells was assessed. The MLL-AF9 
BMCs undergo differentiation upon treatment with 4.29 and MIV-3R, as assessed by 
flow cytometry analysis of CD11b expression, which serves as a differentiation marker of 
myeloid cells. 
 
Figure 4.14.  Quantification of CD11b expression in MLL-AF9 transformed murine 
BMCs treated for 6 days with 4.29 and MIV-3R as detected by flow cytometry (left).  
Wright-Giemsa-stained cytospins for MLL-AF9 transformed murine BMCs after 7 days 
of treatment (right). 
 
  Treatment with more potent 4.29 induces an increase in CD11b expression 
(Figure 4.14). In addition, Wright-Giemsa staining of MLL-AF9 BMCs treated with low 
micromolar concentrations of 4.29 and MIV-3R revealed significant changes in 
morphology of these cells, such as decreased nuclei to cytoplasm ratio, multi-lobed nuclei 
and highly vacuolated cytoplasm.  This demonstrates myeloid differentiation upon 
treatment with both inhibitors (Figure 4.14). Treatment with higher concentration of 4.29 
(6 µM) resulted in terminal differentiation. These provide further evidence to confirm the 
on-target effects and specific mechanism of action for the hydroxy- and 
aminomethylpiperidine inhibitors on the menin-MLL interaction. 
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4.6. Optimization of DMPK properties for Hydroxymethyl Piperidine Series 
4.6.1. Use of Efficiency Metrics to Optimize In Vitro DMPK 
 As previously discussed, first generation menin-MLL inhibitors such as MIV-3 
were useful in vitro tool compounds, but possessed several limitations precluding its use 
in animal models of mixed lineage leukemia.  These included low potency, undesired 
ancillary activity, poor metabolic stability, and high in vivo clearance in rat.  Efforts to 
address these DMPK liabilities paralleled a lead optimization campaign focused on the 
development of low-nanomolar tool compounds for in-depth in vitro studies discussed in 
previous sections. 
Co-crystal structures of MIV-3 in complex with menin were used to perform 
optimization with a systematic structure-based design approach (Figure 4.8).   As shown 
in Figure 4.5, the lead structure MIV-3 possessed four regions that were targeted for 
optimization of potency and DMPK properties: 1) a lipophilic head group containing a 
tertiary carbinol, 2) a basic piperidine core, 3) an acyclic propyl linker, and 4) a 
benzonitrile tail group. 
Initial efforts were focused on strategies to reduce cLogP and utilized efficiency 
metrics including ligand efficiency (LE) and lipophilicity-dependent ligand efficiency 
(LELP) to address high metabolic clearance and low systemic exposure, an issue 
identified with MIV-3. The three pendent rings of the lipophilic head group and tail 
group were identified as liabilities to oxidative metabolism by CYP450 enzymes.   
Analogs prepared were consistent with previous efforts for the hydroxymethylpiperidine 
series. 
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Table 4.2.  Potency and physical properties of cyclopently hydroxymtheyl piperidine 
compounds. 
 
We introduced heterocycles and substituted phenyl rings to the lipophilic head 
group (Table 4.2).  Of note, compounds 4.27, 4.28, and 4.31 featured replacement of the 
phenyl ring with either a pyridine or thiazole.  This substitution led to an increase in 
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potency while improving the cLogP by a full log unit. This was reflected in LELP, with 
compound 4.28 showing an improvement to 11.2.  As demonstrated in Table 4.2, LELP 
proved to be a responsive indicator for driving improvements in both potency and 
lipophilicity, and was used to rank order compounds for in vitro DMPK studies. 
Subsequent efforts focused on retaining the cyclopentyl group while overall polarity was 
addressed at the tail group.  Structural analysis of MIV-3 in complex with menin 
revealed that the nitrile of the tail group engaged in a hydrogen bond interaction with 
Trp341, and this information was used to investigate additional polar substituents that 
contained a hydrogen bond acceptor. 
The sulfonamide group was identified as a suitable replacement in terms of 
potency while decreasing the cLogP by over a full log unit.  Compound 4.31 displayed 
favorable LELP (9.9), within the target range for an in vivo candidate. 
Table 4.3 describes tier 1 DMPK studies for the cyclopentyl compounds.  MIV-3 
was predicted to be rapidly cleared near the rate of blood flow in both human and rat liver 
microsomes, with a fraction unbound from plasma proteins of approximately 1% (PPB fu 
(h, r) = 0.004, 0.013).  Substitution of the phenyl group with the thiazole 4.28 led to a 2-
fold decrease in intrinsic clearance. Similar improvements were observed by substitution 
with a pyridyl group.  Replacement of the nitrile of the tail group with a sulfonamide in 
4.31 further attenuated intrinsic clearance relative to MIV-3 (CLint (h, r) = 16.2, 271) 
while displaying a significantly higher PPB fu (h, r, 0.291, 0.342). 
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Table 4.3. In vitro DMPK and in vivo pharamcokinetics of cyclopentyl 
hydroxymethylpiperidine compounds. 
 
4.6.2. In vivo Pharmacokinetics of Hydroxymethyl Piperidine Compounds 
When optimized analogue 4.31 was submitted for in vivo pharmacokinetic 
studies, it was still rapidly cleared with a half life of <0.2 h (Table 4.3).  Identification of 
the metabolites suggested that oxidation of the cyclopentyl ring by CYP450 enzymes was 
a major metabolic liability.  Earlier SAR studies suggested that similar sized aryl or 
heterocyclic rings could serve as suitable replacements for the cyclopentyl group while 
improving stability to oxidative metabolism.  Of the compounds tested, the 3-
fluorophenyl was identified as the optimal substituent to maintain potency while 
ameliorating CYP450 oxidation. We synthesized hybrid compounds containing 
heteroaryl/aryl substituents at the lipophilic head group and tail group as shown in Table 
4.4. These compounds lowered the ClogP of the series from above 5 to below 2.5, while 
improving LELP to below 10, and potency to below 100 nM, our desired endpoints for 
evaluation in in vivo studies. Improvements in these metrics reflected well in in vitro tier 
1 DMPK studies, for the first time providing compounds with predicted hepatic clearance 
of less than half the rate of blood-flow in both human and rodent models 
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Table 4.4.  Potency and in vitro DMPK parameters of biaryl hydroxymethyl piperidine 
compounds. 
 
We advanced a selection of these compounds to in vivo cassette studies of 
pharmacokinetic properties as shown in Table 4.5.  Importantly, replacement of the 
cyclopentyl group, an identified liability in metabolic identification studies, significantly 
improved half-life in vivo.  Of particular interest was 4.15R, which had a half-life of 10 
hours in rat and 5.5 hours in mouse.  This compound was designated as ML399, the 
second generation probe for in vivo evaluation in animal models of mixed-lineage 
leukemia. 
217 
 
 
Table 4.5.  In vivo pharmacokinetics parameters of biaryl hydroxymethyl piperidine 
compounds. 
 
In order to determine the relevant metabolic pathways of ML399, metabolite 
identification experiments were performed using rat hepatic S9 fraction (Figure 4.15).  
This analysis revealed that the pyridyl group, used to replace the cyclopentyl ring, did not 
undergo oxidative metabolism.  The major metabolite identified in rat S9 was N-
dealkylation at the piperidine core (M1), followed by oxidation of the 3-fluorophenyl 
substituent (M2). 
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Figure 4.15. Identification of major metabolites of ML399. 
 
4.6.3. Ancillary Pharmacology of Hydroxymethyl Piperidine Class 
ML399 was screened in a Eurofins radioligand binding panel of over 60 G 
protein-coupled receptors, ion channels, and transporters at a concentration of 10 µM. 
Several significant activities at ancillary targets were identified with ML399.  Of note 
was binding activity at the hERG potassium channel, a known target for this class of 
terfenidine-type scaffolds.  This was also observed for the sulfonamide analog of ML399.  
Relevant activities are summarized in Figure 4.16.   
 
Figure 4.16. DMPK and ancillary pharmacology profile of ML399. 
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Several strategies to address hERG binding are ongoing, including attenuation of 
basicity of the tertiary amine and adding further polarity to the scaffold.  Structural 
studies of 4.13 in complex with menin revealed that the propyl linker region occupied a 
relatively unhindered area of the binding pocket, and could possibly tolerate further 
derivitization with electron withdrawing and polar groups.  Given the precedence for 
utilizing β-hydroxyl or –fluoro functionalizations to attenuate basicity of piperidine 
scaffolds, we focused on implementing these features in the propyl linker region.  
 
 
 
Figure 4.17.  X-ray crystal structure of 4.13 in complex with menin. 
 
 
The hydroxyl-substituted compound 4.41 was synthesized according to Scheme 
4.5.  The piperidine accessed in Scheme 4.1 affected epoxide ring opening in 56% yield 
to provide the desired compound.  The secondary alcohol provides an attractive handle 
for further derivitization of the propyl linker region, however attempts towards 
deoxofluorination to provide the fluorinated analogue have proven challenging due to the 
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β-heteroatom effects of the propyl chain.  Substitution with polar groups such as the 
hydroxyl were well-tolerated, with the racemic 4.41 retaining potency of the related 
biaryl congeners. This suggests that further functionalization of the propyl linker region 
could be exploited to address ancillary activities. 
 
 
Scheme 4.5.  Synthesis of 4.41.  Reagents and conditions: (a) Acetonitrile, 22, K2CO3, 
30°C, 4h, 67% 
 
4.7. Conclusions 
Menin is a critical oncogenic cofactor of MLL fusion proteins, and the protein-
protein interaction between menin and MLL fusion proteins represents a validated and 
attractive therapeutic target in acute leukemias with translocations of MLL gene.11,20,28  
The development of a novel class of the menin-MLL inhibitors, the hydroxy- and 
aminomethylpiperidine compounds, were identified by a high throughput screen at the 
NIH MLPCN. Medicinal chemistry optimization of the HTS hit led to a significant 
improvement in inhibitory activity, resulting in development of ML227.  
The availability of co-crystal structures of menin with ML227 enabled the 
rational design of modifications to improve both the binding affinity as well as to 
optimize their physicochemical properties.  The resulting compound 4.29 represents the 
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most potent menin-MLL inhibitor developed in these series, providing ~230-fold 
improvement in the activity versus the initial HTS hit 4.1. Importantly, despite a 
relatively low molecular weight (Mw = 416 Da), 4.29 inhibits the menin-MLL interaction 
with an affinity similar to the four-fold larger 12-amino acid MLL-derived peptide. 
Consequently, the ligand efficiency (LE) index
29
 for this compound is relatively high (LE 
= 0.31 for 4.29) as compared to 0.24 average value reported for PPI inhibitors.
5
  
Biological studies demonstrated that this novel class of menin-MLL inhibitors has 
promising on-target biological activity, and represent an attractive chemical scaffold for 
further optimization as they closely mimic all critical interactions of MLL with menin.
22
  
A parallel effort incorporating analysis of physical properties and metrics, as well 
as rational design informed by metabolic identification studies were used to develop 
inhibitors of the menin-MLL interaction with improved potency and stability in vivo.  
This will allow for the evaluation of the hydroxymethylpiperidine class of compounds in 
animal models of mixed lineage leukemia.   
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Experimental Methods 
General Methods: All NMR spectra were recorded on a Bruker 400, 500 or 600 MHz 
instrument.  
1
H chemical shifts are reported in  values relative to residual solvent signals 
in ppm.    Data are reported as follows:  chemical shift, integration, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, br = broad resonance, m = multiplet), 
coupling constant (Hz).  Low resolution mass spectra were obtained on an Agilent 1200 
series 6130 mass spectrometer.  High resolution mass spectra were recorded on a Waters 
Q-TOF API-US plus Acuity system with ES as the ion source.  Analytical thin layer 
chromatography was performed on Sorbent Technologies 250 micron silica plates.  
Visualization was accomplished via UV light, and/or the use of potassium permanganate 
solution followed by application of heat.  Analytical HPLC was performed on an HP1100 
with UV detection at 214 and 254 nm along with ELSD detection, LC/MS (J-Sphere80-
C18, 3.0 x 50 mm, 4.1 min gradient, 7%[0.1%TFA/H2O] : 93%[CH3CN].  Preparative 
RP-HPLC purification was performed on a custom HP1100 automated purification 
system with collection triggered by mass detection or using a Gilson Inc. preparative UV-
based system using a Phenomenex Luna C18 column (50 x 30 mm I.D., 5 m) with an 
acetonitrile (unmodified)-water (0.5 mL/L NH4OH) custom gradient.  Normal-phase 
silica gel preparative purification was performed using an automated Combi-flash 
Companion from ISCO.  Semi-preparative purifications were carried out via stacked 
injections on a Waters Investigator SFC using a 10 x 250 mm Chiral Technologies 
CHIRALPAK ID column heated to 40 degrees Celsius.  Analytical separations were 
carried out on an Agilent 1260 Infinity SFC using a 4.6 x 250 mm Chiral Technologies 
CHIRALPAK ID column heated to 40 degrees Celsius.  Solvents for extraction, washing 
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and chromatography were HPLC grade.  All reagents were purchased from Aldrich 
Chemical Co. and were used without purification.  All polymer-supported reagents were 
purchased from Argonaut Technologies and Biotage. 
 
2. Procedures and Products 
    
 4-(2-hydroxy-3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propoxy)benzonitrile 
(4.1) 
In a round bottom flask equipped with a stir bar, diphenyl(piperidin-4-yl)methanol (500 
mg, 1.77 mmol) was dissolved in DMF (3.54 mL).  Potassium carbonate (294 mg, 2.12 
mmol) was added in a single batch followed by epibromohydrin (291 mg, 2.12 mmol).  
The reaction mixture was warmed to 50
 o
C and stirred for 6 h.  4-hydroxybenzonitrile 
(264 mg, 2.21 mmol) was then added in a single batch, and stirring was continued at 50
 
o
C for 18 h.  The reaction was quenched with H2O and extracted with EtOAc.  The 
combined organic layers were washed with brine, and dried over Na2SO4.  Concentration 
in vacuo afforded the crude product as an oil, which was purified by flash 
chromatography (9:1 CH2Cl2/MeOH) to provide the desired product at as a clear 
amorphous solid in 509 mg (65%).  
1
H NMR (400 MHz, CDCl3)  (ppm): 7.56 (2H, d, J 
= 9 Hz), 7.47 (4H, d, J = 7.6 Hz), 7.30 (4H, t, J = 8 Hz), 7.19 (2H, t, J = 7.5 Hz), 6.96 
(2H, d, J = 9 Hz), 4.07 (1H, m), 3.99 (2H, m), 3.05 (1H, d, J = 11 Hz), 2.89 (1H, d, J = 11 
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Hz), 2.49 (3H, m), 2.33 (2H, m), 2.05 (1H, dt, J = 11.5, 3 Hz), 1.53 (3H, m); 13C NMR 
(100.6 MHz, CDCl3) (ppm): 162.1, 145.9,134.1, 128.4, 126.8, 125.8, 119.3, 115.5, 
104.4, 79.6, 70.7, 65.3, 60.5, 56.0, 52.9, 44.0, 26.7, 26.4;  HRMS (ES+, M+H) calc’d for 
C28H31N2O3: 443.2335, found:  443.2334 
 
    
4-(3-(4-benzhydrylpiperidin-1-yl)propoxy)benzonitrile (4.5) 
In a round bottom flask equipped with a stir bar, 4-benzhydrylpiperidine (2.1 g, 8.46 
mmol) was combined with K2CO3 (6.9 g, 50 mmol) in DMF (40 mL), followed by 1-
bromo-3-chloropropane (1.6 g, 10 mmol).  The reaction progress was monitored by LC-
MS, and upon full consumption of starting material, 4-cyanophenol (1.3 g, 11 mmol) was 
added and the reaction allowed to stir overnight.  The mixture was poured onto water and 
extracted with EtOAc, washed with brine and dried over Na2SO4.  The volatiles were 
removed under reduced pressure and the crude mixture purified on silica gel (9:1 
CH2Cl2/MeOH) to afford 2.7 g (78%) of 4-(3-(4-benzoylpiperidin-1-
yl)propoxy)benzonitrile:  
1
H NMR (400 MHz, CDCl3)  (ppm): 7.57 (2H, d, J = 8.7 Hz), 
7.29 (8H, m), 7.12 (2H, m), 6.94 (2H, m), 4.05 (2H, t, J = 6.5 Hz), 3.52 (1H, d, J = 10.9 
Hz), 2.90 (2H, d, J = 11.7 Hz), 2.50 (2H, t, J = 7.2 Hz), 2.14 (1H, m), 1.97 (4H, m), 1.59 
(2H, d, J = 13 Hz), 1.26 (2H, m); 13C NMR (100.6 MHz, CDCl3) (ppm): 162.5, 143.9, 
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134.1, 128.6, 128.2, 126.3, 119.4, 115.3, 103.9, 66.9, 59.0, 55.4, 54.2, 39.7, 31.5, 26.8;  
HRMS (ES+, M+H) calc’d for C28H30N2O: 411.2436, found:  411.2434 
 
      
(1-(3-phenoxypropyl)piperidin-4-yl)diphenylmethanol (4.6) 
In a round bottom flask equipped with a stir bar, diphenyl(piperidin-4-yl)methanol (300 
mg, 1.06 mmol) was dissolved in DMF (3.0 mL).  Potassium carbonate (295 mg, 2.13 
mmol) was added in a single batch followed by 1-bromo-3-chloropropane (184 mg, 1.17 
mmol).  The mixture was stirred for 6 h, at which point starting material was consumed 
by TLC observation.  Phenol (190 mg, 1.60 mmol) was added to the stirring mixture, and 
the mixture was warmed to 50
 o
C and stirred for 18 h.  The reaction mixture was 
quenched with H2O, and extracted with EtOAc.  Combined organic layers were washed 
with brine and dried over Na2SO4.  Concentration in vacuo afforded the crude product, 
which was purified by flash chromatography (9:1 CH2Cl2/MeOH) to provide the desired 
product in 399 mg (88%) as a white powder.  
1
H NMR (400 MHz, CDCl3)  (ppm): 7.51 
(4H, d, J = 7.5 Hz), 7.31 (6H, m), 7.21 (2H, t, J = 7.5 Hz), 6.95 (1H, t, J = 7.5 Hz), 6.90 
(2H, d, J = 8.2 Hz), 4.02 (2H, t, J = 6 Hz), 3.09 (2H, d, J = 11.5 Hz), 2.61 (2H, t, J = 7.4 
Hz),  2.50 (1H, m), 2.16-2.00 (4H, m), 1.61 (4H, m); 
13
C NMR (100.6 MHz, CDCl3) 
(ppm): 159.0, 146.1, 129.6, 128.4, 126.7, 120.8, 114.6, 79.6, 66.2, 55.5, 54.2, 44.1, 
26.8, 26.2; HRMS (ES+, M+H) calc’d for C27H32NO2: 402.2433, found:  402.2433 
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(1-(3-chloropropyl)piperidin-4-yl)(phenyl)methanone (4.4a) 
To a solution of phenyl(piperidin-4-yl)methanone (500 mg, 2.64 mmol) in dry DMF (8.8 
mL) was added potassium carbonate (803 mg, 5.81 mmol) followed by 1-bromo-3-
chloropropane (500 mg, 3.17 mmol).  Mixture was warmed to 50 
o
C and stirred for 4 h. 
The reaction was quenched with H2O and extracted three times with EtOAc.  The organic 
layers were combined and washed with sat. aqueous NaCl, then dried over Na2SO4 and 
filtered.  Concentration in vacuo provided the crude product which was purified by flash 
chromatography (9:1 CH2Cl2/MeOH) to yield the desired product in 533 mg (75%) as a 
white powder.  
1
H NMR (400 MHz, CDCl3) (ppm): 7.92 (2H, d, J = 7.7 Hz), 7.54 (1H, 
t, J = 7.7 Hz), 7.45 (2H, t, J = 7.7 Hz), 3.59 (2H, t, J = 6.1 Hz), 3.23 (1H, m), 2.96 (2H, 
m), 2.49 (2H, t, J = 7.2 Hz), 2.11 (2H, td, J = 11.2, 3.5 Hz), 1.95 (2H, quintet, J = 6.6 
Hz), 1.84 (4H, m); 
13
C NMR (100.6 MHz, CDCl3) (ppm): 202.6, 136.0, 132.8, 128.6, 
127.8, 55.5, 53.3, 43.6, 43.2, 30.0, 28.7; HRMS (ES+, M+H) calc’d for C15H21NOCl: 
266.1312, found:  266.1312 
 
General Procedure A: 
A solution of (1-(3-chloropropyl)piperidin-4-yl)(phenyl)methanone (100 mg, 0.35 
mmol.) in THF (1.4 mL) was cooled to 0 
o
C.  To this was added organomagnesium halide 
(2 equiv.) dropwise with stirring.  The solution was then slowly warmed to ambient 
temperature, and stirring continued for 2 h, at which point starting material was 
consumed by TLC analysis.  The reaction was quenched with saturated NH4Cl and 
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extracted with EtOAc.  The organic layers were combined and dried over Na2SO4. 
Solution was then transferred to a round-bottom flask, concentrated in vacuo to remove 
solvent, and then dissolved in DMF (1.0 mL).  K2CO3 (98 mg) was added, followed by 4-
hydroxybenzonitrile (63 mg, 0.53 mmol).  Mixture was warmed to 50
 o
C and stirred for 6 
h.  The reaction mixture was quenched with H2O and extracted with EtOAc.  The organic 
layers were combined and washed with sat. aqueous NaCl and dried over Na2SO4.  
Concentration in vacuo provided the crude product, which was purified by flash 
chromatography (9:1 CH2Cl2/MeOH) to provide the desired products. 
 
    
4-(3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propoxy)benzonitrile (4.2) 
Phenylmagnesium bromide (3.0 M in Et2O) was used as described in general procedure A 
to provide the desired product in 99 mg  (66%):  
1
H NMR (400 MHz, CDCl3) (ppm): 
7.55 (2H, d, J = 8.7 Hz), 7.48 (4H, d, J = 7.7 Hz), 7.30 (4H, t, J = 7.7 Hz), 7.18 (2H, t, J 
= 7.7 Hz), 6.92 (2H, d, J =  8.7 Hz), 4.03 (2H, t, J = 6.2 Hz), 2.98 (2H, d, J = 11.8 Hz), 
2.47 (3H, m), 2.30 (1H, br s), 1.98 (4H, m), 1.51 (4H, m); 
13
C NMR (100.6 MHz, CDCl3) 
(ppm): 162.4, 146.05, 134.1, 128.4, 126.7, 125.9, 119.4, 115.3, 103.8,  79.6, 66.8, 55.1, 
54.3, 44.2, 26.7, 26.5; HRMS (ES+, M+H) calc’d for C28H31N2O2: 427.2386, found:  
427.2390 
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4-(3-(4-(hydroxy(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile (4.7) 
Cyclohexylmagnesium bromide (18% in THF) was used as described in general 
procedure A to provide the desired product in 36 mg (30%):  
1
H NMR (400 MHz, 
CDCl3)  (ppm):  7.55 (2H, d, J = 8 Hz), 7.32 (5H, m), 6.92 (2H, d, J = 8 Hz), 4.38 (1H, 
d, J = 8 Hz), 4.03 (2H, t, J = 6 Hz), 3.02 (1H, d, J = 11 Hz), 2.89 (2H, d, J = 11 Hz), 1.96 
(7H, m), 1.63 (1H, m), 1.46 (1H, m), 1.29 (2H, m); 
13
C NMR (100.6 MHz, CDCl3) 
(ppm): 162.3, 143.3, 134.1, 128.5, 127.8, 126.7, 119.4, 115.3, 103.9, 78.9, 66.8, 55.3, 
53.8, 53.7, 43.2, 28.5, 28.4, 26.6; HRMS (ES+, M+H) calc’d for C22H27N2O2: 351.2073, 
found:  351.2074 
 
     
4-(3-(4-(1-hydroxy-1-phenylethyl)piperidin-1-yl)propoxy)benzonitrile (4.8) 
Methylmagnesium Bromide (3.0 M in Et2O) was used as described in general procedure 
A to provide the desired product in 73 mg (58%):  
1
H NMR (400 MHz, CDCl3)  (ppm): 
7.55 (2H, d, J = 8.5 Hz), 7.40 (2H, d, J = 7.8 Hz), 7.33 (2H, t, J = 7.5 Hz), 7.24 (1H, t, J 
= 7.4 Hz), 6.92 (2H, d, J = 9 Hz), 4.02 (2H, t, J = 6.4 Hz), 2.97 (2H, t, J = 12 Hz), 2.47 
(2H, t, J = 7.4 Hz), 1.97 (2H, m), 1.88 (2H, m), 1.63 (2H, m), 1.56 (3H, s), 1.51 (1H, m), 
1.41 (2H, m); 
13
C NMR (100.6 MHz, CDCl3) (ppm): 162.4, 147.4, 134.0, 128.1, 126.8, 
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125.4, 119.4, 115.3, 103.9, 76.1, 66.9, 55.2, 54.3, 47.4, 26.7, 26.7, 26.6, 26.6; HRMS 
(ES+, M+H) calc’d for C23H29N2O2: 365.2229, found:  365.2228 
 
    
 4-(3-(4-(1-hydroxy-1-phenylpentyl)piperidin-1-yl)propoxy)benzonitrile (4.9) 
n-Butylmagnesium chloride (2.0 M in THF) was used as described in general procedure 
A to provide the desired product in 64 mg (45%):  
1
H NMR (400 MHz, CDCl3) (ppm): 
7.54 (2H, d, J = 8 Hz), 7.33 (4H, m), 7.21 (1H, m), 6.91 (2H, d, J = 9.1 Hz), 4.02 (2H, t, J 
= 6.4 Hz), 3.01 (1H, d, J = 11.2 Hz), 2.90 (1H, d, J = 11.2), 2.45 (2H, t, J = 7.2 Hz), 1.95 
(3H, m), 1.82 (4H, m), 1.62 (1H, m), 1.39 (3H, m), 1.25 (3H, m), 0.92 (1H, m), 0.82 (3H, 
t, J = 7.2 Hz); 
13
C NMR (100.6 MHz, CDCl3) (ppm): 162.5, 145.1, 134.1, 128.0, 126.4, 
125.9, 119.4, 115.3, 103.9, 78.4, 66.9, 55.2, 54.3, 46.9, 39.0, 26.7, 26.5, 26.1, 25.7, 23.3, 
14.1; HRMS (ES+, M+H) calc’d for C26H35N2O2: 407.2699, found:  407.2701 
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4-(3-(4-(cyclopropyl(hydroxy)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile 
(4.10) 
Cyclopropylmagnesium bromide (0.5 M in THF) was used as described in general 
procedure A to provide the desired product in 74 mg (56%):  
1
H NMR (400 MHz, 
CDCl3) (ppm): 7.55 (2H, d, J = 9 Hz), 7.45 (2H, d, J = 8 Hz), 7.33 (2H, t, J = 7.5 Hz), 
7.23 (1H, t, J = 7.2 Hz), 6.92 (2H, d, J = 9 Hz), 4.03 (2H, t, J = 6.2 Hz), 3.01 (1H, d, J = 
11 Hz), 2.95 (1H, d, J  =  11 Hz), 2.48 (2H, t, J = 7.2 Hz), 1.94 (4H, m), 1.79 (2H, m), 
1.49 (3H, m), 1.35 (1H, m), 0.60 (1H, m), 0.53 (1H, m), 0.32 (1H, m), 0.09 (1H, m); 
13
C 
NMR (100.6 MHz, CDCl3) (ppm): 162.4, 146.8, 134.1, 128.1, 134.1, 128.0, 126.7, 
125.7, 119.4, 115.3, 103.9, 75.9, 66.9, 55.2, 54.4, 54.3, 48.0, 26.8, 26.7, 26.6, 18.2, 2.7, -
0.1; HRMS (ES+, M+H) calc’d for C25H31N2O2: 391.2386, found:  391.2383 
 
     
4-(3-(4-(1-hydroxy-2-methyl-1-phenylpropyl)piperidin-1-yl)propoxy)benzonitrile 
(4.11) 
Isopropylmagnesium chloride (2.0 M in THF) was used as described in general procedure 
A to provide the desired product in 56 mg (41 %):  
1
H NMR (400 MHz, CDCl3)  (ppm): 
7.54 (2H, d, J = 9 Hz), 7.32 (4H, m), 7.21 (1H, t, J = 7 Hz), 6.90 (2H, d, J = 9 Hz), 4.00 
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(2H, t, J = 6 Hz), 3.00 (1H, d, J = 11.5 Hz),  2.97 (1H, d, J = 11.5 Hz), 2.50 (2H, t, J  =  7 
Hz), 2.32 (1H, sept, J = 7 Hz), 2.05-1.84 (6H, m), 1.45 (1H, m), 1.25 (3H, m), 0.87 (3H, 
d, J = 7 Hz), 0.76 (3H, d, J = 7 Hz);  13C NMR (125.8 MHz, CDCl3) (ppm): 162.4, 
142.8, 134.1, 127.7, 126.6, 126.5, 119.4, 115.3, 103.9, 80.3, 66.8, 55.2, 54.3, 54.2, 42.9, 
33.3, 26.5, 25.9, 17.4, 16.4; HRMS (ES+, M+H) calc’d for C25H33N2O2: 393.2542, 
found:  393.2542 
 
  
4-(3-(4-(cyclobutyl(hydroxy)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile 
(4.12) 
Cyclobutylmagnesium Bromide (0.2 M in THF) was prepared by dissolving cyclobutyl 
bromide (150 mg, 1.1 mmol) in THF (5.0 mL), followed by addition of magnesium (25 
mg, 1.1 mmol) and a catalytic amount of iodine.  The mixture was stirred for 2 h at 
ambient temperature, and was used as described in general procedure A to provide the 
desired  product in 85 mg (60 %):  
1
H NMR (400 MHz, CDCl3) (ppm): 7.54 (2H, d, J = 
8 Hz), 7.34 (2H, d, J = 7.5 Hz), 7.30 (2H, t, J = 7.5 Hz), 7.20 (1H, t, J = 7 Hz), 6.90 (2H, 
d, J = 9 Hz), 4.00 (2H, t, J =  6 Hz), 3.14 (1H, pent, J = 9 Hz), 2.97 (1H, d, J = 11 Hz), 
2.89 (1H, d, J = 11 Hz), 2.44 (2H, t, J = 7.5 Hz), 2.14 (1H, pent, J = 9 Hz), 1.94 (4H, m), 
1.80 (4H, m), 1.59 (4H, m), 1.41 (1H, m), 1.28 (2H, m); 
13
C NMR (100.6 MHz, CDCl3) 
(ppm): 162.4, 143.8, 134.1, 127.9, 126.6, 126.3, 119.2, 115.3, 103.9, 73.3, 68.8, 55.2, 
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54.3, 54.2, 45.5, 42.6, 26.9, 26.6, 26.4, 23.4, 23.1, 17.6; HRMS (ES+, M+H) calc’d for 
C26H33N2O2: 405.2542, found:  405.2539 
   
4-(3-(4-(cyclohexyl(hydroxy)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile 
(4.14) 
Cyclohexylmagnesium bromide (18% in THF) was used as described in general 
procedure A to provide the desired product in 59 mg (39%):  
1
H NMR (400 MHz, 
CDCl3)  (ppm): 7.54 (2H, d, J = 9 Hz), 7.31 (4H, m), 7.22 (1H, t, J = 7.5 Hz), 6.90 (2H, 
d, J = 9 Hz), 4.01 (2H, t, J = 6.5 Hz), 3.00 (1H, d, J = 11 Hz), 2.94 (1H, d, J = 11 Hz), 
2.46 (2H, t, J = 7 Hz), 2.00-1.60 (12H, m), 1.50 (1H, d, J = 12 Hz), 1.29 (5H, m), 0.97 
(2H, m), 0.77 (1H, m); 
13
C NMR (100.6 MHz, CDCl3) (ppm): 162.4, 143.2, 134.1, 
127.7, 126.5, 126.4, 119.4, 115.5, 103.9, 80.2, 68.9, 55.3, 54.4, 54.3, 44.2, 42.4, 27.5, 
26.9, 26.8, 26.7, 26.6, 26.5, 26.4, 25.9; HRMS (ES+, M+H) calc’d for C28H37N2O2: 
433.2855, found:  433.2854 
 
   
4-(3-(4-(cyclopentanecarbonyl)piperidin-1-yl)propoxy)benzonitrile (4.23) 
Cyclopentyl(piperidin-4-yl)methanone (2.70 g, 10.0 mmol) was combined with K2CO3 
(6.9 g, 50.0 mmol) in DMF (40.0 mL), followed by 1-bromo-3-chloropropane (1.55 g, 
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10.0 mmol).  The reaction progress was monitored by LC-MS and upon completion of 
the reaction 4-cyanophenol (1.3 g, 11.0 mmol) was added and the reaction allowed to stir 
overnight.  The mixture was poured onto water and extracted with EtOAc, washed with 
brine and dried over Na2SO4.  The volatiles were removed under reduced pressure and 
the crude mixture purified on silica gel (9:1 CH2Cl2/MeOH) to provide the desired 
product in 2.71g (78%) as a light yellow oil:  
1
H NMR (600 MHz, CDCl3)  (ppm): 7.56 
(2H, d, J = 9.0 Hz), 6.93 (2H, d, J = 9.0 Hz), 4.05 (2H, t, J = 6.5 Hz), 3.00 (1H, quintet, J 
= 7.7 Hz), 2.94 (2H, m), 2.49 (2H, t, J = 7.1 Hz), 2.42 (1H, m), 1.99 (4H, m), 1.79 (4H, 
m), 1.68 (6H, m), 1.56 (2H, m); 
13
C NMR (150.9 MHz, CDCl3) (ppm): 215.7, 162.5, 
134.1, 119.4, 115.3, 103.9, 66.8, 55.1, 53.4, 49.4, 48.2, 29.5, 28.1, 26.7, 26.2; HRMS 
(ES+, M+H) calc’d for C21H29N2O2: 341.2229, found:  341.2228 
 
General procedure B: 
 4-(3-(4-(cyclopentanecarbonyl)piperidin-1-yl)propoxy)benzonitrile (30 mg, 0.09 mmol) 
was dissolved in THF (0.7 mL).  Organometallic (2 equiv.) was added dropwise to the 
solution with stirring.  Reaction was then warmed to 50 °C, and stirring was continued 
for 2 h.  Reaction was quenched with sat. aqueous NH4Cl, and extracted with EtOAc.  
The combined organic fractions were washed with saturated NaCl and dried over 
Na2SO4.  Concentration in vacuo provided the crude product, which was purified by flash 
column chromatography (9:1 CH2Cl2/MeOH) to provide the desired products in 35 – 
74% yield. 
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 4-(3-(4-(cyclopentyl(hydroxy)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile 
(4.13, MIV-3) 
Phenylmagnesium bromide (1.0 M in THF) was used as described in general procedure B 
to provide the desired product in 46 mg (74%):  Chiral Separation:  Semi-preparative 
purifications were carried out via stacked injections on a Waters Investigator SFC using a 
10 x 250 mm Chiral Technologies CHIRALPAK IA column heated to 40 °C.  The eluent 
was 55% EtOH(0.1% DEA) in CO2 at a flow rate of 15 mL/minute.  Backpressure was 
maintained at 100 bar. The first eluting peak (11S), retention time = 0.95 min. was 
inferred as the S stereoisomer based upon the absolute configuration observed in the 
electron density map of the X-ray structure of the MIV-3S-Menin complex.  The second 
eluting peak (11R), retention time = 2.3 min. was inferred as the R stereoisomer based 
upon the absolute configuration observed in the electron density map of the X-ray 
structure of the MIV-3R-Menin complex.  
1
H NMR (400 MHz, CDCl3)  (ppm): 7.54 
(2H, d, J = 9 Hz), 7.37 (2H, d, J = 8 Hz), 7.30 (2H, t, J = 8 Hz), 7.22 (1H, t, J = 7 Hz), 
6.88 (2H, d, J = 9 Hz), 4.07 (2H, t, J = 6 Hz), 3.21 (2H, m), 2.67 (3H, m), 2.19 (2H, m), 
2.05 (2H, m), 1.95 (1H, m), 1.82 (1H, m), 1.72 (1H, m), 1.64 (1H, m), 1.59-1.40 (7H, m), 
1.25 (1H, m), 1.07 (1H, m); 
13
C NMR (100.6 MHz, CDCl3) (ppm): 162.4, 143.9, 134.0, 
127.7, 126.5, 126.4, 119.4, 115.3, 103.8, 79.6, 68.9, 55.2, 54.5, 54.4, 45.8, 45.3, 27.5, 
237 
 
27.3, 26.7, 26.4, 26.1, 26.0, 25.6; HRMS (ES+, M+H) calc’d for C27H35N2O2: 419.2699, 
found:  419.2698 
   
4-(3-(4-(cyclopentyl(3-fluorophenyl)(hydroxy)methyl)piperidin-1-
yl)propoxy)benzonitrile (4.24)   
3-Fluorophenylmagnesium bromide (1.0 M in THF) was used as described in general 
procedure B to provide the desired product in 22 mg (57%):  
1
H NMR (400 MHz, CDCl3) 
 (ppm): 7.55 (2H, d, J = 9 Hz), 7.26 (1H, m), 7.13 (2H, m), 6.90 (3H, m), 4.02 (2H, t, J 
= 6 Hz), 3.06 (2H, m), 2.66 (1H, quintet, J = 8.5 Hz), 2.55 (2H, m), 2.03 (3H, m), 1.93 
(1H, d, J = 13 Hz), 1.71 (4H, m), 1.57 (1H, m), 1.47 (6H, m), 1.10 (2H, m);  13C NMR 
(100.6 MHz, CDCl3) (ppm): 162.8 (d, JCF = 247 Hz), 162.3, 146.8 (d, JCF = 6 Hz), 
134.1, 129.1 (d, JCF = 8 Hz), 122.3 (d, JCF = 3 Hz), 119.4, 115.3, 114.1 (d, JCF = 24 Hz), 
113.4 (d, JCF = 21 Hz), 103.9, 79.4, 66.7, 55.1, 54.2, 54.1, 46.0, 45.2, 27.4, 26.8, 26.3, 
26.1, 26.0, 25.9, 25.5; HRMS (ES+, M+H) calc’d for C27H34N2O2F: 437.2604, found:  
437.2604 
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4-(3-(4-(cyclopentyl(3,5difluorophenyl)(hydroxy)methyl)piperidin-1-
yl)propoxy)benzonitrile (4.25) 
3,5-Difluorophenylmagnesium bromide (0.5 M in THF) was used as described in general 
procedure B to provide the desired product in 15 mg (36%):  
1
H NMR (400 MHz, CDCl3) 
 (ppm): 7.55 (2H, d, J = 9 Hz), 6.91 (4H, t, J = 8 Hz), 6.66 (1H, tt, J = 9.0, 2.2 Hz), 4.00 
(2H, t, J = 6.3 Hz), 2.99 (2H, d, J = 11 Hz), 2.60 (1H, quintet, J = 9 Hz), 2.47 (2H, t, J = 
7 Hz), 1.93 (5H, m), 1.75 (1H, m), 1.68-1.32 (10H, m), 1.05 (2H, m);  
13
C NMR (100.6 
MHz, CDCl3) (ppm): 162.83 (dd, JCF = 247, 12 Hz), 162.3, 148.6 (t, JCF = 8 Hz), 134.1, 
119.4, 115.3, 109.8 (d, JCF = 24 Hz), 104.0, 102.0 (t, JCF = 24 Hz), 79.5, 77.3, 66.7, 55.2, 
54.2, 54.1, 46.1, 45.4, 27.3, 26.9, 26.4, 26.2, 25.9, 25.5; HRMS (ES+, M+H) calc’d for 
C27H33N2O2F2: 455.2510, found:  455.2513 
 
    
4-(3-(4-((3-chlorophenyl)(cyclopentyl)(hydroxy)methyl)piperidin-1-
yl)propoxy)benzonitrile (4.26) 
3-Chlorophenylmagnesium bromide (0.5 M in THF) was used as described in general 
procedure B to provide the desired  product in 24 mg (60%):  
1
H NMR (400 MHz, 
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CDCl3)  (ppm): 7.56 (2H, d, J = 8.7 Hz), 7.42 (1H, s), 7.26 (2H, t, J = 7.6 Hz), 7.22 (1H, 
m), 6.92 (2H, d, J = 8.7 Hz), 4.02 (2H, t, J = 6.3 Hz), 2.97 (2H, d, J = 11 Hz), 2.70 (1H, 
quintet, J = 9 Hz), 2.47 (2H, t, J = 7 Hz), 1.95 (5H, m), 1.76 (1H, m), 1.71-1.41 (9H, m), 
1.29 (1H, m), 1.04 (2H, m);  
13
C NMR (100.6 MHz, CDCl3) (ppm): 162.4, 146.2, 
134.1, 133.9, 128.9, 127.0, 126.8, 125.0, 119.4, 115.3, 103.9, 79.5, 66.8, 55.2, 54.3, 54.2, 
45.9, 45.3, 27.5, 27.1, 26.5, 26.3, 26.1, 26.0, 25.6; HRMS (ES+, M+H) calc’d for 
C27H34N2O2Cl: 453.2309, found:  453.2305 
  
   
 4-(3-(4-(cyclopentyl(hydroxy)(pyridin-2-yl)methyl)piperidin-1-
yl)propoxy)benzonitrile (4.27) 
2-Pyridylmagnesium bromide (0.25 M) was used as described in general procedure B to 
provide the desired product in 13 mg (35%). 
1
H NMR (400 MHz, CDCl3)  (ppm): 8.52 
(1H, d, J = 5 Hz), 7.70 (2H, t, J = 8 Hz), 7.57 (2H, d, J = 8 Hz), 7.31 (1H, d, J = 8 Hz), 
7.21 (1H, dd, J = 8, 5 Hz), 6.92 (2H, d, J = 8 Hz), 5.72 (1H, br s), 4.03 (2H, t, J = 6 Hz), 
3.03 (1H, m), 2.56 (3H, m), 2.09-1.75 (7H, m), 1.65 (2H, m), 1.49 (4H, m), 1.15 (2H, m), 
0.76 (1H, m);  
13
C NMR (125.8 MHz, CDCl3) (ppm): 162.2, 161.5, 147.0, 136.6, 134.1, 
122.2, 121.1, 119.3, 115.3, 104.1, 78.1, 66.6, 55.1, 54.3, 54.2, 45.8, 45.4, 29.8, 27.1, 26.5, 
26.1, 25.7; HRMS (ES+, M+H) calc’d for C26H34N3O2: 420.2651, found:  420.2650 
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4-(3-(4-(cyclopentyl(hydroxy)(thiazol-2-yl)methyl)piperidin-1-
yl)propoxy)benzonitrile (4.28)  
Thiazol-2-yllithium (0.15 M in THF) was prepared by dissolving 2-bromothiazole (72.2 
mg, 0.44 mmol) in THF and cooling to -78 °C.  n-Butyllithium (0.18 mL, 2.5 M in 
hexanes) was slowly added, and then stirred for 20 min. at -78 °C.  The solution was then 
used as described in general procedure B to provide the desired product in 47 mg (75%):  
1
H NMR (400 MHz, CDCl3)  (ppm): 7.70 (1H, d, J = 3.2 Hz), 7.54 (2H, d, J = 8.7 Hz), 
7.28 (1H, d, J = 3.2 Hz), 6.91 (2H, d, J = 8.7 Hz), 4.02 (2H, t, J = 6 Hz), 3.40 (1H, br s), 
3.03 (2H, d, J = 11.2 Hz), 2.55 (3H, m), 2.05-1.85 (6H, m), 1.75 (2H, m), 1.47 (8H, m), 
1.21 (1H, m); 
13
C NMR (100.6 MHz, CDCl3) (ppm): 175.7, 162.3, 114.6, 134.1, 141.6, 
134.1, 119.4, 119.2, 115.3, 103.9, 80.9, 66.8, 55.1, 54.1, 47.5, 45.1, 26.7, 26.4, 26.3, 26.0, 
25.8, 25.5; HRMS (ES+, M+H) calc’d for C24H32N3O2S: 426.2215, found:  426.2212 
 
    
(1-(3-chloropropyl)piperidin-4-yl)(pyridin-2-yl)methanone (4.4b) 
To a solution of piperidin-4-yl(pyridin-2-yl)methanone (791 mg, 2.72 mmol) in dry DMF 
(9.1 mL) was added potassium carbonate (1.13 g, 8.16 mmol) followed by 1-bromo-3-
chloropropane (514 mg, 3.26 mmol).  Mixture was warmed to 50 
o
C and stirred for 4 h. 
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The reaction was quenched with H2O and extracted three times with EtOAc.  The organic 
layers were combined and washed with sat. aqueous NaCl, then dried over Na2SO4 and 
filtered.  Concentration in vacuo provided the  crude product which was purified by flash 
chromatography (9:1 CH2Cl2/MeOH) to yield the desired product in 790 mg (83%) as a 
light yellow oil:  
1
H NMR (400MHz,CDCl3)  (ppm): 8.66 (1H, d, J = 4.4 Hz), 8.01 (1H, 
d, J = 8.3 Hz), 7.82 (1H, t, J = 7.8 Hz), 7.44 (1H, m), 3.83 (1H, m), 3.59 (2H, t, J = 6.5 
Hz), 2.95 (2H, d, J = 11.2 Hz), 2.50 (2H, t, J = 7.2 Hz), 2.16 (2H, m), 1.94 (4H, m), 1.77 
(2H, m); 
13
C NMR (100.6 MHz, CDCl3) (ppm): 203.7, 152.7, 148.8, 136.9, 126.9, 
122.4, 55.7, 53.2, 43.3, 42.2, 30.0, 28.1; HRMS (ES+, M+H) calc’d for C14H20N2OCl: 
267.1264, found: 267.1263 
 
     
 4-(3-(4-((3-fluorophenyl)(hydroxy)(pyridin-2-yl)methyl)piperidin-1-
yl)propoxy)benzonitrile (4.15) 
A solution of (1-(3-chloropropyl)piperidin-4-yl)(pyridin-2-yl)methanone (100 mg, 0.35 
mmol.) in THF (1.41 mL) was cooled to 0 
o
C.  To this was added 3-
Fluorophenylmagnesium bromide (1.0 M in THF) dropwise with stirring.  The solution 
was then slowly warmed to ambient temperature, and stirring continued for 2 h, at which 
point starting material was consumed by TLC analysis.  The reaction was quenched with 
sat. aqueous NH4Cl and extracted with EtOAc.  The organic layers were combined and 
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dried over Na2SO4. Solution was then transferred to a round-bottom flask, concentrated in 
vacuo to remove solvent, and then dissolved in DMF (1.0 mL).  K2CO3 (76 mg, 0.55 
mmol) was added, followed by 4-hydroxybenzonitrile (131 mg, 1.10 mmol).  Mixture 
was warmed to 50
 o
C and stirred for 6 h.  The reaction mixture was quenched with H2O 
and extracted with EtOAc.  The organic layers were combined and washed with sat. 
aqueous NaCl and dried over Na2SO4.  Concentration in vacuo provided the crude 
product, which was purified by reverse-phase HPLC chromatography to provide the 
desired product as an off-white powder in 106 mg (65%).  Chiral Separation:  Semi-
preparative purifications were carried out via stacked injections on a Waters Investigator 
SFC using a 10 x 250 mm Chiral Technologies CHIRALPAK ID column heated to 40 
°C.  The eluent was 50% IPA (0.1% DEA) in CO2 at a flow rate of 15 mL/minute.  
Backpressure was maintained at 100 bar. The first eluting peak (18R), retention time = 
3.09 min..  The second eluting peak (18S), retention time = 3.79 min.  1H NMR (500 
MHz,CDCl3)  (ppm): 8.85 (1H, d, J = 6 Hz), 8.43 (1H, d, J = 7.4 Hz), 8.37 (1H, t, J = 
7.4 Hz), 7.79 (1H, t, J = 6.6 Hz), 7.59 (4H, m), 7.37 (1H, dd, J = 16, 8 Hz), 6.96 (3H, m), 
4.33 (1H, br s), 4.01 (2H, t, J = 6 Hz), 3.59 (3H, m), 3.25 (2H, m), 3.07 (1H, m), 2.58 
(1H, m), 2.44 (3H, m), 1.72 (1H, d, J = 14 Hz), 1.59 (1H, d, J = 14 Hz); ); 13C NMR 
(125.8 MHz, CDCl3) (ppm): 162.8 (d, JCF = 247 Hz), 162.2, 161.9, 148.4 (d, JCF = 6.2 
Hz), 147.4, 137.4, 134.1, 129.8 (d, JCF = 8.1 Hz), 122.4, 121.5, 120.4, 119.4, 115.3, 
113.9, 113.7, 113.5, 113.3, 104.0, 78.6, 66.7, 54.9, 54.0, 26.5, 25.6, 25.3; HRMS (ES+, 
M+H) calc’d for C27H29N3O2F: 446.2244, found: 446.2248 
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4-(3-(4-((3-fluorophenyl)(hydroxy)(pyridin-2-yl)methyl)piperidin-1-
yl)propoxy)benzenesulfonamide (4.16) 
A solution of (1-(3-chloropropyl)piperidin-4-yl)(pyridin-2-yl)methanone (100 mg, 0.35 
mmol.) in THF (1.41 mL) was cooled to 0 
o
C.  To this was added 3-
fluorophenylmagnesium bromide (1.0 M in THF) dropwise with stirring.  The solution 
was then slowly warmed to ambient temperature, and stirring continued for 2 h, at which 
point starting material was consumed by TLC analysis.  The reaction was quenched with 
saturated NH4Cl and extracted with EtOAc.  The organic layers were combined and dried 
over Na2SO4. Solution was then transferred to a round-bottom flask, concentrated in 
vacuo to remove solvent, and then dissolved in DMF (1.0 mL).  K2CO3 (76 mg, 0.55 
mmol) was added, followed by 4-hydroxybenzenesulfonamide (190 mg, 1.10 mmol).  
Mixture was warmed to 50
 o
C and stirred for 6 h.  The reaction mixture was quenched 
with H2O and extracted with EtOAc.  The organic layers were combined and washed 
with sat. aqueous NaCl and dried over Na2SO4.  Concentration in vacuo provided the 
crude product, which was purified by reverse-phase HPLC chromatography to provide 
the desired product as an off-white powder in 136 mg (74%):  
1
H NMR (400 MHz, 
CDCl3)  (ppm): 8.47 (1H, d, J = 4.9 Hz), 7.82 (2H, d, J = 8.9 Hz), 7.67 (1H, td, J = 10, 7 
Hz), 7.44 (1H, d, J = 8 Hz), 7.36 (2H, m), 7.26 (1H, m), 7.16 (1H, m), 6.93 (2H, d, J = 9 
Hz), 6.87 (1H, m), 6.05 (1H, br s), 5.10 (1H, br s), 4.02 (2H, t, J = 6 Hz), 2.92 (2H, m), 
2.46 (2H, t, J = 7 Hz), 2.36 (1H, t, J = 11 Hz), 1.94 (4H, m), 1.62 (2H, m), 1.45 (1H, d, J 
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= 13 Hz), 0.97 (1H, d, J = 13 Hz); 
13
C NMR (100.6 MHz, CDCl3) (ppm): 163.1 (d, JCF 
= 242 Hz), 162.5, 162.1, 148.4 (d, JCF = 7 Hz), 147.3, 137.4, 133.8, 129.8 (d, JCF = 8 Hz), 
128.6, 122.3, 121.5, 120.4, 114.8, 113.7 (d, JCF = 21 Hz), 113.4 (d, JCF = 22 Hz), 78.6, 
66.9, 55.0, 54.1, 54.0, 44.7, 26.7, 26.0, 25.8;  HRMS (ES+, M+H) calc’d for 
C26H31N3O4SF: 500.2019, found:  500.2020 
 
    
4-(3-(4-(cyclopentyl(hydroxy)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile 
(4.29) 
A CHCl3 (4.78 mL, 0.25 M) solution of 4-(3-(4-
(cyclopentyl(hydroxy)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile (1.0 g, 2.39 
mmol) and sodium azide (1.16 g, 17.9 mmol) was cooled to 0 
o
C.  To the solution, H2SO4 
was added dropwise (0.28 mL, 9.3 mmol).  The mixture was allowed to warm to rt over 
4h with stirring, then cooled to 0 
o
C and treated with NH4OH until pH was basic.  The 
biphasic solution was extracted with CH2Cl2 (3x) and the organic layers combined and 
dried over MgSO4.  Concentration under reduced pressure and concentration in vacuo 
afforded a crude oil which was purified by flash column chromatography (9:1 
CH2Cl2/MeOH) to afford a colorless oil comprising an inseperable mixture of the desired 
azide and an elimination byproduct in 30 mg that was carried on to the next step.  
 4-(3-(4-(Azido(cyclopentyl)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile (30 mg, 
0.07 mmol) was dissolved in degassed EtOH (0.5 mL) and Pd/C (2.7 mg) added in one 
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portion.  Reaction was placed under a balloon of H2 gas and allowed to stir for 4 h at 
ambient temperature.  The reaction was filtered over Celite and rinsed with MeOH.  The 
filtrate was concentrated to afford an oil.  RP-HPLC preparative purification afforded the 
desired product as a TFA salt.  The mixture was treated with a StratoSpheres SPE MP-
carbonate resin cartridge to give title compound as a free base in 20 mg (2%).  Chiral 
Separation:  Semi-preparative purifications were carried out via stacked injections on a 
Waters Investigator SFC using a 10 x 250 mm Chiral Technologies CHIRALPAK ID 
column heated to 40 °C.  The eluent was 50% MeOH(0.1% DEA) in CO2 at a flow rate 
of 15 mL/minute.  Backpressure was maintained at 100 bar. The first eluting peak (19S), 
retention time = 3.97 min. was inferred as the S stereoisomer based upon the absolute 
configuration observed in the electron density map of the X-ray structure of the 4.29 R-
Menin complex.  The second eluting peak (19R), retention time = 5.38 min. was inferred 
as the R stereoisomer based upon the absolute configuration observed in the electron 
density map of the X-ray structure of the 4.29 R-Menin complex. 
1
H NMR (600 MHz, 
CDCl3) 7.54 (2H, d, J = 6.0 Hz), 7.43 (2H, d, J = 7.2 Hz), 7.31 (2H, t, J=7.2 Hz), 7.22 
(1H, t, J = 7.2 Hz), 6.91 (2H, d, J = 6.0 Hz), 4.02 (2H, t, J = 8.4 Hz), 3.05-2.96 (2H, m), 
2.62 (1H, m), 2.47 (2H , br s), 1.96-1.89 (4H, m), 1.73 (1H, m), 1.62-1.40 (9H, m), 1.29-
1.24 (2H, m), 1.13-1.05 (2H, m);
 13
C NMR (150.9 MHz, CDCl3) (ppm): 162.4, 144.5, 
134.1, 127.6, 127.5, 126.1, 119.42, 115.3, 103.9, 66.9, 61.3, 55.2, 54.7, 54.6, 46.4, 45.6, 
27.6, 27.1, 26.7, 26.6, 26.5, 25.9, 25.6; HRMS (ES+, M+H) calc’d for C28H30N2O2: 
418.858, found:  418.2857 
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(1-benzylpiperidin-4-yl)(cyclopentyl)(pyridin-2-yl)methanol (4.33) 
2-Bromopyridine (873 mg, 5.54 mmol), was dissolved in THF (30 mL), and cooled to -78 
°C.  To this solution was added n-butlyllithium (2.2 mL, 2.5 M in hexanes, 5.53 mmol) 
dropwise with stirring.  Stirring was continued for 20 min.  (1-Benzylpiperidin-4-
yl)(cyclopentyl)methanone (500 mg, 1.84 mmol) dissolved in THF (2.0 mL), was added 
dropwise to stirring solution of pyridin-2-yllithium at -78 °C.  The mixture was stirred for 
20 min. and then slowly warmed to room temperature.  Reaction was stirred for 2 h, then 
quenched with sat. aqueous NH4Cl.  The mixture was extracted with EtOAc, and the 
organic layers combined and washed with sat. aqueous NaCl and dried over Na2SO4.  
Concentration in vacuo provided the crude product, which was purified by flash column 
chromatography (9:1 CH2Cl2/MeOH) to provide the desired product as a white solid in 
599 mg (93%):   
1
H NMR (400 MHz, CDCl3)  (ppm): 8.51 (1H, d, J = 4.7 Hz), 7.66 
(1H, t, J = 8.1 Hz), 7.30-7.17 (7H, m), 5.66 (1H, br s), 3.45 (2H, d, J = 2.0 Hz), 2.90 (2H, 
m), 2.62 (1H, quintet, J =  8.5 Hz), 1.97-1.61 (8H, m), 1.47 (4H, m), 1.14 (2H, m), 0.69 
(1H, m); 
13
C NMR (125.8 MHz, CDCl3) (ppm): 162.1, 146.9, 138.5, 136.3, 129.3, 
128.2, 127.0, 121.9, 121.2, 78.3, 63.5, 54.5, 54.3, 46.0, 45.8, 27.9, 27.1, 26.6, 26.5, 26.2, 
25.7; HRMS (ES+, M+H) calc’d for C23H31N2O: 351.2436, found:  351.2433 
247 
 
   
4-(3-(4-(cyclopentyl(hydroxy)(pyridin-2-yl)methyl)piperidin-1-
yl)propoxy)benzenesulfonamide (4.31) 
In a Parr vessel, (1-benzylpiperidin-4-yl)(cyclopentyl)(pyridin-2-yl)methanol (500 mg, 
1.84 mmol) was dissolved in EtOH (10 mL).  The solution was degassed by bubbling 
Argon through the solution for 10 min.  Pd(OH)2 was then added and the vessel was 
quickly inserted into the Parr Shaker apparatus.  The system was purged with H2 three 
times, and H2 pressure was then set to 70 psi.  The vessel was heated to 50 °C, and 
shaken for 12-24 h.  When the reaction progress was complete by LCMS, the mixture 
was filtered through a celite pad and washed with EtOH.  The filtrate was concentrated in 
vacuo to yield the crude product, which was carried forward to the next step. 
Cyclopentyl(piperidin-4-yl)(pyridin-2-yl)methanol (30 mg, 0.12 mmol) was dissolved in 
DMF (1.0 mL).  4-(3-chloropropoxy)benzenesulfonamide (29 mg, 0.12 mmol) and 
K2CO3 (32 mg, 0.23 mmol) were added and reaction was warmed to 50 °C.  Stirring was 
continued overnight.  The reaction mixture was quenched with aqueous NH4Cl.  The 
mixture was extracted with EtOAc, and the organic layers combined and washed with sat. 
aqueous NaCl and dried over Na2SO4.  Concentration in vacuo provided the crude 
product, which was purified by RP-HPLC to provide the desired product as a white solid 
in 23 mg (42%):  
1
H NMR (500 MHz, CDCl3)  (ppm): 8.45 (1H, d, J = 4.7 Hz), 7.80 
(2H, d, J = 8.4 Hz), 7.65 (1H, t, J = 7.8 Hz), 7.27 (1H, d, J = 7.8 Hz), 7.17 (1H, t, J = 6.1 
Hz), 6.90 (2H, d, J = 7.8 Hz), 5.66 (1H, br s), 5.06 (2H, br s), 3.98 (2H, t, J = 6.4 Hz), 
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2.98 (1H, d, J = 10.2 Hz), 2.91 (1H, d, J = 10.2 Hz), 2.58 (1H, m), 2.44 (2H, m), 1.96-
1.69 (8H, m), 1.60-1.42 (6H, m), 1.12 (2H, m), 0.69 (1H, m); 
13
C NMR (125.8 MHz, 
CDCl3) (ppm): 162.4, 161.8, 147.0, 136.5, 133.8, 128.6, 122.0, 121.2, 114.8, 78.3, 66.9, 
55.2, 54.5, 54.4, 45.8, 45.7, 27.6, 27.1, 26.6, 26.5, 26.4, 26.1, 25.7; HRMS (ES+, M+H) 
calc’d for C25H36N3O4S: 474.2427, found:  474.2430 
 
 
4-(3-(4-((3-fluorophenyl)(hydroxy)(pyridin-2-yl)methyl)piperidin-1-yl)-2-
hydroxypropoxy)benzonitrile (4.41) 
In a round bottom flask with stir bar, amine 4.39 (0.47 g, 1.22 mmol), was dissolved in 
MeCN (6.08 mL) To the stirring solution was added K2CO3(0.252 g, 1.82 mmol) in a 
single batch.  After 5 minutes stirring, epoxide 4.40 (0.426 g, 2.43 mmol) was added at 
room temperature. The mixture was then heated to 40 °C and stirring continued 2h. 
The reaction mixture was then filtered and eluted with EtOAc, and the filtrate was 
concentrated in vacuo to give a white solid, which was purified by flash column 
chromatography (1:1 Hex/EtOAc) to provide the desired product as a white powder in 
300 mg (54%). 
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tert-butyl 4-(cyanodiphenylmethyl)piperidine-1-carboxylate (4.42) 
tert-butyl 4-bromopiperidine-1-carboxylate (1.00 g, 3.78 mmol) and 2,2-
diphenylacetonitrile (1.23 g, 6.34 mmol) was dissolved in THF (10.6 mL), and t-BuOK 
(0.71 g, 6.34 mmol) was carefully added.  Reaction was stirred at ambient temperature 
overnight and monitored by LCMS.  After completion, the reaction was quenched with 
H2O and extracted three times with EtOAc.  The organic layers were washed with brine, 
dried over Na2SO4, and concentrated in vacuo.  The crude oil was purified by flash 
column chromatography (4:1 Hex/EtOAc) to provide product as white gummy powder in  
1.11 g  (75%) 
 
 
4-(3-(4-(cyanodiphenylmethyl)piperidin-1-yl)propoxy)benzenesulfonamide (4.43) 
In a round bottom flask with stir bar, 4.42 (0.30 g, 0.80 mmol) was dissolved in 4M 
HCl/Dioxanes (3.98 mL, 15.94 mmol) at ambient temperature.  The clear solution was 
stirred for 3h until reaction was complete by LCMS analysis.  The solution was 
concentrated in vacuo to provide the deprotected amine as the HCl salt in quantitative 
yield.  This product was used directly in the following step. 
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The deprotected piperidine was dissolved in DMF (4.00 mL) in a round bottom flask with 
stir bar.  To this was added K2CO3 followed by 1-bromo-3-chloropropane.  Reaction was 
heated to 40 °C and stirring continued for 4h until progress complete by LCMS analysis.  
At this time 4-hydroxybenzenesulfonamide was added and stirring continued at 40 °C for 
16h. The mixture was then cooled to ambient temperature and filtered to remove solid 
K2CO3 and precipitants.  Crude reaction mixture was purified by reverse-phase HPLC 
chromatography (5-95% MeCN in 5% NH4OH/H2O) to provide the desired product as a 
white crystalline solid in 0.31 g (80%). 
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-5-147
User: 
Acquired: 4/1/2014 8:26 AM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-04-
01 08-24-46\2BB-0101.D
Method LUX CELLULOSE-2 2-20 IPA 
DEA.M
Location: 1,2:B,2
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 5.037 51.4 0.0 0.0 268.1
2 5.263 48.6 0.0 0.0 268.1
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-5-146
User: 
Acquired: 4/1/2014 10:32 AM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-04-
01 10-30-26\2BA-0101.D
Method IA 2-20 MEOH DEA.M
Location: 1,2:B,1
Description: 
  Area % Area % Area %  
Peak # Time UV210 UV254 TIC(+) BPM
1 2.577 45.9 0.0 0.0 246.2
2 2.859 54.1 0.0 0.0 246.2
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-5-163
User: 
Acquired: 11/17/2014 3:24 PM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-11-
17 15-22-49\2FB-0101.D
Method IA 2-20 MEOH DEA.M
Location: 1,2:F,2
Description: 
  Area % Area % Area %  
Peak # Time UV210 UV254 TIC(+) BPM
1 2.513 4.6 0.0 0.0 246.2
2 2.681 95.4 0.0 0.0 246.2
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-5-160 racemic
User: 
Acquired: 12/16/2014 10:07 AM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-12-
16 09-55-14\1AF-0201.D
Method IC 2-20 IPA DEA.M
Location: 1,1:A,6
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 4.373 50.3 0.0 0.0 276.2
2 4.561 49.7 0.0 0.0 276.2
Page 1 of 1 Printed: 12/16/2014 12:07 PM
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-6-33
User: 
Acquired: 12/16/2014 2:29 PM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-12-
16 14-17-53\1AH-0201.D
Method IC 2-20 IPA DEA.M
Location: 1,1:A,8
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 4.380 4.3 2.0 0.0 380.2
2 4.504 95.7 98.0 0.0 276.2
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-5-175 racemic
User: 
Acquired: 12/15/2014 3:01 PM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-12-
15 14-49-34\1AG-0201.D
Method IC 2-20 IPA DEA.M
Location: 1,1:A,7
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 4.582 50.5 0.0 0.0 245.2
2 4.851 49.5 0.0 0.0 245.1
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-5-175 enantiomer
User: 
Acquired: 12/15/2014 3:21 PM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-12-
15 14-49-34\1AF-0401.D
Method IC 2-20 IPA DEA.M
Location: 1,1:A,6
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 4.594 5.3 0.0 0.0 245.2
2 4.829 94.7 0.0 0.0 238.2
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-6-36
User: 
Acquired: 11/26/2014 7:34 AM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-11-
26 07-00-32\1AI-0401.D
Method LUX CELLULOSE-2 2-20 IPA 
DEA.M
Location: 1,1:A,9
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 3.279 49.3 48.9 0.0 256.1
2 3.449 50.7 51.1 0.0 256.1
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-6-43
User: 
Acquired: 11/26/2014 7:54 AM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-11-
26 07-52-33\1BA-0101.D
Method LUX CELLULOSE-2 2-20 IPA 
DEA.M
Location: 1,1:B,1
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 3.242 92.0 93.7 0.0 256.1
2 3.449 8.0 6.3 0.0 256.2
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VCNDD MRB4-12475 Agilent SFCMS
Sample Name: TJS-5-55
User: 
Acquired: 1/24/2013 12:14 PM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2013-01-
24 12-12-40\2EE-0101.D
Method: CHIRALPAK_IC_30_IPA.M
Location: 1,2:E,5
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 3.009 48.9 49.6 57.8 162.1
2 3.918 51.1 50.4 42.2 162.2
Page 1 of 1 Printed: 1/24/2013 12:22 PM
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-6-18
User: 
Acquired: 11/26/2014 11:07 AM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-11-
26 11-06-02\1AF-0101.D
Method IC 5-50 IPA DEA.M
Location: 1,1:A,6
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 5.565 8.4 3.8 0.0 162.2
2 6.526 91.6 96.2 0.0 162.1
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-6-15 racemic
User: 
Acquired: 11/25/2014 2:49 PM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-11-
25 14-38-20\1AG-0201.D
Method LUX CELLULOSE-4 2-20 IPA 
DEA.M
Location: 1,1:A,7
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 4.489 47.1 0.0 0.0 260.2
2 4.778 52.9 0.0 0.0 260.2
Page 1 of 1 Printed: 11/26/2014 8:45 AM
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-6-27
User: 
Acquired: 11/25/2014 2:40 PM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-11-
25 14-38-20\1AF-0101.D
Method LUX CELLULOSE-4 2-20 IPA 
DEA.M
Location: 1,1:A,6
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 4.490 95.2 0.0 0.0 260.2
2 4.837 4.8 0.0 0.0 260.2
Page 1 of 1 Printed: 11/26/2014 8:46 AM
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-6-26 racemic
User: 
Acquired: 11/26/2014 8:24 AM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-11-
26 07-52-33\1AH-0401.D
Method IC 5-30 IPA DEA.M
Location: 1,1:A,8
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 3.893 50.6 0.0 0.0 368.1
2 4.243 49.4 0.0 0.0 368.1
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VCNDD MRB4-12475 Agilent 1260 SFCMS
Sample Name: TJS-6-38
User: 
Acquired: 11/26/2014 8:14 AM
Filename: 
C:\CHEM32\1\DATA\SINGLE 2014-11-
26 07-52-33\1BB-0301.D
Method IC 5-30 IPA DEA.M
Location: 1,1:B,2
Description: 
  Area % Area % Area %  
Peak # Time UV220 UV254 TIC(+) BPM
1 3.974 8.2 0.0 0.0 245.1
2 4.241 91.8 0.0 0.0 368.1
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4. Chiral SFC Traces 
   4-(3-(4-(cyclopentyl(hydroxy)(phenyl)methyl)piperidin-1-
yl)propoxy)benzonitrile, 4.13: 
Semi-preparative purification: 
 
 
 
 
 
First Eluting Peak: 
 
Second Eluting Peak: 
 
 
     4-(3-(4-((3-fluorophenyl)(hydroxy)(pyridin-2-
yl)methyl)piperidin-1-yl)propoxy)benzonitrile, 4.15:
 
Semi-preparative purification: 
 
 
Racemic Analytical Chiral SFCMS: 
 
 
First Eluting Peak: 
 
 
 
Second Eluting Peak: 
 
 
 
 
 
 
 
 
 
 
   4-(3-(4-(cyclopentyl(hydroxy)(phenyl)methyl)piperidin-1-
yl)propoxy)benzonitrile, 4.29: 
Semi-preparative purification: 
 
Racemic Analytical Chiral SFCMS: 
 
 
 
 
 First Eluting Peak: 
 
 
 
 
Second Eluting Peak: 
 
 
 
 
 
